

Provider Manual Show Me Healthy Women (SMHW)

Table of Contents June 30, 2021 – June 29, 2022

Section	Content	Page
1.	Overview	
	Overview of SMHW/WISEWOMAN Programs	1.1
	Show Me Healthy Women Vision and Mission	1.1
	WISEWOMAN Vision and Mission	
	History	1.2
	National Breast and Cervical Cancer Early Detection Program WISEWOMAN	
	NBCCEDP and WISEWOMAN Similarities	1.3
	At-A-Glance Comparison of NBCCEDP and WISEWOMAN	1.4
	Contractual Agreements	
	What We Do	
	Show Me Healthy Women Advisory Board	1.6
	Advisory Board Responsibilities	
2.	Provider Contract Requirements	
	Provider Contract Requirements	2.1
	Complete SMHW/WISEWOMAN Information Update Form	
	Recruit Clients	
	Attend Training	
	Register Clients for Services	
	Comply with HIPAA Regulations	
	Utilize Medical Staff	
	Obtain Permission for RN to Provide Services	
	Laboratories	
	MQSA	
	Report Results-Mammography	
	On-Site Quality Assurance Reviews	
	Notify Clients	
	Billing Clients	

Electronic Data and Reports
Reporting Form
Electronic Reimbursement
Recording and Maintaining Documentation
Assure Follow-up
Communicating with Subcontractors
Subcontractor Requirements
Refer Tobacco Users
Submit Personnel Information
Collaborate
Providers Who Terminate Participation
Submit Letter
Continue to Report
Work with RPC
Provider Application Approval Criteria
Commitment
Accreditation
Capacity
Location
Commitment to Clients
Experience
Network
Compliance
Application Denial
Client Eligibility
Client Eligibility Guidelines
Age Eligibility Includes 35 to 64 Year-Old Women
Transgender Clients
Income Guidelines
Insurance Status of Uninsured or Underinsured
Current Breast or Cervical Cancer
MO HealthNet (Medicaid)
Medicare
Insurance
Documentation and Certification of Client Eligibility
Free Transportation for Clients

3.

	Travel Voucher Instructions
4.	SMHW Screening Recommendations
	SMHW Screening Recommendations
	Green History Form4.3
	Clinical Requirements for SMHW Services
5.	Diagnostic Breast Services and Treatment Coordination
	Diagnostic Breast Services and Treatment Coordination

	Specialist Consultation Guidelines
	Specialist Consultation Reminder
	Diagnostic Services Available5.6
	Guidelines for Breast Diagnostic Services
	CBE Suspicious for Cancer
	Non-palpable Mammography Abnormality
	Ultrasound
	Breast Biopsies
	Fine Needle Aspiration, Core Needle, Stereotactic, Incisional or Excisional
	3-D Mammography/Tomosynthesis
	Flowchart: Selecting the correct form when entering a mammogram 5.8
	Guidelines for the Management of Breast Self-Exam (BSE)
	Reported Symptoms 5.10
	Guidelines for the Management of Clinical Breast Exam (CBE) Results 5.11
	Guidelines for the Management of a "Suspicious for Cancer" CBE and
	First Follow-up Test is a Diagnostic Mammogram 5.12
	Guidelines for the Management of Women who Have Suspicious for
	Cancer CBE and first Follow-up Test is NOT a Mammogram 5.14
	Diagnostic Breast Follow-up Algorithms 5.16
	Purple Breast Form 5.19
	Alert Value Follow-Up
6.	Abnormal Cervical Screening Results
	Abnormal Cervical Screening Results 6.1
	Suspicious or Abnormal Cervical Results
	Determination of Screening Results
	Pending Abnormal Screening Results
	Protocol for Rescreen
	Pelvic Examination
	Pap Test
	Specialist Consultation Guidelines
	Specialist Consultation Reminder
	Not Considered a Specialist Consultation
	Diagnostic Services Available
	Pap Test Exceptions
	Guidelines for Cervical Diagnostic Services
	High-Risk Human Papillomavirus (HPV) Testing
	riigii-itiak ridinarri apiilomaviida (rii v) realing

	Cervical Conization	
	Yellow Cervical Form	6.7
	ASCCP Algorithms and 2020 Updated Consensus Guidelines are located at http://www.asccp.org/	
	Alert Value Follow-up	6.8
	SMHW providers shall	
	Cervical situations that require follow-up within 90 days	
7.	MO HealthNet - BCCT Act	
	MO HealthNet Breast and Cervical Cancer Treatment Act	7.1
	Basic BCCT Act Eligibility Guidelines	7.2
	BCCT Temporary MO HealthNet Authorization Letter (Presumptive Eligibility)	
	BCCT MO HealthNet Application (Extended BCCT coverage) Extending MO HealthNet Treatment Eligibility beyond the presumptive period	
	Instructions to Transfer a client from another state BCCT Program	
	MO HealthNet Treatment Services Covered	7.6
	Covered Services	
	SMHW Provider Responsibilities	7.7
	SMHW Regional Program Coordinator BCCT Responsibilities	
	Family Support Division Responsibilities	7.9
8.	Performance Indicators	
	Performance Indicators	8.1
	Quality Assurance	8.2
	Quality Assurance Follow-Up	
	Quality Assurance Provider Expectations	
	Client Rights	
	Intake and Eligibility Guidelines	
	Screening and Diagnostic Protocols	
	Clinic Management	
	SMHW Quality Assurance Form	8.5
9.	Billing Guidelines	
	Billing Guidelines	9.1
	Provider Reimbursement Guidelines	

	ons for Denial ders will not receive reimbursement under the following	
_	rcumstances	
Insurance Guide	elines	9.3
Administrative F	Referral Fee	9.4
Direct Billing Dia	agnostic Providers	9.5
Mammography	Van Billing Guidelines	9.5
Screening/Refe	rring Provider Responsibilities	9.6
Direct Billing Dia	agnostic Provider Responsibilities	9.6
Breast & Cervic	al Reimbursement Rates by CPT Codes	9.7
Forms		
Forms		10.1
Clien	t/Patient Navigation	
SMH	W/WISEWOMAN Information Update	
SMH	W Eligibility Agreement (English & Spanish)	
Greei	n Patient History (English & Spanish)	
Blue	Screening Report	
Purpl	e Breast Diagnosis and Treatment	
Yellov	w Cervical Diagnosis and Treatment	
BCC	T Temporary MO HealthNet Authorization	
	Γ Medical Assistance Application (Mo HealthNet)	
	ication of Need for Treatment – Breast/Cervical Cancer est for Literature	
MOHSAIC		
	ent Forms for MOHSAIC Entry	11 1
	n Patient History Form	11.1
	Screening Report	
	e Breast Diagnosis and Treatment Form	
	w Cervical Diagnosis and Treatment Form	
	ess	11 3
	HSAIC	
	on 1: The CLIENT	
	on 2: Financial	

10.

11.

12.	Patient Navigation
	Patient Navigation12.1
	'Navigation-Only' Enrollment Status12.2
	Patient Navigation Services12.3
	MOHSAIC Navigation Form Sections12.5
	Terminating Patient Navigation12.12
	Case Management
	Terminating Case Management12.13
	Lost to Follow-up Cases12.13
	Quality Assurance/Quality Improvement
	SMHW Cancer Resources12.15
13.	Appendices
	Providers13.1
	Client Referral
	RPC Contact Information
	SMHW Regional Program Coordinator County List13.2
	Request for Literature Form13.3
	Available Literature in English13.4
	Available Literature in Spanish13.6
	Most Commonly Asked Questions
	Acronyms/Abbreviations13.12
	Glossary of Terms13.16

Missouri Department of Health and Senior Services

Division of Community and Public Health / Bureau of Cancer and Chronic Disease Control
920 Wildwood Drive, PO Box 570, Jefferson City MO 65102-0570


Telephone: 573-522-2845 or toll-free at: 866-726-9926 Fax: 573-522-3023

Web address: www.health.mo.gov/showmehealthywomen

Funded in part by CDC Grant # NU58DP006299 Show Me Healthy Women Grant Year 30

Overview

Overviev	v of SMHW/WISEWOMAN Programs	1.1
Show Me	e Healthy Women Vision and Mission	1.1
WISEWO	DMAN Vision and Mission	1.2
History		1.2
	National Breast and Cervical Cancer Early Detection Program WISEWOMAN	
NBCCE	OP and WISEWOMAN Similarities	1.3
At-A-Gla	nce Comparison of NBCCEDP and WISEWOMAN	1.4
Contract	ual Agreements	1.5
	What We Do	
Show Me	e Healthy Women Advisory Board	1.6
	Advisory Board Responsibilities	



Overview of Show Me Healthy Women and WISEWOMAN Programs

Welcome to the Missouri Show Me Healthy Women (SMHW) and Well-Integrated Screening and Evaluation for Women Across the Nation (WISEWOMAN) programs offered through the Missouri Department of Health and Senior Services (DHSS). The purpose of the SMHW and WISEWOMAN Provider Manuals is to help participating health professionals understand program requirements and provide services to program-eligible women.

This manual is intended to offer an integrated approach in providing SMHW and WISEWOMAN services. It is designed to provide important information needed to enroll clients into the SMHW and WISEWOMAN programs, explain health professional roles and responsibilities, define reimbursable services, and provide necessary reimbursement and billing information. It also includes a framework for clinical guidelines to adhere to program standards. The SMHW and WISEWOMAN staff are available to assist providers on a regular basis using e-mail, telephone, and on-site visits as needed. Help is available from the SMHW and WISEWOMAN staff by calling toll-free at 866-726-9926 or 573-522-2845.

Show Me Healthy Women Vision and Mission

Vision Statement

Improve the quality of life in Missouri through the cure and elimination of breast and cervical cancers.



Mission Statement

Support quality screening, diagnostic and treatment services, in accordance with current medical standards of care, for breast and cervical cancers for all women in Missouri. This is achieved by education, community outreach, and resource development in partnership with public and private entities, communities, and citizens.

WISEWOMAN Vision and Mission

Vision Statement

A world where any woman can access preventive health services and gain the wisdom to improve her health.



Mission Statement

Provide low-income, underinsured or uninsured 40-64 year-old women with the knowledge, skills and opportunities to improve their diet, physical activity and other life habits to prevent, delay or control cardiovascular and other chronic diseases.

History



National Breast and Cervical Cancer Early Detection Program

http://www.cdc.gov/cancer/nbccedp/

The United States Congress passed the Breast and Cervical Cancer Mortality Prevention Act of 1990 (Public Law 101-354) to establish the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) in 1990. The Centers for Disease Control and Prevention (CDC) authorizes the NBCCEDP to provide grants to states, American Indian/Alaska Native tribes, and U.S. Territories to carry out cancer early detection activities.

WISEWOMAN

http://www.cdc.gov/wisewoman

Congress amended the NBCCEDP Public Law 101-354 in 1993 to create the WISEWOMAN Program. The WISEWOMAN Program addresses women's risk for heart disease and stroke by providing cardiovascular disease (CVD) health screenings and risk reduction lifestyle education for NBCCEDP clients.

NBCCEDP and WISEWOMAN Similarities

NBCCEDP shares an established infrastructure with WISEWOMAN to provide integrated services including:

- Recruiting and working with women eligible for services
- Delivering screening services through an established health care delivery system
- · Collecting and reporting minimum data elements (MDEs) used to track, monitor and evaluate program efforts
- Providing professional development opportunities for staff, providers and partners
- Providing public education to raise awareness about the need for women to receive program services
- Assuring that quality care is provided to women participating in the program

At-A-Glance Comparison of NBCCEDP and WISEWOMAN

Topic	NBCCEDP/SMHW	WISEWOMAN
First state/tribal health agency was funded	1990	1995 Three demonstration projects were funded.
Number of nation-wide funded programs	50 states, District of Columbia, 5 territories, and 12 tribal organizations	20 states and 2 tribal organizations
Program administration	CDC's Division of Cancer Prevention and Control Program, Services Branch, National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP)	CDC's Division for Heart Disease and Stroke Prevention, Program Development and Services Branch, NCCDPHP
Services provided	Cancer screening: clinical breast exam (CBE), pap test and mammography Diagnostic tests to identify breast and cervical problems Referral to health care providers for medical management of conditions for women with abnormal or suspicious test results Referral to the Missouri Tobacco Quitline for women who smoke	Heart Disease and Stroke Risk Factor Screenings: Cholesterol and high-density lipoprotein (HDL), A1C or glucose, high blood pressure (HBP), waist/hip circumference, height/weight for body mass index (BMI), Risk Counseling Diagnostic office visit to identify/confirm a new diagnosis of HBP, diabetes, elevated cholesterol Referral to community-based resources, Lifestyle Education Programs, Missouri Tobacco Quitline, uncontrolled HBP

Contractual Agreements

The SMHW program utilizes contracts with service providers to deliver program services. Contracts are available for SMHW only services or for providers who choose to deliver both SMHW and WISEWOMAN services.



What We Do

- Establish annual contracts for screening providers
- Provide an easily accessible program manual that describes screening, follow-up, education, and reporting guidelines based on national CDC guidelines
- Require providers to utilize the Clinical Laboratory Improvement Amendments of 1988 (CLIA) approved laboratories or assure laboratory equipment is CLIA waived
- Provide Regional Program Coordinators (RPCs) for each geographic region to assist providers with training, technical assistance, and tracking clients with abnormal values to ensure clients receive appropriate followup
- Provide training and technical assistance to provider staff
- Provide client recruitment targeting ethnically diverse program-eligible women
- Provide client educational materials and tools
- Provide required reporting forms and data system for submitting service reports
- Reimburse providers for allowable services according to the Medicare 01 region rates
- Monitor provider services to assure quality standards
- Maintain a central data system for tracking and reporting required data to CDC
- Assist the service providers with client case management/follow-up and annual evaluation screening efforts
- Provide promotional items, literature, and other public educational materials when available

Show Me Healthy Women Advisory Board

The SMHW Advisory Board strengthens the program's activities in the state of Missouri through professional and policy development, public and clinical education, private partnerships, and coalition building.

Advisory Board Responsibilities

- Advise SMHW management on SMHW issues
- Assist SMHW in enhancing the breast and cervical cancer control knowledge and skills of Missouri's health care professionals
- Assist SMHW in identifying appropriate breast and cervical cancer control legislation
- Establish task forces, as necessary, to assist SMHW in developing cancer control policies, such as cervical and breast cancer screening protocols and policies, diagnostic guidelines, and funding applications
- Assist SMHW in identifying partners who will extend and enhance the work of SMHW

The SMHW Advisory Board is composed of representatives of organizations that are, or potentially can be, involved in SMHW activities and of individuals with special expertise in breast and cervical cancers. The board has approximately 30 members. Elected board members serve a two-year term. The Board meets quarterly and meetings are open to the public.

Provider Contract Requirements

Provider Contract Requirements	2.1
Complete SMHW/WISEWOMAN Information Update Form Recruit Clients Attend Training Register Clients for Services Comply with HIPAA Regulations Utilize Medical Staff Obtain Permission for RN to Provide Services Laboratories MQSA Report Results-Mammography On-Site Quality Assurance Reviews	Notify Clients Billing Clients Electronic Data and Reports Reporting Form Electronic Reimbursement Recording and Maintaining Documentation Assure Follow-up Communicating with Sub- contractors Subcontractor Requirements Refer Tobacco Users Submit Personnel Information Collaborate
Providers Who Terminate Participation Submit Letter Continue to Report Work with RPC	2.6
Provider Application Approval Criteria Commitment Accreditation Capacity Location Commitment to Clients	Experience Network Compliance Application Denial

Provider Contract Requirements

All of the following provider contract requirements must be met.

Complete SMHW/WISEWOMAN Information Update Form

Complete and sign the SMHW-WISEWOMAN Information Update Form annually. The SMHW/WISEWOMAN Information Update Form is located at http://www.health.mo.gov/living/healthcondiseases/chronic/showmehealthywomen/forms.php

Recruit Clients

Recruit clients by the following activities:

- Utilize public education resources provided by DHSS to recruit eligible women
- Collaborate with American Cancer Society (ACS), National Cancer Institute (NCI), American Heart Association (AHA), local cancer control coalitions, and other local partners
- Display recruitment and educational information in waiting areas and examination rooms
- Provide materials on screening services to all eligible women attending clinics in the facility
- Coordinate recruitment activities with the DHSS staff and the designated area RPC
- Schedule women for annual screenings at a minimum of 10-month intervals following initial or annual screening
- Recruit WISEWOMAN clients from SMHW clients

Attend Training

- Attend SMHW/WISEWOMAN provider staff training
- New providers of SMHW/WISEWOMAN services must participate in an on-site training session by DHSS staff prior to providing services
- Ensure staff is well trained in program protocols prior to delivering services. Require at least one staff
 member to participate in an orientation training delivered by DHSS program staff upon initial contract
 application
- Facilitate attendance/participation of staff members responsible for submission of data forms and clinical services at annual trainings that provide policy and procedure updates and review
- Request DHSS training sessions when new staff are hired

Register Clients for Services

- Obtain clients' signatures on the SMHW-WISEWOMAN Client Eligibility Agreement Form.
- Annually provide clients with the current DHSS patient privacy rights statement in accordance with Health Insurance Portability and Accountability Act (HIPAA) regulations prior to receiving services annually. The client must receive this information along with the HIPAA statement from the provider facility. The provider must retain documentation of this action.

Comply with HIPAA Regulations

• Comply with current HIPAA regulations (http://www.health.mo.gov/information/hipaa/) in delivering services.

Utilize Medical Staff

- Provision of services is dependent upon current license or certification with the State of Missouri.
- Utilize medical doctors, doctors of osteopathy, nurse practitioners, certified nurse midwives, clinical nurse specialists, certified physician assistants, and registered nurses (RNs) with specialized training within the registered nurse's scope of practice to provide services.

Obtain Permission for RN to Provide Services

Obtain written approval from DHSS for the RN to provide breast and cervical screening services for SMHW clients. Submit the following information in a written request to SMHW:

- A letter documenting previous practice;
- A licensure or certification numbers; and
- Documentation of any of the following breast and/or cervical cancer screening training:
 - Length of the preceptorship;
 - Number of pap tests, CBEs, and pelvic examinations completed during the preceptorship. A minimum of 10 pap tests, CBEs, and pelvic examinations must be performed in order for the RN to be eligible to provide screening services; and
- The preceptor must verify that the nurse completed these examinations with minimal or no difficulty.

Laboratories

Utilize only laboratories that adhere to all applicable standards established under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 or are CLIA waived. Laboratories must report pap test findings using the Bethesda System 2001.

MQSA

Comply with Mammography Quality Standards Act (MQSA). Prior authorization by SMHW and DHSS is required for MQSA-accredited mobile mammography vans based out-of-state.

Report Results-Mammography

Report mammography test results in the American College of Radiology BIRADS system.

On-Site Quality Assurance Reviews

Agree to on-site record reviews by qualified DHSS staff six months after initial services begin and every two years thereafter, or more frequently if requested by the DHSS.

Notify Clients

Notify clients of non-program-covered services. Notify the client in writing of any services not covered by the programs prior to providing any non-program-covered services.

Billing Clients

Ensure clients receive no bills (invoices) for services covered by the SHMW or WISEWOMAN programs.

Electronic Data and Reports

Enter all data and reports electronically with accompanying Current Procedural Terminology (CPT) codes into the SMHW central data management computer-tracking program, Missouri Health Strategic Architectures and Information Cooperative (MOHSAIC).

Reporting Form

Submit a fully completed reporting form within 60 days of the last date of service. An exception should be noted for end-of-grant-year services. The end-of-year billing deadline notification is sent to providers annually.

Electronic Reimbursement

Agree to receive SMHW/WISEWOMAN reimbursements through Electronic Fund Transfer (EFT). SMHW/WISEWOMAN reimbursement rates and CPT codes can be viewed in Section 9; Billing Guidelines.

Recording and Maintaining Documentation

Complete and maintain documentation on all client eligibility, screening, and case management services outlined in this manual. Maintain client records for at least seven years. All SMHW enrolled clients with an abnormal screening result must be assessed for their need of case management services and provided with such services accordingly. Examples of screening results which would require a case management assessment would be BIRADS 3, 4, 5 for mammograms; and Atypical Squamous Cells of Undetermined Significance (ASCUS), Low-grade Squamous Intraepithelial Lesion (LSIL), and high grade lesions for pap tests. Case management services conclude when a client initiates treatment, refuses

treatment, or is no longer eligible for the SMHW program. When a woman concludes her cancer treatment, and is released by her treating physician to return to a schedule of routine screening, she may return to the program and receive services if she meets eligibility requirements.

Assure Follow-up

Assure all clients identified on screenings that have suspicious, abnormal, or alert test results receive appropriate follow-up services, including case management, rescreen, diagnostic evaluation, treatment referral and/or education services according to program protocols. These services may be provided directly by the contracted provider or by an established referral sub-contractor that meets SMHW/WISEWOMAN program requirements. All test results shall be maintained in the clients medical records for monitoring purposes.

Communicating with Sub-contractors

Ensure that communications with sub-contractors include notification and approval from the SMHW/WISEWOMAN provider prior to the subcontractor's provision of additional tests. This communication is necessary to be sure the subcontractor's services and reimbursements will meet SMHW/WISEWOMAN program guidelines. Providers are also responsible for ensuring that clients understand why they are being referred and what services will be provided. It is the recommendation of DHSS that a written agreement between each sub-contractor and each SMHW/WISEWOMAN provider is complete.

Subcontractor Requirements

Ensure subcontractors meet the requirements specified in these guidelines (i.e., MQSA, CLIA, etc.). Subcontracted services may include:

- Pap test processing and interpretation
- Cervical conization
 - Loop Electrosurgical Excision Procedure (LEEP)*
 - Cold knife conization (covered as diagnostic, not treatment)*
- Endocervical curettage (alone)
- Colposcopy with or without biopsy
- Endometrial biopsy with Atypical Glandular Cells (AGC)
- * Refer to Cervical Section of Manual

- Mammography
- Specialist consultation
- Breast ultrasound
- Fine needle aspiration (FNA)
- Core needle biopsy
- Stereotactic biopsy
- Surgical incisional biopsy
- Excisional breast biopsy
- WISEWOMAN laboratory test
- WISEWOMAN lifestyle education
- WISEWOMAN diagnostic office visit

Refer Tobacco Users

Ensure that SMHW and WISEWOMAN clients who use tobacco products are referred to the Missouri Quitline 800-QUIT-NOW (800-784-8669) for free counseling. The Missouri Quitline is available free of charge to all Missouri SMHW and WISEWOMAN participants. Be sure to have the client complete a fax referral form and fax the form to the Quitline.

Submit Personnel Information

Submit written changes of clinical, administrative and personnel contact changes to DHSS within 30 days.

Collaborate

Collaborate with the Missouri Department of Social Services (DSS), Family Services Division (FSD) regarding clients diagnosed with breast/cervical cancer. These clients may be eligible for treatment through the Breast and Cervical Cancer Treatment (BCCT) Act.



Providers Who Terminate Participation

Submit Letter

Submit a letter to DHSS 30 days before the date of anticipated termination of services. The letter must include the date of termination of SMHW/WISEWOMAN services.

Continue to Report

Continue to report all diagnostic and/or treatment information after termination on the appropriate SMHW/WISEWOMAN forms to complete all outstanding follow-up cases. To accomplish this, a provider should work closely with the Regional Program Coordinator (RPC) in their area.

Work with RPC

Work with the RPC to inform clients where they may obtain SMHW/WISEWOMAN services in their area once the provider terminates participation.

Provider Application Approval Criteria

The DHSS approves or disapproves providers based on the following criteria:

Commitment

Commitment and ability to meet the contract requirements;

Accreditation

Accreditation or certification status of the site and clinical staff:

Capacity

Capacity to submit timely and accurate data and billing reports to DHSS via the MOHSAIC electronic reporting system;

Location

Located in area of need in relation to other SMHW/WISEWOMAN providers and to the population to be served;

Commitment to Clients

Commitment and ability to serve clients with special emphasis on priority-eligible populations, particularly women 35-64 years of age or older and women who have rarely or never been screened;

Experience

Successful experience in providing comprehensive breast and cervical cancer screening, education and referral services, either through existing on-site facilities or referral linkages. Access to CLIA-approved laboratory and/or MQSA accredited mammography facility;

Network

Ability to network with the ACS and NCI, and other educational state and regional resources;

Compliance

Compliance with current HIPAA regulations; and

Application Denial


If an application is denied, a contact list identifying other SMHW/WISEWOMAN providers in the same geographic area will be provided. Applicants may use this information to facilitate referrals for women in need of SMHW/WISEWOMAN services.

The Provider Application can be found at:

http://www.health.mo.gov/living/healthcondiseases/chronic/showmehealthywomen/forms.php.

Client Eligibility

Client Eli	gibility Guidelines
	Age Eligibility Includes 35 to 64 Year-Old Women Transgender Clients Income Guidelines Insurance Status of Uninsured or Underinsured Current Breast or Cervical Cancer MO HealthNet (Medicaid) Medicare Insurance
Documer	tation and Certification of Client Eligibility
Free Trar	sportation for Clients
Travel Vo	ucher Instructions
	Does the client need transportation? Secure client address and telephone number. Does the client need any special assistance? Travel Vouchers Cancellation
SMHW/W	ISEWOMAN Transportation Providers Fiscal Year 2022 (List)
SMHW/W	ISEWOMAN Transportation Providers Fiscal Year 2022 (Map)



Client Eligibility Guidelines

SMHW eligibility has three primary criteria; income level, health insurance status, and age guidelines. Income guidelines are based on 200 percent of the federal poverty guidelines. The SMHW program reimburses only for services when there is no other funding source available. Women 35 to 64 years of age are eligible for services; some service restrictions apply by age categories.

SMHW/WISEWOMAN Programs are the payers of last resort. Providers may call program RPC for guidance.

Age Eligibility Includes 35 to 64 Year-Old Women

Some exceptions pertain to guidelines for services available to clients older than 64 based on insurance. Please see page 3.3 for further information.

Transgender Clients

- Screening and diagnostic services are available for male-to-female transgender clients who have/are taking hormones as long as they meet program eligibility guidelines.
- Screening services are available for female male transgender individuals who have not yet undergone complete hysterectomy or bilateral mastectomy because these individuals are genetically female.
- The CDC does not make a recommendation on routine screening with this population; transgender women are eligible under federal law to receive appropriate cancer screening.
- To determine medical necessity of screening, CDC recommends providers discuss the risks and benefits
 of screening with all eligible clients.

Income Guidelines

Household Size	SMHW Annual	SMHW Monthly	SMHW weekly	SMHW Hourly
1	\$25,760.00	\$2,147.00	\$495.00	\$12.38
2	\$34,840.00	\$2,903.00	\$670.00	\$16.75
3	\$43,920.00	\$3,660.00	\$845.00	\$21.12
4	\$53,000.00	\$4,417.00	\$1019.00	\$25.48
5	\$62,080.00	\$5,173.00	\$1,194.00	\$29.85
6	\$71,160.00	\$5,930.00	\$1,368.00	\$34.21
7	\$80,240.00	\$6,687.00	\$1,543.00	\$38.58
8	\$89,320.00	\$7,443.00	\$1,718.00	\$42.94
Each additional person, add:	\$4,540.00	\$757.00	\$174.00	\$4.36

• Clients must have an income at or below 200 percent of the federal poverty income guidelines. Adjusted gross income on tax return or net amount on pay stub determines income eligibility.

Insurance Status of Uninsured or Underinsured

Health Insurance Status++

- No health insurance
- Health insurance does not cover services
- Client states she is unable to pay deductible
- Have MO HealthNet with Spend-down, but have not met Spend-down
- Income eligible for Medicare Part B, but unable to pay premium
- Clients eligible to receive Medicare benefits but not enrolled in Medicare should be encouraged to enroll
- ++ Women with full MO HealthNet (ME Code 05) Medicare Part B, POS or HMO health coverage are not eligible for services. Assess Mo HealthNet (ME Code 13) Permanently and Totally Disabled for level of coverage.
- Providers may use the Client Eligibility Agreement form to document insurance status of the client.
 Copies of these forms are located on pages 10.6-.7 or download a copy at: http://health.mo.gov/living/healthcondiseases/chronic/showmehealthywomen/forms.php.

Current Breast or Cervical Cancer

Women who are currently diagnosed with a breast and/or cervical cancer are not eligible for SMHW
services. Women being currently treated for breast or cervical cancer are also not eligible for SMHW
services. However, once cancer treatment is completed the client may return to SMHW for routine
screenings as long as eligibility guidelines are met.

MO HealthNet (Medicaid)

- Women with MO HealthNet Managed Care coverage may be eligible for SMHW services if they are
 enrolled in the Extended Women's Health Services/EWHS, Uninsured Women's Health Services/UWHS,
 or have an unaffordable MO HealthNet spend-down. These women are eligible for screening/diagnostic
 services through SMHW. Extended Women's Health Services/EWH'S and Uninsured Women's Health
 Services does not cover diagnostic services. The woman must meet all SMHW eligibility guidelines.
- SMHW Clients who reach age 65 and older or women previously not enrolled age 65 and older do not qualify for BCCT.

Medicare

- Women enrolled in Medicare Part B are not eligible for SMHW services. Medicare Part B covers breast and cervical cancer screenings. Refer women with Medicare Part B coverage to providers who accept Medicare reimbursement.
- Women who meet SMHW/WISEWOMAN eligibility requirements and state they cannot pay the premium
 to enroll in Medicare Part B, or are not eligible to enroll in Medicare Part B, are eligible for SMHW/
 WISEWOMAN screening services. If women are eligible to receive Medicare Part B benefits and are not
 enrolled, encourage them to enroll.

Insurance

- The client's insurance <u>must</u> be billed first; when billing DHSS, include the insurance payment amount on reporting forms in the "Comments" section. SMHW will only reimburse up to the total amount allowed for the procedure per program guidelines. The total amount allowed and reimbursed by SMHW for each CPT code includes any payments received from insurance companies, not in addition to insurance payments.
- SMHW and WISEWOMAN are the payers of last resort.
- Women enrolled in prepaid/managed care and health plans (such as Health Maintenance Organizations [HMOs], Point of Service Plans [POS] and MO HealthNet Managed Care [formerly MC+]) are not eligible for SMHW/WISEWOMAN services.

For further guidance regarding clients with insurance, please see page 9.3.

Documentation and Certification of Client Eligibility

The client must sign a SMHW Client Eligibility Agreement form that is retained in the client's record each year. (Download a copy of this form at:

http: health.mo.gov/living/healthcondiseases/chronic/showmehealthywomen/forms.php or pages 10.6 [English] and 10.7 [Spanish]).

Providers must obtain documentation of income, age eligibility and address, if available, on an annual basis and place a copy of the documentation in the client's record. (Electronic or paper medical records are acceptable.)

The following may be used for proof of age and income.				
Age	Income			
 Driver License Medicare Card Birth Certificate U.S. Passport 	 Income tax forms (annual adjusted gross income) Food Stamps WIC Voucher Social Security Award Letter Unemployment Insurance Pay Stub (net amount) 			

Once eligibility is determined, screening providers must verify eligibility on all reporting forms. To comply with the quality assurance policy, 50 percent of client records must contain proof of eligibility.

Provider must retain information in clients' charts regarding the green history form, (pages 10.8 [English] and 10.9 [Spanish] or at:

http: www.health.mo.gov/living/healthcondiseases/chronic/showmehealthywomen/forms.php), and review this information with each additional annual screening. Client records must be retained and available for seven years.

Free Transportation for Clients

Free transportation is available for SMHW/WISEWOMAN clients. Providers can request a travel voucher booklet by contacting Show Me Healthy Women/WISEWOMAN staff or the Regional Program Coordinator (RPC) assigned to their area. All program services qualify for transportation services, including initial office visits, lab visits, follow-up diagnostic office visits, lifestyle education sessions, and annual evaluation screenings in the contracted counties.

3 SHOW ME	Transportation Voucher
l ealthy 2	County:
Women	Trip Date:
FREE Breast and Cervical	Appointment Times P
Cancer Screening	
Program	Client Signature:
Removing barriers to life saving cancer screenings for women.	Clinic Signature:

Note:

Call the SMHW/WISEWOMAN office toll-free at 866-726-9926 or 573-522-2845, to receive a book of 48 vouchers.

Travel Voucher Instructions

Funds are available through SMHW and WISEWOMAN to cover the cost of transportation to help remove the barrier of access to care in receiving screening, diagnostic, and education services.

Transportation services are available in most counties and St. Louis City. Please call the RPC for assistance. See pages 3.8 and 3.9 for a complete list of transportation providers and their contact information. Services are available Monday through Friday, with charges based on urban or county trips and one-on-one or regular-route travel. When a client calls to make an appointment for a SMHW or WISEWOMAN screening or diagnostic, or education services, please ask her the following questions **before** making an appointment date and time for her:

Does the client need transportation?

If yes, explain that free transportation is available for SMHW participants. A transportation provider will pick her up at her home, take her to the appointment, and return her to her home. Check with the transportation provider in your area for the transportation schedule. Ensure the client's appointment date and time coincides with the transportation provider's schedule.

Secure client address and telephone number.

If the client does not have a telephone, ask for a neighbor's telephone number or for another number where she can be reached. The transportation driver may not be familiar with the client's address and may need directions to the residence.

Does client need any special assistance?

If the client needs an assistant or helper, SMHW will pay for transportation for one extra person. The assistant or helper should be 17 years of age or older. If a disabled client needs more than one assistant, call SMHW for approval. If the client has special medical equipment such as a wheelchair or oxygen, please inform the transportation provider at the time of scheduling.

Travel Vouchers

Complete the travel voucher, and include the facility name and site code number. The provider can mail or fax the completed travel voucher to the transportation provider including the date and time of the appointment. A copy of the voucher may be given to the client. The transportation provider will secure the client's signature on pickup.

Cancellation

Notification of cancellation to the transportation provider is required to avoid a penalty charge to SMHW/WISEWOMAN for the cost of the round trip. Provide a **one** business-day notice to cancel a trip. Contact the transportation provider for questions related to transportation services. See page 3.8 and 3.9 for a complete list of transportation providers, service areas, and contact information. Address SMHW questions to the central office by calling toll-free at 866-726-9926 or 573-522-2845.

SMHW/WISEWOMAN Transportation Providers Fiscal Year 2022

Contractor/County(ies)


CVNEDCV

Telephone Number

244 CCC E7E2

SYNERO	3Y			314-666-5752
	St. Charles County	St. Louis City	St. Louis County	
Oats, Inc	c			573-443-4516
	Adair	Cooper	Lafayette	Platte
	Andrew	Dade	Lawrence	Polk
	Atchison	Dallas	Lewis	Pulaski
	Audrain	Davies	Lincoln	Putnam
	Barry	DeKalb	Linn	Ralls
	Barton	Douglas	Livingston	Randolph
	Bates	Franklin	McDonald	St. Clair
	Benton	Gasconade	Macon	Saline
	Boone	Gentry	Maries	Schuyler
	Buchanan	Greene	Marion	Scotland
	Caldwell	Grundy	Mercer	Shelby
	Callaway	Harrison	Miller	Stone
	Camden	Henry	Moniteau	Sullivan
	Carroll	Hickory	Monroe	Taney
	Cass	Holt	Montgomery	Vernon
	Cedar	Howard	Morgan	Warren
	Chariton	Jackson	Newton	Webster
	Christian	Jasper	Nodaway	Worth
	Clark	Jefferson	Osage	Wright
	Clay	Johnson	Ozark	
	Clinton	Knox	Pettis	
	Cole	Laclede	Pike	
No Cont	ract			Call local RPC for assistance
	Bollinger	Franklin	Pemiscot	St. Francois
	Butler	Howell	Perry	Ste. Genevieve
	Cape Girardeau	Iron	Phelps	Shannon
	Carter	Madison	Ray	Stoddard
	Crawford	Mississippi	Reynolds	Texas
	Dent	New Madrid	Ripley	Washington
	Dunklin	Oregon	Scott	Wayne

SMHW/WISEWOMAN Transportation Providers Fiscal Year 2021




Map revisions issued as transportation vendors are added or deleted. Contracts with additional transportation vendors are pending.				
	SYNERGY	314-666-5752		
	Oats, Inc.	573-443-4516		
	No contract	Call local RPC for assistance.		

Please check the Transportation Services Catalog for other transportation options that may help your clients receive appropriate services: <u>Transportation Services Catalog (http:</u> www.health.mo.gov/atoz/pdf/transportationservices.pdf).

SMHW Screening Recommendations

SMHW Screening Recommendations4	.1
Provider Responsibilities Initial Screening Annual Screening Rescreening	
Green History Form4	.3
Clinical Requirements for SMHW Services4	.4
Comprehensive Breast and Cervical Screening Annual Screening Protocol Breast Cancer Screening Magnetic Resonance Imaging (MRI) High Risk for Breast Cancer Cervical Cancer Screening High Risk for Cervical Cancer	
Blue Screening Form4	.9
SMHW Clinical Service Summary4	.10



SMHW Screening Recommendations

Routine screening and early detection are vital to reducing morbidity and mortality from breast and cervical cancer. Regular screening and early detection decreases mortality and improves quality of life for all individuals. Regular clinical breast exams, mammography, pelvic exams, and pap tests are the best screening methods available for breast and cervical cancers and pre-cancerous conditions.

Provider Responsibilities

- Schedule annual breast and cervical cancer screenings appropriately for clients.
- Notify clients in advance of recommended screening dates. If the client does not schedule an
 appointment after the first notification, a second attempt shall be made.

Initial Screening

The initial screening is:

The <u>first</u> screening performed on a woman by a SMHW provider.

<u>OR</u>

• If a client has not been seen for five years for a SMHW screening by the same provider.

NOTE:

Initial clients need to complete a SMHW green history form (pages 10.8 [English] and page 10.9 [Spanish]) or download a copy at:

http://www.health.mo.gov/living/healthcondiseases/chronic/showmehealthywomen/forms.php

Annual Screening

The annual screening is:

• The process of returning for an annual screening test at a predetermined interval. SMHW defines an annual screening to be 10 months or greater from the initial screening or previous annual screening.

NOTE:

Annual clients need to review and update the green history form at <u>each annual visit</u> either by completing a new form or by reviewing and initialing updates and initialing the new form with the date of the current visit.

Rescreening

Rescreening is:

• An additional screening visit resulting from an <u>abnormal</u> initial or <u>abnormal</u> annual screening that is less than 10 months from an initial or annual screen.

NOTE:

If there is a delay in the rescreening visit for 10 months or more from the date of the annual/initial visit, reimbursement occurs only after the rescreen meets breast/cervical criteria for an <u>annual</u> screening.

Green History Form

All forms are annually associated with their specific grant year. When submitting an electronic or a paper form, use the version of the form that is the grant year which corresponds with the date of service. At the beginning of each grant year there are multiple versions of this form in Missouri Health Strategic Architectures and Information Cooperative (MOHSAIC). Click on the correct version when entering electronic forms. If using paper forms, check for the year of the form in the lower left corner: example (3/14).

NOTE:

All clients who participate in SMHW **must** complete a Patient History Form also referred to as green history form at the initial screening. The green history form is available in English and Spanish. Assistance may be given to the client for completion of the form. To order blank forms from SMHW call toll-free at 866-726-9926 or 573-522-2845.

- Information from the green history form is used to verify a client's eligibility for screening, as well as statistics to evaluate the program. Some information from the green history form is also reported to the Centers for Disease Control and Prevention (CDC). Keep all information confidential.
- The information on the original form shall be entered electronically in the MOHSAIC system. File all reported information in the client's record.
- Access MOHSAIC electronic forms at https://healthapps.dhss.mo.gov/smhw/.
- A copy of the green history form is located on page 10.8 [English] and page 10.9 [Spanish] or download a copy at: http://health.mo.gov/living/healthcondiseases/chronic/showmehealthywomen/forms.php.
- If you have additional questions, please call SMHW toll-free at 866-726-9926 or 573-522-2845 for general assistance with central office staff.
 - If you have questions or concerns regarding specific issues with MOHSAIC, contact the ITSD Help Desk by telephone at 800-347-0887 or by e-mail at support@health.mo.gov.

Clinical Requirements for SMHW Services

The screening services outlined in the following pages are clinical requirements and shall be completed by the provider of SMHW services in order to be considered for reimbursement. Age restrictions and income guidelines always apply. Providers must have the capability to provide or offer access to the following services:

Comprehensive Breast and Cervical Screening

- Clinical Breast Exam (CBE) provided annually for all women
- Assessment for High Risk for breast and cervical cancer
- Client education on the importance of obtaining screenings for breast and cervical cancer according to the appropriate screening schedules
- Routine screening mammogram offered annually or every other year per clinician and client determination, beginning at age 50 and over. (Table 1, page 4.6):
- Special circumstances include:

Offer a mammogram annually if a woman has a personal history of breast cancer

Any client, age 35 or older, who currently has abnormal breast exam results, can receive diagnostic mammograms and other necessary breast diagnostic services covered by the SMHW program

- Complete visual and manual pelvic examination
- Pap test, conventional or liquid-based, at appropriate intervals (Table 2, page 4.7)
- Documentation of providing screening examination results to clients per verbal report or in writing
- Appropriate and timely case management for all clients with suspicious or abnormal results, including rescreening, diagnostic procedures and/or treatment

Annual Screening Protocol

Age restrictions and income guidelines always apply to a client's eligibility for the services described below.

Breast Cancer Screening

- A Clinical Breast Exam (CBE) is required by SMHW for a complete screening. Coordination of a full screening with health care providers is expected.
- CBE is required for reimbursement of a mammogram. Perform a CBE annually on all women, especially if they have had previous breast cancer surgery.
- Provide an annual mammogram to clients with a personal history of breast cancer ages 35 to 64. A
 diagnostic or screening mammogram is at the clinician's discretion.
- SMHW will reimburse for an annual breast cancer screening after ten (10) months has lapsed from the previous annual breast cancer screening. This includes annual CBE for all SMHW women ages 35 to 64 and yearly or every other year screening mammogram for women ages 50 and older.

- Family history of breast cancer does not qualify a woman for routine mammograms.
- A client with self-reporting abnormal breast self-exam (BSE) may be followed with a diagnostic breast
 work-up, with the exception of self-reporting pain and tenderness or family history. If pain and tenderness
 are self-reported, she may be followed with a rescreening CBE in two (2) weeks up to 10 months. If the
 client continues to report pain and tenderness, case management is at the clinician's discretion.

(Diagnostic workup may include services such as diagnostic mammogram, ultrasound, specialist consult and breast biopsy.)

• Mammogram funding for the purpose of screening women 40 to 49 years of age without abnormal breast findings through SMHW may be available. Funding is dependent on availability of donated funds.

NOTE:

To reserve and schedule donated funding for the woman's screening mammogram, obtain prior approval by calling toll-free 866-726-9926 or 573-522-2845.

• Women 35 years of age and older qualify for diagnostic breast services if breast exam findings are abnormal.

Magnetic Resonance Imaging (MRI)

- ALL SCREENING MRIs MUST HAVE PRIOR AUTHORIZATION from the SMHW program manager.
 Contact your RPC with client information for approval from the manager.
- SMHW will pay for a screening breast MRI to alternate with a screening mammogram and documentation of **one of** the following:
 - BRCA mutation
 - A first-degree relative whom is a BRCA carrier
 - A lifetime risk of 20-25% or greater as defined by risk assessment models such as BRCAPRO,
 Tyrer-Cuzick or the Gail Model (as they are highly dependent on family history)
- The CDC suggests providers discuss risk factors with all clients to determine if they are at high risk for breast cancer
- MRI should **NEVER** be done alone as a breast cancer screening tool
- Breast MRI cannot be reimbursed to assess the extent of disease in clients who have already been diagnosed with breast cancer
- To be most effective, it is critical to complete MRIs at facilities equipped with breast MRI equipment and perform MRI-guided breast biopsies



Table 1

Annual Breast Screening Recommendations for Women		
Age Recommendation		
Age 35 to 39 Complete breast exam by health care provider annually		
Age 40 to 49 Complete breast exam by health care provider annually Screening mammogram every 1 to 2 years IF funding is available.		
Age 50 and over Complete breast exam by health care provider annually Mammogram every 1 to 2 years		

The Missouri SMHW program follows guidelines of the CDC and NCI. Clinically evaluate and schedule appropriate diagnostic procedures within 60 days, for symptomatic women.

Screening Mammograms for Women age 40 to 49 (dependent upon funding)

- For preauthorization, please call the DHSS toll-free at 866-726-9926 or 573-522-2845.
- Screening mammogram funding for this age group is only available if donations or other funding sources become obtainable during the current contract year.

High Risk for Breast Cancer

- BRCA mutation.
- A first-degree relative whom is a BRCA carrier.
- A lifetime risk of 20-25% or greater as defined by risk assessment models such as BRCAPRO,
 Tyrer-Cuzick or the Gail Model as they are highly dependent on family history.

Cervical Cancer Screening

- Pap test results of "inadequate specimen" are not reimbursable by SMHW.
- Pap test results initially indicating no endocervical cells should refer to ASCCP guidelines.
- For women who have a cervix, pap tests will be covered every three (3) years if no human papillomavirus (HPV) done, or screening with a combination of a pap test and HPV testing every five (5) years. See blue screening form (pages 10.10-.11).
- Hysterectomy:
 - SMHW will NOT fund pap testing for women who had a hysterectomy for benign (non-cervical neoplasia) conditions. A woman who has no cervix due to a reason other than cancer may have a pelvic exam to establish that there is no cervix.
 - Follow a woman annually for 10 years (conventional or liquid-based pap tests can be annually reimbursed) if reason for hysterectomy is unknown or if it was for cervical intraepithelial neoplasia (CIN) CIN 2, CIN 3, adenocarcinoma in situ (AIS) or cervical cancer in situ, which was biopsydocumented.

- Women who had a hysterectomy for invasive cervical cancer should undergo an annual pap test (conventional or liquid-based) indefinitely as long as they are in good health.
- Annual pap test may be done only for persons who meet specific high-risk guidelines for cervical cancer per CDC and/or SMHW Advisory Board approval.

Table 2

Annual Cervical Cancer Screening Recommendations for Women*			
Recommendation			
 Pelvic exam may be offered annually or with Pap testing schedule Conventional or Liquid-based Pap test every 3 years Or			
- Combination pap test and human papillomavirus (HPV) test every 5 years			
 Pap is NOT covered for those whom have undergone a hysterectomy <u>unless</u>: (Page 4.8). Refer to Table 3a and 3b for details. They have a remaining cervix 			
Or			
 They had surgery for CIN 2, CIN 3; CIS/AIS (eligible for annual pap for 10 years from date of hysterectomy). They have invasive cervical cancer (eligible for annual pap) 			

Pap findings are reported using the 2001 Bethesda System Guidelines.

The Missouri SMHW program follows guidelines of the CDC and American Society for Colposcopy and Cervical Pathology (ASCCP) for screening and diagnostic recommendations.

NOTE: *Intervals above are guidelines for asymptomatic women only. Evaluate and schedule appropriate diagnostic procedures quickly, **preferably within 60 days**, and within a maximum of 90 days for symptomatic women.

Table 3a

Cervical Cancer Risk Factors to Consider

Women who warrant annual Pap test (conventional or liquid-based) must have a personal history of one of the following HIGH RISK factors:

- Hysterectomy for invasive cervical cancer. Screenings may continue indefinitely, as long as they are in good health.
- CIN 2, CIN 3 or CIS/AIS lesions documented by tissue biopsy after hysterectomy (not based on Pap results). Follow routine pap intervals after the client has 10 years of annual pap test with negative results.
- Hysterectomy with reason unknown and not obtainable. Follow routine Pap intervals after the client has 10 years of annual pap test with negative results.

If Pap test is performed for one the following reasons, please note this in the comments section on the blue screening form.

- Human immunodeficiency virus positive (HIV+)/Immunocompromised from another health condition
- Kidney or other organ transplant
- Medication for severe arthritis or other collagen vascular disease
- Diethylstilbestrol exposure in utero

Table 3b

Risk factors which are NOT adequate to warrant annual pap screening:

- Smoking
- Low income
- Numerous sexual partners (known or suspected)
- HSIL unless histologically diagnosed with a biopsy

Blue Screening Form

All forms are annually associated with their specific grant year. When submitting an electronic or a paper form, use the version of the form that is the grant year wh`ich corresponds with the **date of service**. At the beginning of each grant year there are multiple versions of this form in MOHSAIC (page 10.10-.11). Be sure to click on the correct version when entering electronic forms. If using paper forms, check for the year of the form in the lower left corner: example (3/14).

NOTE:

The Screening Report Form, also referred to as blue screening form, **must be completed** for all clients participating in the SMHW program. Please order blank forms from SMHW by calling 573-522-2845 or toll-free at 866-726-9926.

- Information from the blue screening form is used to verify clients' eligibility for screening, as well as
 diagnostic services that are recommended. Some information from the blue form is reported to the CDC.
 Keep all information confidential.
- The information on the original form shall be entered electronically in the MOHSAIC system. File all reported information in the client's record.
- Access MOHSAIC electronic forms at https://healthapps.dhss.mo.gov/smhw/.
- A copy of the blue screening form is located on pages 10.10-.11 or download a copy at: http://health.mo.gov/living/healthcondiseases/chronic/showmehealthywomen/forms.php
- If you have additional questions, please call SMHW toll-free 866-726-9926 or 573-522-2845 for general assistance with central office staff.
- If you have questions or concerns regarding specific issues with MOHSAIC, contact the ITSD Help Desk by telephone at 800-347-0887 or by e-mail at support@health.mo.gov.

SMHW Clinical Service Summary

Provider Service	SMHW Client	
Initial and Annual Screening: SMHW 20-minute office visit	 SMHW Client: Provide verification of household income, date of birth Sign eligibility agreement form to participate in SMHW/WISEWOMAN services Complete green history form (pages 10.89) 	
	SMHW Provider:	
	 Verify client eligibility and retains a copy of the documentation in the chart Give a copy of HIPAA form to client Review client history form with client; update or clarify information on subsequent annual visits Perform CBE on women age 35 to 64 or older Refer clients 50 years and older whose CBE is normal or benign for screening mammogram at one to two year intervals Perform pelvic exam on all women ages 35 to 49. Offer pelvic exam to women ages 50 to 64 or older Perform pap tests per SMHW/CDC protocols and intervals depending on age, previous screening cycle, presence of cervix, reason for hysterectomy, and previous pap result (page 4.7, Table 2 and 4.8 Table 3 guidelines) Schedule follow-up as needed. Refer clients with abnormal breast and cervical results for diagnostic exams as needed Submit green history form and blue screening form 	

(Continued on next page)

(Continued from previous page)

Provider Service	SMHW Client	
Tobacco Quitline:	SMHW Provider: 1. Refer clients who smoke to the Missouri Tobacco Quitline, 800-QUIT-NOW (800-784-8669) 2. Provide Quitline card	
Diagnostic Office Visit: 20- or 30-minute office visit. *Specific timeframes may apply.	 SMHW Referrals/Diagnostics: Follow abnormal breast results within 60 days of result Follow abnormal cervical results by diagnostic tests within 60 to 90 days Refer women age 35 to 64 or older who have abnormal CBE, qualifying self-reporting symptoms, or personal history of breast cancer for diagnostic mammogram and possibly other breast diagnostics Schedule client for cervical follow-up rescreens or further cervical diagnostic services as needed For alert/abnormal screening results, complete documentation of scheduled or completed medical evaluation and results on appropriate sections of the blue screening form Electronically submit purple breast form and yellow cervical form Contact RPC for any client refusals or patterns of missed appointments 	

Diagnostic Breast Services and Treatment Coordination

Provider Assurances Suspicious or Abnormal Breast Results Determination of Screening Results	
Pending Abnormal Screening Results	
Rescreen Protocols	5.3
CBE Mammogram New Breast Lump Ultrasound	
Specialist Consultation Guidelines	5.5
Specialist Consultation Reminder	
Diagnostic Services Available	5.6
Guidelines for Breast Diagnostic Services	5.7
CBE Suspicious for Cancer Non-palpable Mammography Abnormality Ultrasound Breast Biopsies Fine Needle Aspiration, Core Needle, Stereotactic, Incisional or Excisio 3-D Mammography/Tomosynthesis	nal
Flowchart: Selecting the correct form when entering a mammogram	5.8
	1. SHOWME

Diagnostic Breast Services and Treatment Coordination

Guidelines for the Management of Breast Self-Exam (BSE) Reported Symptoms	5.9
Guidelines for the Management of Clinical Breast Exam (CBE) Results	5.10
Guidelines for the Management of a "Suspicious for Cancer" CBE and First Follow-up Test is a Diagnostic Mammogram	5.11
Guidelines for the Management of Women who have Suspicious for Cancer CBE and first follow-up test is NOT a Mammogram	5.13
Diagnostic Breast Follow-up Algorithms	5.15
Purple Breast Form	5.18
Alert Value Follow-Up	5.19



Diagnostic Breast Services and Treatment Coordination

A mandatory component as a provider of the SMHW program is the responsibility for providing clinical case management of abnormal findings as well as reporting the abnormal findings, and the outcomes to the SMHW program on a timely basis.

The clinician, using current standards of practice and the established SMHW breast cancer screening protocols, determines abnormal findings clinical case management type and frequency.

Provider Assurances

Providers Must Ensure the Following

Suspicious or Abnormal Breast Results

Clients with suspicious or abnormal breast results will receive the necessary case management as determined by the clinician based on current standards of practice for rescreening, diagnosis, and/or appropriate treatment. Clinicians will report data to SMHW. In order to meet the program requirements, two diagnostic tests must be completed after an abnormal CBE. In the event a second diagnostic test is not completed, include a detailed comment in the comment section of the breast (purple) form as to why a second diagnostic test was not completed.

CDC 60 days or less from result of suspicious for cancer screening to diagnosis

Standard 60 days or less from time of cancer diagnosis to start of treatment

Breast Exception

An exception in counting the number of days has been made for women referred into the program for diagnostic evaluation after an abnormal breast test result is received from a provider <u>outside</u> of the SMHW program. In this instance, the interval shall begin on the referral date for diagnostic testing rather than the date of the initial abnormal breast test.

Determination of Screening Results

Suspicious screening results will be determined as normal or abnormal through short-term rescreen or diagnostic procedures.

- Notify and explain to the client with abnormal findings the need for any additional diagnostic service(s).
- SMHW requires two documented attempts for client follow-up, if needed.
 - Direct telephone communication has been shown to be the most effective contact.
 - If unable to reach client by telephone, a letter should be sent indicating there is need for additional diagnostic testing or treatment. For legal purposes, providers are encouraged to use a certified letter.
 - If no response is received after the second attempt or the client refuses further diagnostics and/or treatments, notify your RPC.

Pending Abnormal Screening Results

If abnormal screening results are pending for ten (10) months or longer, client eligibility must be checked and a new annual screening test must be performed prior to the initiation of further diagnostic studies. SMHW will only reimburse for additional diagnostic services if the client continues to meet SMHW eligibility guidelines.

- For clients referred to direct billing diagnostic providers (page 9.5), continue to track that the client receives/attends the scheduled appointments.
- For a client diagnosed with cancer, SMHW providers must provide the following information to SMHW:
 - Date treatment started
 - Type of treatment initiated
 - Name of the facility where treatment occurred

Note:

Contact the RPC in your area (pages 13.1-.2) with questions.

Rescreen Protocol

CBE

For a first occurrence of breast pain and tenderness, SMHW will only reimburse for an office visit for the CBE. SMHW does not reimburse for breast diagnostics for a first occurrence of breast pain/tenderness.

A rescreen CBE can be performed after 14 days or within 10 months of an initial CBE with the first time reported pain /tenderness. Please see page 5.10, condition number four (4).

A repeat CBE is an option as a rescreen, performed 14 days to 10 months after a CBE deemed suspicious for cancer and after performance of appropriate diagnostic test confirmed non-cancer diagnosis. If no prior SMHW documentation is submitted, it is acceptable to enter the first occurrence of pain/tenderness in the comments section of MOHSAIC.

Mammogram

- SMHW will pay up to four consecutive probable benign mammograms within a two-year period. The standard recommendation of a probable benign mammogram is four consecutive six-month follow-ups (a complete cycle of two years). However, if during this follow-up cycle the test result is downgraded to a benign finding (Category II), additional follow-up is not required. If the result remains probably benign or upgraded to a higher category, another type of additional diagnostic testing must be performed within 60 days.
- A repeat mammogram is an option within ten (10) months if the previous mammogram reported to SMHW was a "Category 0, Need evaluation or film comparison". If "Category 0, Need evaluation or film comparison" is the result reported on a mammogram; film comparison, additional mammography, or ultrasound images are needed within 60 days. If possible, providers should not enter this result until the final result is available. However, if "Category 0, Need evaluation or film comparison" is noted on the blue screening form (pages 10.10-.11) providers should complete the film comparison or take additional images within 60 days. The film comparison result should be reported in the Comments section on the purple breast form (pages 10.12-.13) if the blue screening form has already been submitted. Additional imaging would also be reported on the purple breast form (pages 10.12-.13).

Reporting Directions:

If a client receives breast diagnostic procedures that recommend a rescreen mammogram or rescreen ultrasound (typically in six months), the current purple breast form (pages 10.12-.13) should be entered as "Work-up complete". When the rescreen mammogram is submitted it shall be on a blue screening form (pages 10.10-.11) entered as "Rescreen". Refer to the flowchart on page 5.9 on selecting the correct form type for entering of mammograms.

New Breast Lump

 For clients who received an annual SMHW screening that was normal, but later notes a new breast lump, SMHW will not cover the cost of the second office visit, but will pay for the diagnostic testing if the CBE is abnormal. If the clinician does not find a lump and chooses to complete diagnostic testing as a result of the breast self-examination, SMHW will cover the cost of the diagnostics.

Ultrasound

• Ultrasound may be used as a rescreening tool when a mammogram is not appropriate. Rescreen must be less than ten months from original abnormal ultrasound screening.

Limitation:

SMHW will not reimburse for more than two consecutive ultrasound tests with the result of "probably benign" without further diagnostic testing planned within 60 days (something other than ultrasound such as a specialist consult or biopsy). See page 5.16.

Reporting Directions:

If a client receives breast diagnostic procedures that recommend a follow-up/rescreen mammogram or ultrasound in six months, enter as "Work-up complete" on the current purple breast form (pages 10.12-.13). Submit the rescreen ultrasound on a purple breast form with "Rescreen ultrasound" box checked.

Specialist Consultation Guidelines

A SMHW client may be referred for a specialist consultation following abnormal screening and diagnostic test results. Refer clients requiring a specialist consultation to a surgeon, OB/GYN specializing in breast and/or cervical health, or a physician or nurse practitioner who works for a cancer diagnostic or treatment center. Referral to the same screening examiner is not a specialist consult.

Limitation:

Reimbursement for breast and/or cervical specialist consultation following abnormal results is limited to one breast and one cervical referral per client in a contract year.

Specialist Consultation Reminder

Retain a copy of the consult in the client's chart. Do not submit a copy to SMHW.

Diagnostic Services Available

ATTENTION:

Complete breast diagnostic services within 60 days of an abnormal screen.

DIAGNOSTIC SERVICES

Breast Cancer

- Diagnostic mammogram (Digital or Conventional)
- Breast ultrasound
- Ductogram/Galactogram (single duct)
- FNA without pathology
- FNA clinical procedure plus pathology
- FNA deep tissue under guidance plus pathology
- Core needle biopsy
- Stereotactic biopsy
- Incisional biopsy
- Excisional biopsy
- Specialist consultation
- Facility fees
- General anesthesia*

Protocols: The frequency and type of services is at the discretion of the clinician based on current standards of practice and on the protocols included on pages 5.10 - 5.18

^{*}Only one (1) anesthesia fee reimbursement paid for when performing multiple biopsies during the same operation.

^{*}Payment: Services are paid at an outpatient rate only. SMHW program reimburses for services as indicated on pages 9.7-9.12.

Guidelines for Breast Diagnostic Services

CBE Suspicious for Cancer

Completely evaluate and appropriately refer women age 35 and older with a clinically suspicious lesion.

Non-palpable Mammography Abnormality

- Mammography results reported by a radiologist with reference to American Cancer Society (ACS)
 categories "Suspicious abnormality" (Category 4) or "Highly suggestive of malignancy" (Category 5)
 should be referred to a surgeon.
- "Additional Imaging Pending" (Category 0) should be followed by additional views, comparison of films and/or ultrasound within 60 days. If comparison of previous films is needed, only the final result of the comparison study should be reported. Providers who have already submitted reporting forms with the "Additional Imaging Pending" (Category 0) should enter results on the Breast Diagnosis and Treatment form in the Comments section.

Ultrasound

- Ultrasound may be recommended when the CBE is suspicious for cancer and mammogram is not appropriate.
- Abnormal ultrasound requires additional diagnostic imaging.
- Refer women whose results are Category 4 or Category 5 to the BCCT program with or without a biopsy.

Breast Biopsies:


Fine Needle Aspiration, Core Needle, Stereotactic, Incisional or Excisional

 The BSE, CBE and/or imaging mammogram/ultrasound must be suspicious for cancer and information submitted to SMHW before the program will reimburse for breast biopsies.

3-D Mammography/Tomosynthesis

SMHW will reimburse for clients who undergo 3-D mammography (Tomosynthesis).

FLOWCHARTSelecting the Correct Form When Entering a Mammogram



Guidelines for the Management of *Breast Self-Exam (BSE)*Reported Symptoms

MOHSAIC Reporting Form: (Blue) Screening Form Section B1 and B2

(1) Self-reported Lump	Option 1) Clinician to perform CBE and it is their discretion to follow in less than 60 days with 2 diagnostic tests per program guidelines: - Diagnostic mammogram, - Specialist consult, or - Ultrasound, - Breast biopsy Option 2) Clinician to perform CBE and it is their discretion to follow in 14 days – 10 months with a rescreen CBE	
(2) Nipple Discharge (Especially unilateral spontaneous clear or bloody drainage)	Option 1) Clinician to perform CBE and it is their discretion to follow in less than 60 days with 2 diagnostic tests per program guidelines : - Diagnostic mammogram, - Specialist consult, or - Ultrasound, - Breast biopsy	
	Option 2) Clinician to perform CBE and it is their discretion to follow in 14 days – 10 months with a rescreen CBE	
(3) Skin Changes (dimpling, retraction, new nipple inversion, ulceration or Paget's	Option 1) Clinician to perform CBE and it is their discretion to follow in less than 60 days with 2 diagnostic tests per program guidelines : - Diagnostic mammogram, - Specialist consult, or - Ultrasound, - Breast biopsy	
disease)	Option 2) Clinician to perform CBE and it is their discretion to follow in 14 days – 10 months with a rescreen CBE	
(4) Pain/Tenderness	If pain and tenderness are reported, client may be followed with a rescreen CBE in 14 days to 10 months. If client continues to report pain and tenderness twice, and breast cancer is a concern, it is the clinician's discretion for additional follow-up or 2 diagnostic tests per program guidelines, insert statement in comment section at bottom of screening form that additional diagnostics are being done following a second rescreen. If the client comes with a recent previous history of a documented pain or tenderness complaint, make a note in the comments when the physician documented the issue, and report it as a second occurrence of pain on the blue screening form. Please consult the RPC for your area for clarification.	
(5) Other	Example: Personal history of treated breast cancer. In this case, client may receive a diagnostic mammogram annually.	
	Example: Known BRCA carrier. At this time, screening guidelines are not altered due to genetic predisposition for breast cancer.	
(6) Family History	At this time, screening guidelines are not altered due to family history of breast cancer.	

Guidelines for the Management of Clinical Breast Exam (CBE) Results

*Indicates suspicious for cancer and <u>requires</u> additional follow-up in less than 60 days from the date of the abnormal CBE result.

MOHSAIC Reporting Form: Blue screening Form Sections B3 and B4

(1) Benign Finding	Fibrocystic changes, diffuse lumpiness that is not clinically suspicious, clearly defined symmetrical thickening, tenderness, or nodularity palpated in the same location in both breasts Examples include: fibroadenomas, multiple secretory calcifications, oil cysts, lipomas, galactoceles, mixed density hamartomas, intramammary lymph nodes, vascular calcification, implants, and architectural distortion related to previous surgery	CBE may be repeated in 14 days to 10 months. (NOT eligible for SMHW reimbursed diagnostics with these results)	
(2) *Discrete Palpable Mass	includes masses that may be diffuse, poorly defined thickening, asymmetric thickening/nodularity, cystic or solid		
(3) *Nipple Discharge	whether or not there is a palpable mass especially spontaneous unilateral, clear, serous, sanguineous or serosanguineous	Focal pain and tenderness can be evaluated at the clinician discretion. 2 diagnostic tests are to be performed per program guidelines (if something different is done, make a note in the comments section	
(4) *Nipple Excoriation, Areolar Scaliness, or Erythema	(clinically suspicious of Paget's Disease)	of the form). - Diagnostic Mammogram - Ultrasound - MRI (SMHW does not reimburse for diagnostic MRI)	
(5) *Skin Changes	dimpling; retraction; new nipple inversion/peau d'orange; ulceration; one breast lower than usual; prominent veins, unilateral; unusual increase in size, unilateral lymph nodes; also swelling of upper arm. (clinically suspicious of Inflammatory Breast Cancer)	 Breast Consult FNA Biopsy SMHW program does not reimburse for skin biopsy. 	
(6) *Abnormal clavicular, or axillary lymph nodes, or swelling of upper arm.	Enlarged, tender, fixed or hard palpable supraclavicular, infraclavicular or axillary lymph nodes, also swelling of upper arm.	Reassess clinical/pathology correlation if tissue biopsy results are benign. Also, consider repeating the biopsy.	

Guidelines for the Management of a "Suspicious for Cancer" CBE and First Follow-up Test is a Diagnostic Mammogram

*All diagnostic follow-up should be completed in less than 60 days from the date of the abnormal CBE

page 1 of 2

*If the <u>first</u> test following an abnormal CBE is a mammogram, no matter the mammogram result (Category 0-5), an additional, different type of diagnostic test should be completed within 60 days of the abnormal CBE result.

*Use a diagnostic mammogram, rather than a screening mammogram, if a mammogram is preferred following an abnormal CBE.

The typical standard of care following an abnormal (suspicious for cancer) CBE when the first diagnostic test performed is a mammogram, is to complete another type of diagnostic test such as specialist consult, ultrasound, FNA, or tissue biopsy. If this protocol is not followed, justification of why a second test is not needed must be documented in the comment section at the bottom of the breast (purple) diagnostic form.

Mammogram Result Category 0

Assessment Incomplete

Option 1	Option 2	Option 3	
Compare to Previous Films	Additional Diagnostic Mammogram Views	Ultrasound	
(Enter Results on a Purple Diagnostic Form)	(Enter Results on a Purple Diagnostic Form)	(Enter Results on a Purple Diagnostic Form)	
If comparison does not clinically clarify mammogram result to a specific category 1-5, should perform ultrasound or refer to specialist and progress using program guidelines for breast follow-up as clinically indicated. (Note: It is preferable to hold purple MOHSAIC reporting form submission until comparison results can be entered on the initial form)	If additional mammogram views do not clinically clarify result to a specific category 1-5, should perform ultrasound or refer to specialist and progress using program guidelines for breast follow-up as clinically indicated. (Note: Updates of the additional mammogram views should be submitted on a purple breast diagnostic MOHSAIC form) in the Comments section.	If Ultrasound result does not clinically correlate to the CBE result, should refer to specialist and progress to other SMHW covered diagnostic tests and progress using program guidelines for breast follow-up as clinically indicated. (Note: Ultrasound result should be submitted on a purple breast diagnostic MOHSAIC form)	

Once Mammogram Result is Clarified from Category 0 to a Specific Category 1-5, Refer to Next Page for Follow-up Guidelines:

SMHW staff note that at times, the original screening provider performs a diagnostic mammogram and when the client is referred to another direct biller for further diagnostics, the direct biller is repeating a mammogram. Please avoid this duplication of services when possible, to conserve funding, service and appointment efforts. If the original provider is highly suspicious of cancer, please consider where the woman would go for treatment if she is found to have breast cancer and refer for the diagnostic mammogram as appropriate. If the potential treating provider is located a significant distance away and it would create a hardship for the client to travel for the initial diagnostics please take that situation into consideration.

(Follow-up Guidelines for Mammogram results Categories 1-5 is on the next page.)

Guidelines for the Management of a "Suspicious for Cancer" CBE and First Follow-up Test is a Diagnostic Mammogram

*All diagnostic follow-up should be completed in less than 60 days from the date of the abnormal CBE.

page 2 of 2

*If the <u>first</u> test following an abnormal CBE is a mammogram, no matter what the mammogram result is (Category 0-5), an **additional**, <u>different</u> type of diagnostic test <u>should</u> be completed within 60 days of the abnormal CBE result.

The typical standard of care following an abnormal (suspicious for cancer) CBE when the first diagnostic test performed is a mammogram, is to complete another type of diagnostic test such as specialist consult, ultrasound, FNA, screening MRI (prior approval by SMHW Manager), or tissue biopsy. If this protocol is not followed, justification of why a second test is not needed must be documented in the comment section at the bottom of the breast (purple) diagnostic form.

Mammogram Result Category 1 or 2 Negative or Benign	Mammogram Result Category 3 Probably Benign Examples include non-calcified mass, focal asymmetry and cluster of round calcifications.	Mammogram Result Category 4 or 5 Suspicious Abnormality or Highly Suggestive of Malignancy
Should Perform Another type of Breast Diagnostic Testing (as clinically indicated) such as: Ultrasound Surgical Consult FNA Tissue Biopsy Screening MRI (obtain prior approval from SMHW manager)	Should Perform Another type of Breast Diagnostic Testing (as clinically indicated) such as: Ultrasound Surgical Consult FNA Tissue Biopsy Screening MRI (obtain prior approval from SMHW manager)	 Perform Ultrasound (if clinically appropriate) to quality client for BCCT OR If Ultrasound is not clinically appropriate or US result is Category 1-3; perform a Breast Consult AND FNA or Tissue Biopsy as clinically indicated. (Note: It is preferable to qualify client for BCCT services by obtaining abnormal Ultrasound results of 4 or 5 rather than SMHW reimbursement for a biopsy – but if necessary, biopsy is payable by SMHW)

Perform Follow-up per Guidelines as Listed Below:

Please Note: If clinician recommends other clinical protocol to be considered, please contact the SMHW RPC or the central office SMHW staff at toll-free 866-726-9926. The above are considered to be typical guidelines and not definitive practice standards appropriate for every situation. These guidelines address protocols that are reimbursable by the SMHW program. See provider manual for more specific information regarding covered services.

^{*} A <u>diagnostic mammogram</u> rather than a screening mammogram should be used if a mammogram is preferred following an abnormal CBE.

Guidelines for the Management of Women Who Have Suspicious for Cancer CBE and First Follow-up Test Is NOT a Mammogram

		(Must offer 1 or more clinically appropriate tests below)	Page 1 of 2
Ultrasound	Category 1 (Negative) or Category 2 (Benign)	Diagnostic Referral based on CBE result.	
	Category 3 (Probably Benign)	Clinician's discretion May proceed to Surgical Consult, FNA, or Biopsy within 60 days, May designate work-up complete and return to routine screening, May rescreen every 6 to 12 months for 1 to 2 years* May rescreen at shorter intervals if medically necessary *If there are more than two consecutive "probably benign" results, client must have follow-up with another type of diagnostic testing such as surgical consult, FNA or biopsy, or continue rescreening schedule.	
	Category 4 (Suspicious Abnormality) or Category 5 (Highly Suggestive of Malignancy)	specialist consult and tissue biopsy can be performed through the BCCT program. Perfor to Section 7 PCCT and complete and culprit form on page 10.16	r is positive for breast cancer, for the BCCT MO HealthNet treatment eligibility. See Section and submit form on page 10.17.
	Category 0 (Assessment Incomplete)	Compare to previous films, complete additional mammogram views, or perform Ultrasound	
.,	Category 1 (Negative) or Category 2 (Benign)	Work-up may be complete if another test result is not suspicious for cancer	
Mammogram (Mammogram is <u>NOT</u> the first test following an abnormal CBE)	Category 3 (Probably Benign)	Clinician's discretion to proceed to Ultrasound, Surgical Consult, FNA, screening MRI (prior approval obtained from SMHW manager), or Biopsy within 60 days or Designate work-up complete & may rescreen at 6-month intervals for the next 6-24 months* *If there are two consecutive "probably benign" results, client must have some other type of further diagnostic testing done such as surgical consult, FNA, or biopsy within 60 days of abnormal CBE result	
	Category 4 (Suspicious Abnormality) or Category 5 (Highly Suggestive of Malignancy)	 Must proceed to Ultrasound, Surgical consult, FNA, or Biopsy If Ultrasound result is a Category 4 or 5, complete and submit form on page 10.16 before proceeding these ultrasound results, clients will be eligible to receive any further diagnostic and treatment service program as well as health care for other medical issues that may occur. MO HealthNet requires prior a procedures, including ultrasound. Ed, please contact your RPC. The above are considered to be typical guidelines and not definitive proactive services. 	s through the MO HealthNet authorization for many

These guidelines are primarily to address protocols that are reimbursable by the SMHW program. See provider manual for more specific information regarding covered services.

Guidelines for the Management of Women Who Have Suspicious for Cancer CBE and First Follow-up Test Is NOT a Mammogram

	(Must offer 1 d	or more clinically appropriate tests below. Enter results on a purple breast form.) Page 2 of 2		
Specialist Consult	Category 1 (Negative) or Category 2 (Benign)	Work-up may be complete if another test result is not suspicious for cancer		
	Category 3 (Probably Benign)	 Clinician's discretion to complete additional work-up if another test result is not suspicious for cancer <u>OR</u> May designate work-up complete and may perform rescreen CBE within the next 6 -10 months 		
	Category 4 (Suspicious Abnormality) or Category 5 (Highly Suggestive of Malignancy)	Typically determination is made to perform a FNA or Biopsy within 60 days of abnormal CBE result		
	Negative	When clearly benign or negative, work-up may be complete		
	Indeterminate	Typically is followed by a surgical biopsy – or FNA may be repeated within 60 days of abnormal CBE result		
Fine Needle Aspiration	Suspicious for Malignancy	Typically is followed by a surgical biopsy within 60 days of abnormal CBE result		
Aspiration	Malignancy	 When cancer is clearly identified, refer to BCCT for treatment and report initial breast cancer treatment to RPC within 3 days of diagnosis Refer client to full BCCT by submitting BCCT MO HealthNet Application form, (page 10.17) if not submitted previously. 		
	Benign	 Work-up may be complete and/or clinician's discretion to perform rescreen of any abnormal Mammogram/Ultrasound results in 6-12 months for 1-2 years 		
Biopsy Pathology	Benign Atypical or Indeterminate	Refer to Specialist: Possible Excisional Biopsy per surgeon/radiologist recommendation		
Findings	Malignant or Ductal Carcinoma In Situ (DCIS)	 Refer to BCCT for treatment and report initial breast cancer treatment to RPC. Refer client to full BCCT by submitting BCCT MO HealthNet Application form, (page 10.17) if not submitted previously. 		

^{*}If Clinician has other clinical protocol to be considered, please contact the central office staff. The above are considered to be typical guidelines and not definitive practice standards for every situation. These guidelines are primarily to address protocols that are reimbursable by the SMHW program.

See provider manual for more specific information regarding covered services.

Diagnostic Breast Follow-up Algorithms

Page 1 of 3

		ULTRASOUND Follow-Up Enter results on a purple breast form		
Category 1 Negative	Category 2 Benign	Category 3 Probably Benign	Category 4 Suspicious Abnormality	Category 5 Highly Suggestive of Malignancy
Diagnostic Referral based on CBE resu			 Qualifies for BCCT PE (temporary eligibility) referral Tissue biopsy is typically performed through the BCCT/MO HealthNet program. Refer to Section 7. Please note: MO HealthNet prior authorization for procedures may be required. 	
		SPECIALIST CONSULT Follow-Up Enter results on a purple breast diagnostic form.		
Category 1 Negative	Category 2 Benign	Category 3 Probably Benign (Examples include: Symmetrical thickening/thickened tissue/nodularity palpated in the same location in both breast; irregularity or lumpiness that is not clinically suspicious)	Category 4 Suspicious Abnormality	Category 5 Highly Suggestive of Malignancy
Work-up may be complete if another test result is not suspicious for cancer		Clinician's discretion: May complete additional diagnostic work-up within 60 days, May designate work-up complete and return to routine screenings, or May designate work-up complete and may rescreen within the next 6-10 months.	Typically the determination is made to perform a Tissue Biopsy. If client is BCCT eligible prior to biopsy, MO HealthNet prior authorization for procedures may be required.	

Diagnostic Breast Follow-up Algorithms

Page 2 of 3

Diagnostic MAMMOGRAM Follow-Up				
Category 0 Assessment	Category 1 Negative	Category 3 Probably Benign	Category 4 Suspicious Abnormality	
Incomplete	or Category 2 Benign Examples include calcified fibroadenomas, multiple secretory calcifications, fat containing lesions (oil cysts), lipomas, galactoceles, mixed density hematomas and others.	Examples include non-calcified mass, focal asymmetry, cluster of round calcifications and others.	or Category 5 Highly Suggestive of Malignancy	
 Compare to previous films, Complete additional mammogram views, or Perform ultrasound as indicated. 	Clinician's discretion: Work-up may be complete if another test result is not suspicious for cancer. If complete, return to routine screening: Annual CBE/Mammogram/Breast Awareness Exception: If CBE result was abnormal, additional diagnostic work-up within 60 days of date of abnormal CBE is required. Work-up may include any or all of the following: Ultrasound, Breast Consult, and Tissue Biopsy. If benign and CBE result was not abnormal, may rescreen at 3 to 5 months and then further follow-up may be done based on surgeon's recommendations.	Clinician's discretion: May proceed to Ultrasound, Surgical Consult, FNA, or Biopsy within 60 days, or May designate work-up complete and return to routine screening, or May rescreen every 6 to 12 months for 1 to 2 years*, or If medically necessary, may rescreen at shorter intervals. If there are two consecutive "probably benign" results, clinician may follow-up with another type of diagnostic testing such as surgical consult, FNA or biopsy, or continue rescreening schedule.	Should be referred to a surgeon, and Must proceed to ANOTHER DIAGNOSTIC TEST such as Surgical Consult AND Tissue Biopsy. Tissue biopsy includes Incisional, Core Needle, Ultrasound Guided, Stereotactic, or Excisional.	

Diagnostic Breast Follow-up Algorithms

Page 3 of 3

FINE NEEDLE ASPIRATION Follow-Up

(Enter results on a purple breast diagnostic form)

Breast cyst aspiration procedure is only to be done if the cyst is complex or suspicious for breast cancer on imaging. It is NOT approved for payment if the cyst is benign on imaging and is being aspirated for pain management or reduction of a benign cyst.

Negative	Indeterminate	Suspicious for Malignancy or Malignancy
Work-up may be complete	Possible repeat or surgical biopsy per surgeon/radiologist recommendation	 If not already enrolled, enroll in BCCT If client is BCCT eligible <u>prior</u> to biopsy, MO HealthNet prior authorization for procedures may be required If breast cancer is diagnosed, remember to report to RPC date and type of first cancer treatment

BIOPSY Follow-Up

(Enter results on a purple breast diagnostic form)

Benign	Benign Atypical	Indeterminate	Suspicious for Malignancy or Malignancy
Diagnostic Mammogram/US in 6-12 months for 1-2 years	Possible Excisional Biopsy per surgeon/radiologist recommendation	Refer to specialist	 If not already enrolled, enroll in BCCT If client is BCCT eligible <u>prior</u> to biopsy, MO HealthNet prior authorization for procedures may be required If breast cancer is diagnosed, remember to report to RPC date and type of first cancer treatment

Purple Breast Form

All forms are specific for each grant year. When submitting an electronic or a paper form, use the version of the form that is dated correctly to correspond with the date of service. At the beginning of each grant year there are multiple versions of this form in MOHSAIC. Click on the correct version when entering electronic forms. If using paper forms, check for the year of the form in the lower left corner.

NOTE:

Breast Diagnosis and Treatment Form, also referred to as purple breast form, is to collect complete follow-up information for all clients with abnormal breast screening results.

Please order blank forms from SMHW by calling toll-free at 866-726-9926 or 573-522-2845.

- The blue screening form must accompany or precede the purple breast form. A SMHW or a non-SMHW provider must base the diagnostic service on an abnormal screening result.
- Information from the purple breast form is required by CDC and is crucial for statistical reports and studies. All information received is confidential.
- The information on the original form shall be entered electronically in the MOHSAIC system. All reported information shall be filed in the client's record.
- MOHSAIC electronic forms can be accessed at https://healthapps.dhss.mo.gov/smhw/.
- A copy of the purple breast form is located in Section 10 Forms or download a copy at: http://health.mo.gov/living/healthcondiseases/chronic/showmehealthywomen/forms.php
- If you have additional questions, please call the RPC for the provider area or toll-free 866-726-9926 or 573-522-2845 for general assistance with central office staff.
- If you have questions or concerns regarding specific issues with MOHSAIC, contact the ITSD Help Desk by telephone at 800-347-0887 or by e-mail at support@health.mo.gov.

Refer to Section 10, Forms Section or follow link to forms: http://health.mo.gov/living/healthcondiseases/chronic/showmehealthywomen/forms.php.

Alert Value Follow-Up

The MOHSAIC electronic reporting system has been programmed to produce lists of clients and the SMHW providers who reported abnormal, suspicious for cancer results. These lists are forwarded at least weekly to the RPCs. The RPCs check the MOHSAIC reporting system to determine if follow-up is reported timely. If no information is entered into MOHSAIC regarding the necessary follow-up, the RPC will contact the provider to ensure that follow-up has occurred and that it will be reported by the provider; or, if the provider or client is experiencing difficulty in completing the follow-up, the RPC will assist in contacting the client or in finding appropriate resources.

SMHW Providers Shall

- Implement some form of internal tracking and reminder system to ensure that SMHW clients who have
 abnormal breast test results suspicious for cancer receive further medical evaluation and treatment
 within 60 days. This assures scheduling follow-up visits and procedures are completed timely. In
 addition, client attendance for appropriate follow-up needs to be monitored. If there is a missed
 appointment, reschedule the appointment and assist with removing barriers such as transportation
 difficulties.
- Implement some form of internal tracking and reminder system to ensure that women who have
 abnormal cervical test results receive further medical evaluation and treatment within 90 days. This
 ensures that scheduling follow-up visits and procedures are completed timely. In addition, client
 attendance for appropriate follow-up needs to be monitored. If there is a missed appointment, reschedule
 the appointment and assist with removing barriers to care, such as transportation.
- Promptly notify the RPC when a client is referred to BCCT in order to ensure timely and complete followup, complete and accurate tracking and documentation as such. Please report additional information to the RPC who can enter the information onto forms as needed, such as treatment of cancers found.
- SMHW requires two documented attempts for client follow-up, if needed.
 - Direct telephone communication is the most effective contact method.
 - If unable to reach client by telephone, a letter should be sent indicating there is need for additional diagnostic testing or treatment. For legal purposes, providers are encouraged to use a certified letter.
 - If no response after the second attempt or the client refuses further diagnostics and/or treatments, notify the RPC.
 - Utilize a tracking system to ensure that clients show up for scheduled visits and receive the appropriate diagnostic or treatment services.
 - If clients do not keep follow-up appointments, implement attempts to reach the client for rescheduling the appointment by telephone or by mail within 30 days.
 - If the client is no longer reachable or attempts to contact the client fail, please inform the RPC for the provider area within **30 days**.

Abnormal Cervical Screening Results

Abnormal Cervical Screening Results6.1
Suspicious or Abnormal Cervical Results Determination of Screening Results Pending Abnormal Screening Results
Protocol for Rescreen
Pelvic Examination Pap Test
Specialist Consultation Guidelines
Specialist Consultation Reminder Not Considered a Specialist Consultation
Diagnostic Services Available
Pap Test Exceptions
Guidelines for Cervical Diagnostic Services
High-Risk Human Papillomavirus (HPV) Testing Cervical Conization
Yellow Cervical Form6.7
ASCCP Algorithms and 2020 Update Consensus Guidelines are located at http://www.asccp.org/
Alert Value Follow-up
SMHW providers shall Cervical situations that require follow-up within 90 days
O SHOW ME Vicality Women

Abnormal Cervical Screening Results

A mandatory component as a provider of the SMHW program is the responsibility for providing clinical case management of abnormal findings, as well as reporting the abnormal findings and the outcomes to the SMHW program on a timely basis.

The clinician, using current standards of practice and the established SMHW cervical cancer screening protocols, determines abnormal findings clinical case management type and frequency.

Providers must ensure the following

Suspicious or Abnormal Cervical Results

Clients with suspicious or abnormal cervical results will receive the necessary case management as determined by the clinician based on current standards of practice for rescreening, diagnosis and/or appropriate treatment, and clinicians will report data to SMHW.

CDC Standard

60 days or less from a suspicious for cancer screening result to diagnosis. 90 days or less from time of CIN 2 or CIN 3/CIS diagnosis to start of treatment.

Pap Test Exceptions:

An exception to extend the diagnostic follow-up interval to 90 days for women with an abnormal pap test result of ASC-H or worse, including 'presumed abnormal' is allowable.

An exception in counting the number of days for women referred into the program for diagnostic evaluation after a received abnormal pap test result from a provider <u>outside</u> of the SMHW program is allowable. In this instance, the interval shall begin on the referral date for diagnostic testing rather than the date of the initial pap test.

Determination of Screening Results

Suspicious screening results will be determined as normal or abnormal through short-term rescreen or diagnostic procedures.

- Notify and explain to the client with abnormal findings the need for any additional diagnostic service(s).
- SMHW requires two documented attempts for client follow-up, if needed.
 - Direct telephone communication has been shown to be the most effective contact.

- If unable to reach client by telephone, a letter should be sent indicating there is need for additional diagnostic testing or treatment. For legal purposes, providers are encouraged to use a certified letter.
- If no response is received after the second attempt or the client refuses further diagnostics and/or treatments, notify your RPC.

Pending Abnormal Screening Results

If abnormal screening results are pending for ten (10) months or longer, client eligibility must be checked and a new annual screening test must be performed prior to the initiation of further diagnostic studies. SMHW will only reimburse for additional diagnostic services if the client continues to meet SMHW eligibility guidelines.

- For clients referred to direct billing diagnostic providers (Section 9 Billing Guidelines), continue to track that the client receives/attends the scheduled appointments.
- For a client diagnosed with cancer, SMHW providers must provide the following information to SMHW:
 - Date treatment started
 - Type of treatment initiated
 - Name of the facility where treatment occurred

Protocol for Rescreen

Follow these guidelines in the instances where performance of a rescreen is needed.

Pelvic Examination

• A repeat pelvic exam is optional as a rescreen in less than ten (10) months if the previous abnormal pelvic exam reported to SMHW was not within normal limits due to an abnormal <u>cervical</u> finding.

Pap Test

- Reimbursement occurs only when pap test is in accordance with the ASCCP guidelines.
- SMHW does reimburse for HPV DNA genotyping.
- HPV DNA genotyping is not considered the same as HPV testing.
- HPV DNA specific genotyping 16/18 is an ASCCP option that recommends being done with normal pap/HPV positive results to determine if further diagnostic follow-up is needed.
- Or, the provider can choose not to do genotyping and co-test (pap/HPV) in one year.
- Both are acceptable ASCCP options.

Reporting Directions:

Report a rescreen pap test on a blue screening form (pages 10.10) with the category "Rescreen" marked in the "Visit type" box.

- See link to ASCCP Guidelines on page 6.7.
- If rescreen results are suspicious for cancer, proceed with diagnostic procedures as indicated by ASCCP guidelines.

Specialist Consultation Guidelines

A SMHW client may be referred for a specialist consultation following abnormal screening and/or diagnostic test results. Refer clients requiring a specialist consultation to a surgeon, OB/GYN specializing in breast and/or cervical health, or a physician or nurse practitioner who works for a cancer diagnostic or treatment center.

Limitation:

Reimbursement for cervical specialist consultation following abnormal results is limited to one cervical referral per client per contract year.

Specialist Consultation Reminder

Retain a copy of the consult in the client's chart. Do not submit a copy to SMHW.

Not Considered a Specialist Consultation

- Referral to the same screening examiner is not a specialist consultation.
- Referral for the standard/routine follow-up, such as a colposcopy by a nurse practitioner for a LSIL, is not
 eligible for a specialist consultation. (The appropriate follow-up is known; therefore, referral for a
 specialist consultation to determine the management of the problem is not required).

Limitation:

If the provider requests reimbursement for a specialist consult on the same day as the colposcopy, information **must be** included in the comments as to why the specialist consult is being billed (i.e., a "cervical wash" was done to verify pap test results prior to proceeding to colposcopy). SMHW will not reimburse for the specialist consult if a rationale is not included and no additional procedure is completed.

Diagnostic Services Available

ATTENTION:

Complete cervical diagnostic services within 60 days unless there is an exception.

Pap Test Exceptions

- An allowable exception is to extend the diagnostic follow-up interval to 90 days for women with an abnormal pap test result of ASC-H or worse, including "Presumed abnormal."
- An exception in counting the number of days has been made for women referred into the program for diagnostic evaluation after an abnormal pap test result is received from a non-SMHW provider. In this instance, the interval shall begin on the referral date for diagnostic testing rather than the date of the initial pap test.

LIMITATIONS FOR DIAGNOSTIC SERVICES

Cervical Cancer

- Colposcopy without biopsy
- Colposcopy with cervical biopsy
- Colposcopy with endocervical curettage (ECC)
- Cervical biopsy (polypectomy)
- Endocervical Curettage (ECC)
- Endometrial biopsy

(NOTE: Colposcopy with endometrial biopsy can be reimbursed only if cervical and/or endocervical biopsies are performed during the colposcopy.)

- Conization may be done by:
 - Cold knife (refer client to BCCT/MO HealthNet if done as treatment)
 - LEEP will only be reimbursed by SMHW if being performed for continued diagnostic work-up (refer client to BCCT/MO HealthNet/ Medicaid if done as treatment)
- Specialist consultation

Payment: Paid services are at an outpatient rate only. SMHW program reimburses for services as indicated in Section 9 – Billing Guidelines.

Protocols: The frequency and type of services is at the discretion of the clinician based on current standards of practice and on the protocols included from ASCCP algorithms http://www.asccp.org.

Guidelines for Cervical Diagnostic Services

If the repeat pap test is more than ten (10) months from the previous pap test, then the pap test should be part of a complete annual screening.

NOTE:

SMHW will not reimburse for more than two consecutive abnormal pap tests with a result of LSIL or ASC-US without further diagnostic testing, as recommended by the SMHW Advisory Board in July 2001.

High-Risk Human Papillomavirus (HPV) Testing

- For five (5) years, the SMHW program will not reimburse for additional HPV testing if the initial pap result is negative.
- If the HPV is positive, refer to the ASCCP guidelines.

Cervical Conization

- Conization by LEEP, or cold knife, is usually considered to be treatment and is covered by MO HealthNet BCCT. If colposcopy is inadequate, or the client is not eligible for BCCT, please call your RPC for additional instructions to meet the client's need.
- All LEEP and cold knife procedures qualify for presumptive eligibility for Presumptive Eligibility BCCT
 with a pap test result of, HSIL, AGC or worse followed by a colposcopy or tissue pathology, even if the
 tissue pathology is benign/CIN I.

NOTE:

SMHW funding pays for the colposcopy; LEEP and cold knife are typically paid by BCCT funding.

Algorithms for Cervical Diagnostic Services are available for viewing at http://www.asccp.org/Default.aspx.

Yellow Cervical Form

All forms are specific for each grant year. When submitting an electronic or a paper form, use the version of the form that is dated correctly and corresponds with the date of service. At the beginning of each grant year there are multiple versions of this form in MOHSAIC. Click on the correct version when entering electronic forms. If using paper forms, check for the year of the form in the lower left corner.

NOTE:

The Cervical Diagnosis and Treatment Form (yellow cervical form – pages 10.14-.15) is to collect complete follow-up information for all clients with abnormal cervical screening results. Please order blank forms from SMHW by calling toll-free at 866-726-9926 or 573-522-2845.

- A blue screening form must accompany or precede the yellow cervical form. A SMHW or a non-SMHW
 provider must base the diagnostic service on an abnormal screening result.
- The CDC requires information from the yellow cervical form and is crucial for statistical reports and studies. Keep all information confidential.
- Enter the information on the original form into the MOHSAIC system. File all reported information in the client's record.
- Access MOHSAIC electronic forms at https://healthapps.dhss.mo.gov/smhw/.
- A copy of the yellow cervical form is located on pages 10.14-.15 or download a copy at: http://health.mo.gov/living/healthcondiseases/chronic/showmehealthywomen/forms.php
- If you have questions or concerns regarding specific issues with MOHSAIC, contact the ITSD Help Desk by telephone at 800-347-0887 or by e-mail at support@health.mo.gov.

ASCCP Algorithms are available online in PDF format in English and Spanish. Visit http://www.asccp.org/screening-guidelines.

The 2020 Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors are available online at http://www.asccp.org/guidelines. This is an additional reference tool when the ASCCP Algorithms directs you to "Manage per ASCCP Guidelines."



Alert Value Follow-up

The MOHSAIC electronic reporting system produces lists of clients and the SMHW providers who reported abnormal, suspicious for cancer results. The RPCs receive these lists at least weekly. The RPCs check the MOHSAIC reporting system to determine if follow-up is timely. If no information is entered into MOHSAIC regarding the necessary follow-up, the RPC will contact the provider to ensure that follow-up has occurred and that it will be reported by the provider; or, if the provider or client is experiencing difficulty in completing the follow-up, the RPC will assist in contacting the client or in finding appropriate resources.

SMHW providers shall

- Implement some form of internal tracking and reminder system to ensure that SMHW clients who have abnormal breast test results suspicious for cancer receive further medical evaluation and treatment within 60 days. This ensures that scheduling follow-up visits and procedures are complete and timely. In addition, client attendance for appropriate follow-up needs to be monitored. If there is a missed appointment, reschedule the appointment and assist with removing barriers such as transportation difficulties.
- Implement some form of internal tracking and reminder system to ensure that women who have
 abnormal cervical test results receive further medical evaluation and treatment within 90 days. This
 ensures that scheduling follow-up visits and procedures are complete and timely. In addition, monitor
 client attendance for appropriate follow-up. If there is a missed appointment, reschedule the appointment
 and assist with removing barriers such as transportation.
- Promptly notify the RPC via e-mail, telephone, or fax when a client is referred to Presumptive or Full BCCT in order to ensure timely and complete follow-up, complete and accurate tracking and documentation as such. Please report additional information to the RPC who can enter the information as needed, such as treatment of cancers found.
- SMHW requires two documented attempts for client follow-up.
 - Direct telephone communication is the most effective contact method.
 - If unable to reach client by telephone, a letter must be sent indicating there is need for additional diagnostic testing or treatment. For legal purposes, providers are encouraged to use a certified letter.
 - If no response after the second attempt or the client refuses further diagnostics and/or treatments, notify your RPC.
 - Utilize a tracking system to ensure that clients show up for scheduled visits and receive the appropriate diagnostic or treatment services.
 - If clients do not keep follow-up appointments, implement attempts to reach the client for rescheduling the appointment by telephone or by mail within 30 days.
 - If the client is no longer reachable or attempts to contact the client fail, please inform the RPC for that provider's area within **30 days**.

Cervical situations that require follow-up within 90 days include:

- "Diagnostic work-up planned" is marked on any of the reporting forms for abnormal <u>cervical</u> findings.
- "Referred for diagnostic testing" is marked on the blue screening form or the yellow <u>cervical</u> form for abnormal cervical findings.
- Yellow cervical forms that are marked with "abnormal suspicious for cancer results", or are marked
 as "positive for cervical cancer", require the "Status of Final Diagnosis section B" to be completed.
 Any diagnostic result on the diagnostic form that has an "*" in Section B requires a Final Diagnosis be
 marked in Section C.


Final Diagnostic Results in Section B or C that indicate malignancy need to have Section D Cervical Treatment completed with the status of treatment, type of treatment, treatment facility, and date treatment started inserted.

NOTE:

If clinician recommends other clinical protocol to be considered, please contact the SMHW RPC or the central office SMHW staff toll-free at 866-726-9926. ASCCP guidelines are considered to be typical guidelines and not definitive practice standards appropriate for every situation.

MO HealthNet BCCT Act

MO HealthNet Breast and Cervical Cancer Treatment Act	7.1
Basic BCCT Act Eligibility Guidelines	7.2
BCCT Temporary MO HealthNet Authorization Letter (Presumptive Eligibility) BCCT MO HealthNet Application (Extended BCCT coverage) Extending MO HealthNet Treatment Eligibility beyond the presumptive period Instructions to Transfer a client from another state BCCT Program	
MO HealthNet Treatment Services Covered	7.6
Covered Services	
SMHW Provider Responsibilities	7.7
SMHW Regional Program Coordinator BCCT Responsibilities	7.8
Family Support Division Responsibilities	7.9



MO HealthNet Breast and Cervical Cancer Treatment Act



Beginning in October 2000, signed federal legislation allows funded programs in the NBCCEDP to participate in the MO HealthNet BCCT Act. In July 2001, Governor Bob Holden signed legislation authorizing matching funds for Missouri to participate in the Missouri Medicaid program, now known as the MO HealthNet program, effective August 28, 2001. (State Statute RSMo Section 208.151 [25] is available at https://revisor.mo.gov/main/OneSection.aspx?section=208.151&bid=47992&hl=208.151.%u2044.)

Most women who receive a SMHW paid screening and/or diagnostic service, and are found to need treatment for breast and/or cervical cancer or a precancerous condition, may be eligible for BCCT in Missouri.

Once a client is enrolled into BCCT, they are qualified for full MO HealthNet benefits, as well as medical services for cancer care. Please note there is also transportation assistance available for the client enrolled in BCCT. Eligibility criteria for MO HealthNet are based on need. Details for BCCT are at http://dss.mo.gov/mhd/general/pages/about.htm.

Basic BCCT Act Eligibility Guidelines

Those who are eligible for the BCCT program **must be enrolled** in the SMHW program prior to tissue biopsy and have screening or diagnostic test paid by SMHW.

- A Missouri resident.
- A female.
- Under the age 65.
- Social Security Number; and
- Citizenship or Qualified Alien Status.
- Diagnosed with breast and/or cervical cancer or cervical precancerous condition through SMHW,
- Need treatment for breast and/or cervical cancers or precancerous conditions as listed below.

NOTE:

Routine monitoring by a physician does not qualify as treatment.

BREAST CANCER DIAGNOSIS

Requires a tissue biopsy diagnosed by a pathologist with one of the following

- Ultrasound result of "suspicious abnormality" (BI-RADS category 4) or "highly suggestive of malignancy" (BI-RADS category 5)
- Carcinoma in situ
- Invasive breast cancer

NOTE: If there is not a breast cancer diagnosis after a performed biopsy, the client will no longer be eligible for BCCT and will return to SMHW.

CERVICAL CANCER DIAGNOSIS

Requires a tissue biopsy diagnosed by a pathologist with one of the following to be eligible for BCCT:

- CIN 2/moderate dysplasia
- CIN 3/severe dysplasia
- CIS or AIS
- Invasive cancer

Note: Clients with a pap result of High-grade Squamous Intraepithelial Lesion (HSIL), Squamous Cell Cancer, or Atypical Glandular Cells (AGC) are eligible for Presumptive Eligibility, and requires a colposcopy tissue biopsy. Bill the colposcopy to SMHW for reimbursement.

BCCT Temporary MO HealthNet Authorization Letter Presumptive Eligibility

The BCCT Temporary MO HealthNet Authorization letter (page 10.16 or download at: http://www.health.mo.gov/living/healthcondiseases/chronic/showmehealthywomen/forms.php), also referred to as presumptive eligibility (PE), provides temporary and immediate full MO HealthNet benefits. Clients must meet basic BCCT eligibility guidelines (above) to qualify for PE.

MO HealthNet determines the date PE begins. Typically, PE coverage begins on the date of the procedure or diagnostic test that indicate either a precancerous condition or cancer of the breast and/or cervix by tissue pathology that determined the client is eligible for BCCT (pages 7.2-.3).

In order for a SMHW client to obtain PE, e-mail the completed BCCT Temporary MO HealthNet Application (page 10.16) to the MO HealthNet Service Center, Greene County Family Support Division (FSD) (page 7.4). The client receives a copy of the BCCT Temporary MO HealthNet Authorization Letter. An additional copy is retained for the client's record. Notify the RPC of eligible clients. This procedure allows for minimal delays for women in receiving the necessary treatment indicated.

Submit the previously noted documentation for MO HealthNet to determine the date PE begins. PE coverage continues until the earlier of the following dates:

 The last day of the month following the PE decision, if the client does not submit an application for regular BCCT MO HealthNet coverage (page 10.17)

OR

The date the client is determined ineligible or eligible for BCCT MO HealthNet.

BCCT MO HealthNet Application (Extended BCCT coverage) Extending MO HealthNet Treatment Eligibility beyond the presumptive period

For evaluation of continued MO HealthNet coverage, submit the (extended) BCCT MO HealthNet Application form for medical assistance to the FSD's MO HealthNet Service Center at time of cancer diagnosis.

The client must meet the basic BCCT guidelines (page 7.2) and:

- Have a Social Security number,
- Be uninsured or underinsured for breast or cervical cancer treatment.
- Show proof of citizenship/alien status, and
- Submit a completed, signed (extended) BCCT MO HealthNet Application form to the MO HealthNet Service Center via Greene County FSD.

MO HealthNet Service Center

FSD Customer Relations Unit 101 Park Central Square Springfield, MO 65806

E-mail:

Greene.CoDFSIM@dss.mo.gov

Fax: 417-895-6098

Alternate Fax: 417-895-5790

It is important for providers to assist clients in completing and e-mailing the Missouri BCCT MO HealthNet Application for medical assistance as soon as possible (refer to page 10.17). SMHW providers e-mail a copy of the application/temps/etc. to Greene.CoDFSIM@dss.mo.gov. The forms will then be forwarded to the appropriate person. E-mailing the forms are preferable, if unable to utilize e-mail, please fax the form to 417-895-6098 or 417-895-5790 and mail the paper copies to 101 Park Central Square, Springfield, MO 65806. Please see the address listed to the right. Application related questions can be addressed by calling 888-275-5908.

Upon review of the application, and if the client is determined eligible for BCCT MO HealthNet coverage, full MO HealthNet benefits will continue until the treating physician determines treatment for the breast or cervical cancer is complete.

Copies of the BCCT forms are located in Section 10 or downloadable at:

http://www.health.mo.gov/living/healthcondiseases/chronic/showmehealthywomen/forms.php

NOTE:

Routine monitoring by a physician does not qualify as treatment.

Clients determined ineligible for BCCT medical assistance may receive, with prior authorization from SMHW, a cervical conization by LEEP or cold knife.

Instructions to Transfer a client from another state BCCT Program:

- The client should complete the Full BCCT MO HealthNet Application Form (page 10.17)
- Complete the Certification of Need for Treatment Form (pages 10.18-.19)
- Provide the clinic's name and telephone number as contact information to MO HealthNet.
 Information is used to verify enrollment in the Breast and Cervical Program of that state.
- E-mail all documentation to MO HealthNet Service Center at Greene.CoDFSIM@dss.mo.gov.

OR

• Fax, if necessary, to 417-895-6098 or 417-895-5790, and mail all paper copies to:

FSD Customer Relations Unit 101 Park Central Square Springfield, MO 65806

MO HealthNet Treatment Services Covered

Covered Services

- Cervical conization
- LEEP or cold knife if a client received a pap test diagnosis of HSIL or worse, or colposcopy test diagnosis of moderate dysplasia or worse
- Incisional and/or Excisional breast biopsy if ultrasound result is category 4 (suspicious abnormality) or category 5 (highly suggestive of malignancy)
- Incisional and/or Excisional breast biopsy if fine needle aspiration, core needle, or stereotactic biopsy result is malignant
- Breast Cancer Treatment is indicated including chemotherapy, surgery, radiation, and breast reconstruction
- All other MO HealthNet covered medical services, including services not related to the breast or cervical cancer

NOTE:

MO HealthNet services may be subject to prior authorization procedures and limitations. Full MO HealthNet benefits will continue until the treating physician determines treatment for cancer is complete.

SMHW Provider Responsibilities

- Notify client of diagnosis and recommended follow-up (preferably in person). If a specialist is treating the client, ensure that the client received the diagnosis and recommended follow-up.
- Explain the BCCT program and application processes to the client.
- Determine client's presumptive eligibility; complete the BCCT Temporary MO HealthNet Authorization letter (page 10.16).
- E-mail the letter to the FSD's MO HealthNet Service Center within five days of BCCT qualifying test results or diagnosis.
- When MO HealthNet coverage is needed beyond the temporary PE period, assist the client in completing and signing the (extended) Missouri BCCT MO HealthNet Application (page 10.17) or download at:

http://www.health.mo.gov/living/healthcondiseases/chronic/showmehealthywomen/forms.php. Ensure:

- The client receives a copy of the completed application form.
- A copy of the completed form is retained in the client's medical record.
- Verify dates included on eligibility documents are correct before sending to MO HealthNet Service Center.
- Submit the application to the MO HealthNet Service Center for application evaluation as soon as possible after cancer diagnosis.
- FSD's MO HealthNet Service Center shall evaluate the application of each client for other MO HealthNet programs the client may be eligible to receive.
- Notify the SMHW RPC of clients who become eligible for the BCCT MO HealthNet Treatment program. The RPC will track the treatment provider's name, date that the client's treatment regimen started and the type of treatment initiated.
- Ensure entry of the client's history and abnormal screening forms into the MOHSAIC reporting system prior to submitting the BCCT application forms. Utilize the Department Client Number (DCN) assigned to the client when entering the SMHW green history form (page 10.8-.9) into MOHSAIC.
 - This number serves as the MO HealthNet client number for the temporary PE letter and the full BCCT application for benefits.
- Submit date treatment was initiated, type of treatment that was started, and name of treatment
 provider by completing Section D on the purple breast form, and/or Section D on the yellow cervical
 form.
- Check the "yes" box in Section A of the SMHW purple breast or yellow cervical form(s) when BCCT services initiated.

NOTE:

A FSD Certification of Need for Treatment Form (BCC-2, page 10.18) may be given to a treating clinician by the patient for additional information. This form is necessary for the continued coverage of the patient by the BCCT program.

SMHW Regional Program Coordinator BCCT Responsibilities

Regional Program Coordinators will:

- Check with client to assess status of the client's cancer treatment upon request from FSD's MO
 HealthNet.
- Assure treatment initiated and documented in MOHSAIC.
- Inform FSDs MO HealthNet of the following:
- Follow-up biopsy result that does not document cancer diagnosis. In these cases, typically the PE BCCT has been issued for results of ultrasound category 4, category 5, or for HGSIL Pap smear result and the biopsy obtained during the PE timeframe is benign. No treatment is needed, so the extended full BCCT application does not need to be approved,
- Continue to track client's BCCT treatment status and plan of care for breast and/or cervical cancer.
 MO HealthNet eligibility ends when treatment for the breast and/or cervical cancer is completed.
 After the MO HealthNet eligibility end date is documented, SMHW annual services can be offered to the client if all areas of eligibility are met,
- Date client gains insurance coverage,
- Date client moves out of state,
- Date client is determined lost to follow-up after documented attempts by the provider and RPC to inform and assist client with barriers to care, or
- Date client refuses care (signed waiver form or certified letter returned).



Family Support Division Responsibilities

- Enter BCCT Temporary MO HealthNet Authorization letter for presumptive eligibility in the FSD system upon receipt from SMHW provider.
- Enter Missouri BCCT MO HealthNet Application for medical assistance into the FSD system upon receipt from client or the SMHW provider.
- Determine MO HealthNet eligibility for breast and/or cervical cancer treatment and other MO HealthNet programs.
- Report eligibility determination result to the client and the appropriate SMHW provider or RPC.
- After establishment of MO HealthNet approvals for breast and/or cervical treatment, track client's need for continued treatment and continued enrollment in MO HealthNet.
- Request the treating physician's plan of care for breast and/or cervical cancer treatment.
- Utilize SMHW RPC for assistance, if needed.
- Terminate breast and/or cervical cancer treatment eligibility after treatment is completed.
- Notify client and SMHW provider or RPC of termination of breast and/or cervical cancer MO HealthNet treatment eligibility.
- Provide tracking for initial treatment type and date to the SMHW RPC.


Direct questions concerning MO HealthNet treatment for SMHW to SMHW toll-free 866-726-9926 or 573-522-2845

OR

State of Missouri FSD MO HealthNet Service Center Toll-free 888-275-5908 http://dss.mo.gov/fsd/

Performance Indicators

Performance Indicators	3.1
Quality Assurance	3.2
Quality Assurance Follow-Up	
Quality Assurance Provider Expectations	
Client Rights	
Intake and Eligibility Guidelines	
Screening and Diagnostic Protocols	
Clinic Management	
SMHW Quality Assurance Form	3.5



Performance Indicators

The CDC evaluates the SMHW program's ability to meet established core program performance indicators. Performance indicators are evaluated from the Minimum Data Elements (MDEs) submitted by DHSS every October and April. MDEs are standardized data elements that provide consistent information on patient demographics, screening results, education, diagnostic procedures, and treatment information. Collect MDEs on women screened and/or diagnosed with program funds. Obtain MDE data from the history, assessment, screening, and diagnostic reports entered into the MOHSAIC system.

	SMHW CORE PROGRAM PERFORMANCE INDICATORS									
Indicator Type	Program Performance Indicator									
Screening	Initial program pap tests never screened	≥ 20%								
Screening	Screening mammograms provided to women over age 50	≥ 75%								
	Abnormal screening results with complete follow-up	≥ 90%								
Cervical	Abnormal pap screening results (ASC-H or worse, including 'presumed abnormal'); time from screening to diagnoses > 90 days	≤ 25%								
Cancer Diagnostic	Treatment started for diagnosis of high-grade squamous intraepithelial lesion (HSIL), cervical intraepithelial neoplasia (CIN) CIN 2, CIN 3, carcinoma in situ (CIS), Invasive	≥ 90%								
Indicators	HSIL, CIN 2, CIN 3, CIS; time from diagnosis to treatment > 90 days	≤ 20%								
	Invasive carcinoma; time from diagnosis to treatment > 60 days	≤ 20%								
	Abnormal screening results with complete follow-up	≥ 90%								
Breast Cancer Diagnostic	Abnormal screening results of clinical breast exam (CBE), mammogram or ultrasound; time from screening to diagnosis > 60 days	≤ 25%								
Indicators	Treatment started for breast cancer	≥ 90%								
	Breast cancer; time from diagnosis to treatment > 60 days	≤ 20%								

Quality Assurance

The goal of the Quality Assurance (QA) program component is to assure that appropriate services are provided to each client and that program funds are utilized as required by program protocols. QA activities ensure high-quality medical standards of care are provided to women receiving SMHW and WISEWOMAN screenings, diagnostic and education services, as well as referrals for treatment when appropriate.

DHSS monitors and evaluates the quality and appropriateness of client care using the following QA activities:

- Incorporating data edits in the MOHSAIC electronic reporting system that limit the reporting of inappropriate and inaccurate client service records.
- Reviewing electronically submitted client service reports for compliance to standards of care prior to approval for reimbursement.
- Tracking alert values (abnormal testing results) to assure clients' receive appropriate diagnostic services and access to treatment, if needed.
- Performing initial on-site QA monitoring at each new SMHW and WISEWOMAN provider six months after first
 client is served and every two years thereafter. Scheduled QA monitoring occurs at any time deemed
 necessary by DHSS staff because of questionable reports (page 8.5).
- Providing training and technical assistance to providers to improve quality of care based on results of QA monitoring.
- Evaluating client and provider expectations.

Quality Assurance Follow-up

At the time of the provider's on-site review, technical assistance is provided by the RPC to clarify or demonstrate any points of confusion. After the on-site review, follow up with a post-review letter describing any areas needing improvement. Follow-up may be conducted to review success in instituting the recommended improvements. If the RPC determines a provider has consistently not met the program clinical standards, the provider is asked to complete a corrective action plan. Typically, the RPC conducts another review in six (6) months to ensure implementation of the corrective plan and the provider is working to resolve the problem.

Quality Assurance Provider Expectations

QA monitoring will monitor providers' compliance with the following expectations:

Client Rights

- Privacy
- Confidentiality
- Access to test results
- Follow-up of medical problems through referrals, diagnosis and treatment
- Client will not be held financially responsible if identified as a SMHW client
- Access to an interpreter
- Treatment per Civil Rights Act
- Treatment per Americans with Disabilities Act

Intake and Eligibility Guidelines

- Staff knowledge of SMHW/WISEWOMAN eligibility guidelines
- Procedure to screen and identify clients
- Annual review of clients for continued eligibility

Screening and Diagnostic Protocols

- Screening includes pelvic exam, pap test, CBE, and mammogram, if appropriate
- Standards and protocols for follow-up
- Procedure to track clients with abnormal results, including:
 - Name of client
 - Test
 - Date test completed or missed appointments rescheduled
 - Results and that client is notified of results
 - Referrals including tracking that appointments were kept or rescheduled
 - Follow-up visit dates, if needed
 - Documentation of complete Plan of Care/Treatment to include facility, treatment start dates and treatment type
 - Disposition of client status regarding follow-up, refusals of treatment or diagnostic testing recommended. Report to the RPC problems with missed appointments, lost to follow-up or refusals, in a timely manner

Clinic Management


- Staff is trained and familiar with provider guidelines
- Policy and procedures are in place for billing and filing forms
- Procedure to track amount of program funds is in place
- Maintain professionally licensed or certified staff to perform program activities
- Notify SMHW Central Office including RPC of staffing changes promptly regarding need for provider or rescinding clinic staff MOHSAIC access and to schedule SMHW trainings for new hires
- Track clients who receive screening and diagnostic results to provide complete case management from the initiation of care to the end of the plan of care
- If missed appointments or refusals of follow-up recommendations occur, make attempts to contact the client to reschedule and let the RPC know about situations regarding missed or refused follow-up
- The facility is clean with appropriate space for screening
- There is an in-house plan for quality checks at regular intervals
- Provide Navigation Services for women who have not been screened.
 - A minimum of two documented client visits, and
 - A completed navigation form in the record is required.



		SMHW/	WV	V QI	UA.	LI	ГҮ	A	SSI	UR	AN	(C)	ΕF	OI	RΜ	[
rovider Nan	ne:				QΑ	Rev	iew	er:											D	ate:				
							ı Ne	New provider 2 year biennial m					al m	onite	oring	g 🗓]		Re	-mo	nito			
Mammography unit name:									logy	Lat	nar	ne:												
Professional	staff name and ti	tle of those conducting sci	reenii	ngs:																				
Vame/Title:								Nan	ie/T	it1e:														
Vame/Title:							_	Nan																
T here are qu Yes 🔲 No		W trained staff for all ph	iases	of ser	vice	:				vide No		te ha	asao	lea	n an	d in	viti	ng e	nvir	onn	ıent	:		
T here is an I Yes 🔲 No		am for SMHW/WW serv	ices:					SMI Yes	HW.	/WV No	V m	anu	al av	aila	ble	eith	er ha	ard	cop	y or	on l	ine:		
MHW/WW Yes No	materials are pro	ominently displayed:								in pl No		to a	ssur	e fo	llow	-up	of a	bno	rma	l an	d al	ert v	valu	es:
Charts requ		Charts available:		СНА	RT N	MON	ITO	RING	RE	SULT	rs													
Jse: X= Do				Declin														-	Leu	les.		les.	Leu	
	Criter	ia Monitored	20 TOU'S	Charts complete	Chart	Chart 2	Chart 3	Chart 4	Chart 5	Chart 6	Chart 7	Chart 8									Chart 17			
		ted once while SMHW client)	50																					
	Copies of proof of	income updated annually	50																					
Eligibility	ligibility SMHW/WW Eligibility Agreement For signed annually	bility Agreement Form	50																					
	History form (gree	en) updated annually	50																					
	Physical exam = st	sbmitted information	80										Н											
L	Mammogram sche		80					\vdash					\vdash											
	Clients with diseas	se level blood pressure referrals for medical	100																					
		ual submitted results	80																					
	Client notified of S		80																					
		t client notified of WW r results in writing and	80																					
	Abnormal and alert results for SMHW and WW receive appropriate follow-up and referral		80																					
- 1	Procedures and rest		80																					
	SMHW/WW equal	information in chart																						

Billing Guidelines

Billing Guidelines	9.1
Provider Reimbursement Guidelines Reasons for Denial Providers will not receive reimbursement under the following circumstar	nces
Insurance Guidelines	9.3
Administrative Referral Fee	9.4
Direct Billing Diagnostic Providers	9.5
Mammography Van Billing Guidelines	9.5
Screening/Referring Provider Responsibilities	9.6
Direct Billing Diagnostic Provider Responsibilities	9.6
Breast & Cervical Reimbursement Rates by CPT Codes	9.7



Billing Guidelines

The billing guidelines for the DHSS SMHW and providers outlined in this section are effective June 30, 2021.

ATTENTION:

Providers are responsible for tracking their funding amounts. When 80 percent of the provider total for SMHW funds is expended, contact the SMHW office to request an amendment to increase funding.

Fax Request To: 573-522-3023

E-mail To: SMHW Manager

Provider Reimbursement Guidelines

The guidelines for provider reimbursement are in accordance with the Breast and Cervical Cancer Mortality Prevention Act of 1990, Public Law 101-354. Congress amended the NBCCEDP Public Law 10-354 in 1993 to create the WISEWOMAN Program. The conditions and requirements are:

- DHSS/SMHW is the payer of last resort,
- DHSS reimbursements are considered payment in full,
- Service providers and their subcontractors shall not charge the client for any screening/diagnostic services reimbursable by DHSS,
- DHSS clients shall not be charged any administrative fees,
- When services other than the breast and cervical cancer screenings/diagnostics are performed, and/or the WISEWOMAN cardiovascular risk assessment, documentation shall be provided that verifies the client was notified in advance of these services and their cost, and
- DHSS will cover only outpatient services.

Reasons for Denial

Resubmission for denied service will only be considered one time. Submit questions pertaining to client's data reporting form for service denied/adjusted to the DHSS by telephone toll-free at 866-726-9926 or 573-522-2845, or fax to 573-522-3023. Denial will be explained or reconsidered.

No further resubmission will be accepted after the second denial.

Providers will not receive reimbursement under the following circumstances:

- Services are provided to ineligible women
- Standards outlined in the Provider Manual as stated in Sections 4, 5 and 6 are not met Examples:
 - Rescreen CBE after diagnostic work-up will not be reimbursed unless the original screening CBE was abnormal.
 - Rescreen pap test does not follow ASCCP guidelines.
- Breast and/or cervical screening services are incomplete
- Mammography, ultrasound and/or pap test results are reported as unsatisfactory. In the case of unsatisfactory results, the test must be repeated and the results reported to SMHW
- Required client and completed reporting forms are not submitted to SMHW within 90 days of service, with the exception of filing with client's insurance, which must be submitted within 30 days from receipt of the Explanation of Benefits (EOB)
- If information is submitted after the closing date for grant year, it cannot be reimbursed by SMHW/WISEWOMAN or billed to client

Insurance Guidelines

- If the client has insurance, the provider shall first bill the client's insurance company for services received.
- Women who meet the SMHW guidelines and have private insurance or enrolled in PPOs, but who are financially unable to pay the deductible or co-payment, are eligible for SMHW.
- The client's insurance must be billed first; then include the insurance payment amount made to the facility for the covered procedures in the "Comments" section on reporting forms when billing DHSS. SMHW will only reimburse up to the total amount allowed for the procedure per program guidelines. The total amount allowed and reimbursed by SMHW for each CPT includes any payments received from insurance, not in addition to insurance payments.
- In MOHSAIC, under comments, please indicate what insurance provider paid for each procedure in detail by SMHW Approved CPT Code and descriptive line item. For example, \$50.00 for pathology (CPT 88305), \$40.00 for mammogram, (CPT 77067) and \$250 for percutaneous breast biopsy with stereotactic guidance (CPT 19081). Show Me Healthy Women procedures will only reimburse at the contracted program amount which is based on current MEDICARE reimbursement rates (Missouri 01).
- Provider must retain a copy of documentation of the EOB, deductibles or co-payment requirements in the client's chart along with a copy of the client's insurance card. It is the responsibility of the provider to keep a copy of the insurance EOB in the clients' files for quality monitoring.
- The payment received by Show Me Healthy Women is based on Show Me Healthy Women contract
 rates, not the rate of a commercial insurance company, or public. Show Me Healthy Women payment
 is NOT based on the clients' out- of -pocket responsibility as stated in the insurance EOB. SMHW
 payment is determined based on the amount the insurance carrier pays the provider for each
 procedure/CPT code.
- SMHW Providers and their subcontractors cannot bill a SMHW client for any SMHW/WW services.
- Women enrolled in prepaid/managed care and health plans (such as HMOs, POS and MO HealthNet Managed Care [formerly MC+]) are not eligible for SMHW services.
- For additional information about clients with insurance, refer to page 3.2.

NOTE:

SMHW will only reimburse up to the total allowed by SMHW for that procedure. The total amount allowed and reimbursed by SMHW for each CPT includes any payments received from insurance, not in addition to payment received.

Administrative Referral Fee

An administrative referral fee is billable for the following:

- When a SMHW client receives a screening from a clinician that is not a SMHW provider, the SMHW provider must submit to the program the patient history and screening forms containing the screening results from the non-SMHW provider as "Reporting Only"
- Administrative referral fee will be paid one time per client, per provider, during an annual screening cycle
- Direct billing providers may bill an administrative referral fee if the client was referred from another provider for a screening mammogram or diagnostic services
- Bill the administrative referral fee on the blue screening form (pages 10.10-.11) or diagnostic forms (pages 10.12-13).



NOTE:

If your facility bills SMHW for the screening, you cannot bill for the administrative referral fee. The reimbursement fees for SMHW office visits include the fee to complete paperwork and reimbursable once per annual screening cycle.

Direct Billing Diagnostic Providers

SMHW has agreements with the following medical entities, referred to as direct billing diagnostic providers, to provide diagnostic services:

- Barnes Jewish Hospital, St. Louis—St. Louis City
- Barnes Jewish Hospital, St. Peters—St. Charles County
- Bothwell Regional Health Center—Pettis County
- Breast Healthcare Center (Missouri Baptist Hospital), St. Louis—St. Louis County
- Golden Valley Memorial Hospital, Clinton—Henry County
- Hannibal Clinic Operations LLC, Hannibal—Marion County
- Mercy Hospital Jefferson, Crystal City—Jefferson County
- Missouri Delta Medical Center, Sikeston—Scott County
- SSM DePaul Hospital, Bridgeton—St. Louis County
- SSM Health St. Clare Hospital, Fenton—St. Louis County
- SSM St. Joseph Health Center (breast only), St. Charles—St. Charles County
- SSM St. Mary's Health Center, Richmond Heights—St. Louis County
- SSM Health St. Mary's Hospital-Audrain, Mexico—Audrain County
- Mercy Hospital, St. Louis (David C. Pratt Cancer Center) (breast only)—St. Louis County
- Saint Louis University Cancer Center, St. Louis—St. Louis City
- Ste. Genevieve County Memorial Hospital, Ste. Genevieve—Ste. Genevieve County
- Truman Medical Center—Hospital Hill, Kansas City—Jackson County
- Truman Medical Center—Lakewood, Kansas City—Jackson County
- University of Missouri Hospital and Clinics—Ellis Fischel Cancer Center, Columbia—Boone County

Mammography Van Billing Guidelines

Mammography van screen should coordinate with a clinical breast exam performed by a SMHW provider in order to meet quality care guidelines and program requirements. When billing for a mammogram only performed on a mammogram van, select the visit type as "Mammogram Only", mark the "Mammogram Van" box and complete "Section B5 Mammography provider facility" field. Include the name of the facility providing the van and include the word "Van" by the facility name. Example: Ellis Fischel Van.

Note: SMHW program reimburses the office visit of the provider performing the CBE for clients who have or had a mammogram on a mammography van. Each SMHW client should be referred to a primary care physician (PCP) for a CBE. (See Direct Billing Diagnostic Provider Responsibilities on page 9.6)

Screening/Referring Provider Responsibilities

The screening/referring provider shall:

- Verify the client's eligibility for SMHW services according to the SMHW guidelines to include a signed and dated eligibility form (page 10.6).
- Assure that new SMHW clients complete a green history form (pages 10.8 [English] -10.9 [Spanish]).
- Complete/enter the blue screening form (pages 10.10-.11) with the screening results.
- Mammography Van, if a client presents at the mammography van and has not had a clinical breast exam (CBE) continue with screening services but refer them for primary care services so a CBE can be obtained. Document in Section D of the screening form.
- Call and make the appointment for the client with the direct billing diagnostic provider. Transmit copies of the enrollment history, eligibility form, and screening forms to the direct billers.
- Submit the green history and blue screening form information to SMHW as soon as possible with the
 appropriate billing or reporting-only information. If not, delayed payment for both screening and
 diagnostic services may occur.
- Share copies of the client's notations and procedures with the referring practitioner.

Direct Billing Diagnostic Provider Responsibilities

The direct billing/diagnostic provider shall:

- Retain copies of the screening provider's information in their files. The copies should include the screening results, client eligibility form, and history form.
- Provide the necessary diagnostic services.
- Complete a purple breast form (pages 10.12-.13), or a yellow cervical form (pages 10.14-.15), or a blue screening form (pages 10.10-.11), if a screening mammogram was performed. Submit data to SMHW.
- Send copies of the medical and pathology reports back to the referring screening provider. To ensure
 appropriate follow up, document the client has been notified of their results and maintain this
 information in the client's medical record.

The direct billing and screening provider shall coordinate case management services of SMHW clients. Interruption of timely diagnostic services occurs with missed appointments. Reschedule missed appointments promptly.

Breast & Cervical Reimbursement Rates by CPT Code

June 30, 2021 to June 29, 2022

A CPT code followed by TC indicates technical component. A CPT code followed by the number 26 indicates professional fee. All payments are based on Missouri Medicare 01 Rates.

SCREENING REPORT FORM

	CPT Codes	SN	IHW Rate	Description
Referral Fee		\$	25.00	Only one per client, per year, when office visit not paid
Office Visits	99203	\$	103.95	New patient – office visit – <i>detailed</i> history, detailed exam, decision-making; 30-44 minutes (initial)
	99202	\$	67.51	New patient – office visit – expanded problem focused history, and expanded problem focused exam, straightforward-decision-making; 15-29 minutes, -(initial-CBE only)
	99212	\$	52.90	Established patient – office visit – expanded problem history and exam, straightforward decision-making; 10-19 minutes (for repeat pap test and CBE)
	99212A	\$	52.90	Established patient – office visit – 10-19 minutes (CBE only annual)
	99213	\$	84.99	Established patient – office visit – expanded history, exam, straightforward decision-making; 20-29 minutes (annual screening that includes CBE and pelvic exam)
Mammography	77067	\$	121.93	Screening mammogram, bilateral (2 view film study of each breast with computer aided detection) (#77067TC \$87.91/ #7706726 \$34.03)
	77066	\$	150.78	Mammography, diagnostic follow-up, bilateral with computer aided detection (#77066TC \$106.25 / #7706626 \$44.53)
	77065	\$	119.42	Mammography, diagnostic, digital, unilateral with computer aided detection (#77065TC \$83.16 / #7706526 \$36.26)
Tomosynthesis	77063	\$	50.13	Screening digital breast tomosynthesis, bilateral. Must be listed separately in conjunction with CPT code #77067 (#77063TC \$23.41, #7706326 \$26.72)
	G0279	\$	50.13	Diagnostic digital breast tomosynthesis unilateral or bilateral. Must be listed separately in conjunction with either code #77065 or code #77066 (G0279TC \$23.41, G027926 \$26.72)
	···•	·····		

Pap Smear & HPV	88164		Cytopathology (conventional pap test) slides, cervical, or vaginal reported in Bethesda System, manual screening under physician supervision
	88142	\$ 20.26	Cytopathology (liquid-based pap test), cervical or vaginal, collected in preservative fluid, automate thin layer preparation; manual screening under physician supervision
	87624	\$ 35.09	Infectious agent detection by nucleic acid (DNA/RNA) Human Papilloma Virus (HPV), high risk type
	87625	\$	HPV, types 16 and 18 only. Reflex test

Addendum:

HPV DNA testing is a reimbursable procedure if used in conjunction with pap testing or for follow-up of an abnormal pap result or surveillance as per ASCCP guidelines.

The CDC will allow for reimbursement of Cervista HPV HR at the same rate as the Digene Hybrid-Capture 2 HPV DNA Assay. The CDC funds cannot be used for reimbursement of genotyping (e.g., Cervista HPV 16/18).

Screening MRI: High Risk* Only

Magnetic Resonance Imaging (MRI)	77048	\$ 357.27	MRI, breast, with and/or without contrast, unilateral (Reimbursement for breast MRI only in conjunction with a mammogram when a client meets the criteria.) See criteria listed below. <i>Must be preauthorized on an individual basis in advance of the procedure.</i> (#77048TC \$263.74/ #7704826 \$93.53)
	77049	\$ 364.91	MRI, breast, with and/or without contrast, bilateral (Reimbursement for breast MRI only in conjunction with a mammogram when a client meets the criteria.) See criteria listed below. <i>Must be preauthorized on an individual basis in advance of the procedure.</i> (#77049TC \$262.48/ #7704926 \$102.44)

Criteria:

Breast MRI can be reimbursed by the NBCCEDP in conjunction with a screening mammogram when a client has a breast cancer gene (BRCA) mutation, a first-degree relative who is a BRCA carrier, or a lifetime risk of 20 to 25 percent or greater as defined by risk assessment models such as BRCAPRO, etc.. Breast MRI should never be done alone as a breast cancer screening tool. Breast MRI will not be reimbursed by the NBCCEDP to assess the extent of disease in a woman who is already diagnosed with breast cancer. An MRI must be authorized in advance of the procedure. Authorization is determined on an individual basis.

BREAST FORM

	CPT Codes	SMI	HW Rate	Description
Referral Fee		\$	25.00	Only once per client, per year, when office visit not paid (Can be on any form – but one time, per client, per year)

Mammography	77065	\$ 119.42	Mammography, diagnostic, digital, unilateral with computer aided detection (#77065TC \$83.16/ #7706526 \$36.26)
	77066	\$ 150.78	Mammography, diagnostic follow-up, bilateral with computer aided detection (#77066TC \$106.25/ #7706626 \$44.53)
Tomosynthesis	G0279	\$ 50.13	Diagnostic digital breast tomosynthesis unilateral or bilateral. Must be listed separately in conjunction with either code #77065 or code #77066 (G0279TC \$23.41, G027926 \$26.72)
Ultrasound	76641	\$ 100.12	Ultrasound, complete examination of breast including axilla unilateral (#76641TC \$67.66/ #7664126 \$32.46)
	76642	\$ 82.08	Ultrasound, limited examination of breast including axilla unilateral (76642TC \$51.85/ #7664226 \$30.23)
Ductogram	77053	\$ 52.25	Mammary ductogram or galactogram, single duct (#77053TC \$36.03/ #7705326 \$16.22)
Specialist Consultation	99204	\$ 156.27	Specialist consultation for breast; (New patient: detailed history, exam, straightforward decision-making; 45-59 minutes)
Fine Needle Aspiration	10021	\$ 98.09	Fine needle aspiration biopsy without imaging guidance first lesion
	10005	\$ 128.28	Fine needle aspiration biopsy with Ultrasound guidance first lesion
	10007	\$ 294.33	Fine needle aspiration biopsy with Fluoroscopic guidance first lesion
	10009	\$ 450.68	Fine needle aspiration biopsy with CT guidance first lesion
	10011	\$ 450.68	Fine needle aspiration biopsy with MRI guidance first lesion
	10004	\$ 48.08	Fine needle aspiration biopsy without guidance each additional lesion
	10006	\$ 56.73	Fine needle aspiration biopsy with Ultrasound guidance each additional lesion
	10008	\$ 156.06	Fine needle aspiration biopsy Fluoroscopic guidance each additional lesion
	10010	\$ 264.68	Fine needle aspiration biopsy with CT guidance each additional lesion
	10012	\$ 264.68	Fine needle aspiration biopsy with MRI guidance each additional lesions
	88172	\$ 50.82	Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy of specimen(s) (#88172TC \$18.32/ #8817226 \$32.50)

	88173	\$ 143.69	Cytopathology, evaluation of fine needle aspirate; interpretation and report (#88173TC \$79.34/ #8817326 \$64.35)
Percutaneous Biopsy (Core Needle & Stereotactic)	19100	\$ 149.55	Breast biopsy, percutaneous, needle core, not using imaging guidance
	19100	\$ 64.46	Outpatient facility setting
	19081	\$ 543.10	Breast biopsy, with placement of localization device and imaging of biopsy specimen, percutaneous; stereotactic guidance; first lesion
	19081	\$ 151.83	Outpatient facility setting
	19082	\$ 435.72	Breast biopsy, with placement of localization device and image of biopsy specimen, percutaneous; stereotactic guidance; each additional lesion
	19082	\$ 76.08	Outpatient facility setting
	19083	\$ 544.01	Breast biopsy, with placement of localization device and image of biopsy specimen, percutaneous; ultrasound guidance; first lesion
	19083	\$ 143.56	Outpatient facility setting
	19084	\$ 427.86	Breast biopsy, with placement of localization device and image of biopsy specimen, percutaneous; ultrasound guidance; each additional lesion
	19084	\$ 71.06	Outpatient facility setting
	88305	\$ 65.39	Surgical pathology, gross and microscopic examination (#88305TC \$31.29/ #8830526 \$34.11)
		\$ 500.00*	Facility fee, core needle biopsy when done in an outpatient facility setting
		\$ 700.00*	Facility fee, stereotactic breast biopsy when done in an outpatient facility setting
		\$ 700.00*	Facility fee, ultrasound guided breast biopsy when done in an outpatient facility setting
Incisional Breast Biopsy	19101	\$ 323.93	Breast biopsy, open, incisional (no guidance)
	19101	\$ 208.80	Outpatient facility setting
	76098	\$ 39.26	Radiological examination, surgical specimen (#76098TC \$25.28/ #7609826 \$13.98)
	88305	\$ 65.39	Surgical pathology, gross and microscopic examination (#88305TC \$31.29/ #8830526 \$34.11)
		\$ 275.00	General anesthesia (loss of ability to perceive pain associated with loss of consciousness produced by intravenous or inhalation anesthetic agents)
		\$ 1,100.00*	Facility fee, incisional breast biopsy, when done in an outpatient facility setting

19120	\$	486.85	Excision of cyst, fibroadenoma or other benign or malignant tumor, aberrant breast tissue, duct lesion, nipple or areolar lesion; open; one or more lesions
19120	\$	389.43	Outpatient facility setting
19125	\$	537.40	Excision of breast lesion identified by preoperative placement of radiological marker; open; single lesion
19125	\$	432.07	Outpatient facility setting
19126	\$	149.27	Excision of breast lesion identified by preoperative placement of radiological marker, open; each additional lesion, separately identified by a preoperative radiological marker
19281	\$	232.47	Placement of breast localization device, percutaneous; mammographic guidance; first lesion
19281	\$	103.20	Outpatient facility setting
19282	\$	166.22.	Placement of a breast localization device, percutaneous; mammographic guidance; each additional lesion
19282	\$	45.40.	Outpatient facility setting
19283	\$	256.74	Placement of breast localization device, percutaneous; stereotactic guidance; first lesion
19283	\$	91.94	Outpatient facility setting
19284	\$	196.16.	Placement of a breast localization device; percutaneous; stereotactic guidance; each additional lesion
	\$	46.55.	Outpatient facility setting
19285	\$	409.17	Placement of breast localization device, percutaneous; ultrasound guidance; first lesion
19285	\$	78.61	Outpatient facility setting
19286	\$	346.14	Placement of a breasts localization device, percutaneous; ultrasound guidance; each additional lesion
19286	\$	39.01.	Outpatient facility setting
76098	\$	39.26	Radiological examination, surgical specimen (#76098TC \$25.28/ #7609826 \$13.98)
88307	\$	266.78	Surgical pathology, gross and microscopic examination; requiring microscopic evaluation of surgical margins (#88307TC \$191.60/ #8830726 \$75.18)
-	\$	275.00	General anesthesia (loss of ability to perceive pain associated with loss of consciousness produced by intravenous or inhalation anesthetic agents)
	\$	1,650.00*	Facility fee, excisional breast biopsy, when done in an outpatient facility setting
	19120 19125 19125 19126 19281 19281 19282 19282 19283 19283 19283 19284 19285 19285 19286 19286 76098	19120 \$ 19125 \$ 19125 \$ 19125 \$ 19126 \$ 19281 \$ 19282 \$ 19282 \$ 19282 \$ 19283 \$ 19283 \$ 19283 \$ 19283 \$ 19284 \$ \$ 19285 \$ 19285 \$ 19286 \$ 76098 \$ 88307 \$	19120 \$ 389.43 19125 \$ 537.40 19125 \$ 432.07 19126 \$ 149.27 19281 \$ 232.47 19282 \$ 166.22 19282 \$ 45.40 19283 \$ 256.74 19283 \$ 91.94 19284 \$ 196.16 \$ 46.55 \$ 409.17 19285 \$ 78.61 19286 \$ 346.14 19286 \$ 39.01 76098 \$ 39.26 88307 \$ 266.78 \$ 275.00

Magnetic Resonance Imaging (MRI)	**77048	**\$	357.27	MRI, breast, with and/or without contrast, unilateral (Reimbursement for breast MRI only in conjunction with a mammogram when a client meets the criteria.) See criteria listed below. <i>Must be preauthorized on an individual basis in advance of the procedure.</i> (#77048TC \$263.74/#7704826 \$93.53) **Diagnostic MRI is a non-covered service with SMHW. If completed, choose as a Reporting Only option on the claim form.
	77049	**\$	364.91	MRI, breast, with and/or without contrast, bilateral (Reimbursement for breast MRI only in conjunction with a mammogram when a client meets the criteria.) See criteria listed below. <i>Must be preauthorized on an individual basis in advance of the procedure.</i> (#77049TC \$262.48/ #7704926 \$102.44) **Diagnostic MRI is a noncovered service with SMHW. If completed, choose as a Reporting Only option on the claim form.
Patient Navigation	G9012	\$	50.00	Other specified case management service not elsewhere classified. Must follow CDC guidelines as an individualized intervention providing eligible patients who have never been screened or not screened within the last 3-5 years.

NOTE:

Facility fees include \$120.00 for supplies and miscellaneous costs.

CERVICAL FORM

	CPT Codes	SMHW Rate		Description
Referral Fee		\$	25.00	Only once per client, per year, when office visit not paid (Can be on any form – but one time per client per year)
Specialist Consultation	99204	\$	156.27	Specialist consultation for breast; (New patient: detailed history, exam, straightforward decision-making; 45-59 minutes)
Colposcopy without Biopsy	57452	\$	119.47	Colposcopy of the cervix
Colposcopy	57454	\$	160.49	Colposcopy of cervix, with biopsy and endocervical curettage (Endometrial biopsy can only be paid as pathology.)
Polypectomy	57500	\$	149.20	Cervical biopsy, single or multiple, or local excision of lesion, with or without fulguration (separate procedure)
	88305	\$	65.39	Surgical pathology, gross and microscopic examination (#88305TC \$31.29/ #8830526 \$34.11)

^{*} This amount applies when performed service is in an outpatient facility setting and an additional facility fee is charged.

LEEP	57522	\$ 287.68	Loop electrode excision procedure (may be reimbursed as a diagnostic procedure, based upon ASCCP recommendations.) <i>Must be preauthorized on an individual basis in advance of the procedure.</i>
	88305	\$ 65.39	Surgical pathology, gross and microscopic examination (#88305TC \$31.29/ #8830526 \$34.11)
	88307	\$ 266.78	Surgical pathology, gross and microscopic examination; requiring microscopic evaluation of surgical margins (#88307TC \$191.60/ #8830726 \$75.18)
Cold Knife	57461	\$ 339.97	Colposcopy with loop electrode conization of the cervix (may be reimbursed as a diagnostic procedure, based upon ASCCP recommendations.) <i>Must be preauthorized on an individual basis in advance of the procedure.</i>
	88305	\$ 65.39	Surgical pathology, gross and microscopic examination (#88305TC \$31.29/ #8830526 \$34.11)
	88307	\$ 266.78	Surgical pathology, gross and microscopic examination; requiring microscopic evaluation of surgical margins (#88307TC \$191.60/ #8830726 \$75.18)
Endocervical Curettage	57505	\$ 141.92	Endocervical curettage (not done as part of dilation and curettage)
	88305	\$ 65.39	Surgical pathology, gross and microscopic examination (#88305TC \$31.29/ #8830526 \$34.11)
	88307	\$ 266.78	Surgical pathology, gross and microscopic examination; requiring microscopic evaluation of surgical margins (#88307TC \$191.60/ #8830726 \$75.18)
Patient Navigation	G9012	\$ 50.00	Other specified case management service not elsewhere classified. <i>Must follow CDC guidelines as an individualized intervention providing eligible patients who have never been screened or not screened within the last 3-5 years.</i>

Note:


Facility fees include \$120.00 for supplies and miscellaneous costs.

^{*} This amount applies when performed service is in an outpatient facility setting and an additional facility fee is charged.

Forms

Forms	10.1
	Client/Patient Navigation
	SMHW/WISEWOMAN Information Update
	SMHW Eligibility Agreement (English & Spanish)
	Green Patient History (English & Spanish)
	Blue Screening Report
	Purple Breast Diagnosis and Treatment
	Yellow Cervical Diagnosis and Treatment
	BCCT Temporary MO HealthNet Authorization
	BCCT Medical Assistance Application (Mo HealthNet)
	Certification of Need for Treatment – Breast/Cervical Cancer

Request for Literature



Forms

The following pages contain sample forms associated with the SMHW and WISEWOMAN programs.

All current forms are available on the web at:

http://www.health.mo.gov/living/healthcondiseases/chronic/showmehealthywomen/forms.php.

Direct any form related questions to the agency's RPC.



MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES SHOW ME HEALTHY WOMEN (SMHW) CLIENT / PATIENT NAVIGATION

ENROLLMENT SITE / SATELLITE (N.	AME AND ADDRESS)			N/	VIGATOR NAME / DATI	
A. PERSONAL DATA						
NAME (LAST, FIRST, MIDDLE INITIA	L)			PA	RTICIPANT ID	ID TYPE (CHOOSE ONE) Choose an item.
DATE OF BIRTH (MM/DD/YYYY)	CLIENT REFUSES NAV	IGATION SERVICES	CLIENT (CHOOS		eased Unable	to locate Lost to follow-up
B. CLIENT ASSESSM	ENT					
ASSESSMENT TYPE (CHOOSE ONE			DATE OF ASSES	SMENT (MM/DD	/YYYY)	
Choose an item.						
TYPE OF CONTACT DURING ASSES	SSMENT (CHOOSE ONE)		LENGTH OF ASS	ESSMENT (CHC	OOSE ONE)	
Choose an item.			Choose an	item.		
TYPE OF NAVIGATION COMPLETED	(CHOOSE ONE)		SERVICES NEED	ED (CHOOSE C	NE)	
Choose an item.			Choose an	item.		
BARRIERS						
SYSTEM BARRIERS (CHOOSE ALL	THAT APPLY)					
☐ Healthcare provider is >5	0 miles	☐ Housing issue / homele	ess			n a health insurance plan
☐ No healthcare provider		☐ No phone / invalid phor		_	ler unable to bill in:	surance
☐ Transportation schedule	is inconvenient	☐ Unable to schedule an	appointment	☐ Unabl	e to take off work	
Other FINANCIAL BARRIERS (CHOOSE AL	I THAT APPLY)					
☐ Has dependents / is a ca	,	☐ Insurance has high ded	luctible	☐ Lack of	of / cannot afford tr	ansportation
☐ No health Insurance plan	-	☐ Underinsured				,
☐ Other						
PSYCHOSOCIAL BARRIERS (CHOO						
Cultural / faith-based con		☐ Education level			ition required on ca	ancer
☐ Education required on life☐ Education required on so		☐ Education required on r			nent	
☐ Fear / denial	reening / diagnostics	☐ Has concerns about he		Cai Cai C		
☐ Other		- Tido concerno ascarno	C. C. C.			
COMMUNICATION BARRIERS (CHO	OSE ALL THAT APPLY)					
☐ Confused / overwhelmed		☐ Cultural concerns		□ Does	not understand (he	alth literacy)
Needs interpreter		☐ Unable to read				
Other						_
ACTION PLAN						
COUNSELING / COMMUNICATION /						
□ Advocated on client's bel□ Counseled regarding (specified)	naif (specify)					
☐ Discussed client concern		☐ Discussed diagnostic pl	lan ontions	□ Discu	ssed options of ava	ailable services
☐ Discussed treatment plan		☐ Educated client on avai	•		sacu options of ave	anable services
☐ Educated client with "tead	· ·	-				
☐ Notified Regional Program	m Coordinator (RPC)	for assistance				
Provided interpreter servi		,				
Provided culturally appro						
□ Provided educational level□ Other		re / information		☐ Provid	led literacy level ap	ppropriate brochure / informatio
REFERRALS / APPOINTMENTS (CH	OOSE ALL THAT APPLY)					
☐ Referred to SMHW Provi						
Referred to breast and/or	cervical care provide	er (specify)				
Referred to other health	care services (specify)				
Referred to Breast and C				_	ed to transportatio	
Cobodulad appaintment f	or screening services					for diagnostic services
		ICES		□ Referi	ed to legal service	S
☐ Scheduled appointment f	•					
	•					



MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES SHOW ME HEALTHY WOMEN (SMHW) CLIENT / PATIENT NAVIGATION

P.O. Box 570 Jefferson City, MO 65102-0570 (573) 522-2845

SERVICES ENROLLMENT (CHOOSE ALL THAT APPLY)			
☐ Enrolled for Navigation Services only	Enrolled in SMHW Progra	am 🔲 Fa	cilitated enrollment in BCCT Program
☐ Facilitated enrollment in health insurance plan ☐	☐ Facilitated enrollment in N	Medicare / Medicaid	
☐ Other			
DATE ACTION(S) COMPLETED (MM/DD/YYYY)	SERVICES IMPLEMENTATION F	LAN (CHOOSE ONE)	SERVICES INITIATED DATE (MM/DD/YYYY)
	Choose an item.		
DATE NAVIGATION COMPLETED (MM/DD/YYYY)		SMHW ELIGIBLE	
		☐ Yes ☐ No	
C. CLIENT MANAGEMENT			

CLIENT NOTIFIED OF ABNORMAL RESULTS (CHOOSE ONE) Choose an item. DATE NAVIGATION / MANAGEMENT TERMINATED (MM/DD/YYYY) REASON FOR TERMINATION (CHOOSE ONE)

Choose an item.

D. COMMENTS

BARRIERS / ACTION PLAN / MANAGEMENT / NAVIGATION NOTES

DATE NEXT NAVIGATION VISIT OR CALL PLANNED (MM/DD/YYYY)

E. FINAL OUTCOMES FINAL OUTCOMES (CHOOSE ALL THAT APPLY) □ Diagnostic work-up planned □ Diagnostic work-up completed ☐ Enrolled in BCCT Program ☐ Enrolled in a health insurance plan ☐ Enrolled in Medicare / Medicaid ☐ Improved client adherence ☐ Improved timeliness of care ☐ Improved client satisfaction ☐ Provided case management ☐ Received a treatment plan ☐ Reduced care fragmentation ☐ Screening completed – breast ☐ Screening completed – cervical □ Treatment initiated – cancer ☐ Treatment completed – released by MD □ Other _

MO 580-3196 (5-19)



MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES BUREAU OF CANCER AND CHRONIC DISEASE CONTROL, SHOW ME HEALTHY WOMEN (SMHW)

SMHW - WISEWOMAN INFORMATION UPDATE

WEB ADDRESS: www.health.mo.gov/showmehealthywomen



INSTRUCTIONS:

This form is to be completed and submitted at the onset of each fiscal contract year to the SMHW program staff, and at any time during the year that the information changes. This information is used to update the SMHW web page, refer clients for services, and disseminate SMHW contract information to contractors.

AGENCY/DOING BUSINES	SS AS (D	BA) NAME	CC	ORPORATE/PA	ARENT COMPA	NY NAME	(IF APPLICABLE)
STREET ADDRESS			STREE	TADDRESS			
CITY	STATE	ZIP + 4 DIGITS	СПУ		S	TATE ZIF	+4 DIGITS
PUBLIC TELEPHONE NUMBER FOR APPOINTMENT	S FAX NUM	BER	TELEP	HONE NUMBER	<u>'</u>	FAX NUMBER	1
AGENCY NAME	CY NAM	E & STREET ADDRESS	TO SE	ND CONTRAC	CI DOCUMENT	S	
AGENCY NAME							
STREET/PO BOX ADDRESS							
CITY, STATE, ZIP CODE + 4 DIGITS							
	SHO	W ME HEALTHY WOME	N CON	TACT INFORM	IATION		
ADMINISTRATIVE CONTACT NAME		ADMINISTRATIVE E-MAIL ADDRES	SS		ADMINISTRATIVE TE	LEPHONE NUM	BER
CLINICAL CONTACT NAME		CLINICAL EMAIL ADDRESS			CLINICAL TELEPHON	NE NUMBER	
BILLING CONTACT NAME		BILLING E-MAIL ADDRESS			BILLING TELEPHON	ENUMBER	
	WISE	OMAN CONTACT INFO	DMAT	ION (IE APPI I	CARLE)		
ADMINISTRATIVE CONTACT NAME	WIOLI	ADMINISTRATIVE E-MAIL ADDRES		ION (II ALLE	ADMINISTRATIVE TE	LEPHONE NUM	RFR
CLINICAL CONTACT NAME		CLINICAL EMAIL ADDRESS			CLINICAL TELEPHON	NE NUMBER	
BILLING CONTACT NAME		BILLING E-MAIL ADDRESS			BILLING TELEPHON	ENUMBER	
		LIST SATELLITE SITE	ES (IF A	PPLICABLE)			
1. SATELLITE SITE NAME	STREET AD	DRESS		CITY		STATE	ZIP CODE
PUBLIC TELEPHONE NUMBER FOR APPOINTMENT	NTS	CLINICAL CONTACT NAME			CLINICAL CONTACT	E-MAIL ADDRES	S
2. SATELLITE SITE NAME	STREET AD	DRESS		CITY		STATE	ZIP CODE
2. PUBLIC TELEPHONE NUMBER FOR APPOINTME	NTS	CLINICAL CONTACT NAME			CLINICAL CONTACT	E-MAIL ADDRES	S
3. SATELLITE SITE NAME	STREET AD	DRESS		CITY		STATE	ZIP CODE
3. PUBLIC TELEPHONE NUMBER FOR APPOINTME	NTS	CLINICAL CONTACT NAME			CLINICAL CONTACT	E-MAIL ADDRES	S
4. SATELLITE SITE NAME	STREET AD	DRESS		CITY		STATE	ZIP CODE
4. PUBLIC TELEPHONE NUMBER FOR APPOINTMEN	NTS	CLINICAL CONTACT NAME			CLINICAL CONTACT	E-MAIL ADDRES	s
5. SATELLITE SITE NAME	STREET AD	DRESS		CITY		STATE	ZIP CODE
5. PUBLIC TELEPHONE NUMBER FOR APPOINTMEN	NTS	CLINICAL CONTACT NAME		1	CLINICAL CONTACT	E-MAIL ADDRES	s

MO 580-3219 (11-18)

	CLINICAL	EXAM	INERS/LICENSE INFORMATION		
NAME (Clinical Examiner performing screening services)	TITLE		NURSE LICENSE NUMBER (If NP, include RN and NP license number)	РНҮ	SICIAN LICENSE NUMBER
	□ RN □	DO NP PA	RN:	PA: DO: MD:	
	□ RN □	DO NP PA	RN:NP:	PA: DO: MD:	
	□ RN □	DO NP PA	RN: NP:	PA: DO: MD:	
	□ RN □	DO NP PA	RN: NP:	PA: DO: MD:	
	□ RN □	DO NP PA	RN: NP:	PA: DO: MD:	
	□ RN □	DO NP PA	RN: NP:	PA: DO: MD:	
	□ RN □	DO NP PA	RN:NP:	PA: DO: MD:	
	□ RN □	DO NP PA	RN: NP:	PA: DO: MD:	
	□ RN □	DO NP PA	RN: NP:	PA: DO: MD:	
	□ RN □	DO NP PA	RN: NP:	PA: DO: MD:	
	□ RN □	DO NP PA	RN:	PA: DO: MD:	
	□ RN □	DO NP PA	RN:	PA: DO: MD:	
I certify to the best of my knowledge and illegible, incomplete, and/or not signed.	belief that all in	nformat	tion provided is true and accurate. I und	lerstand thi	s form will be returned if it is
SIGNATURE					DATE
PRINTED NAME AND TITLE OF PERSON SIGNING					
MO 580-3219 (11-18)			2		

MO 580-3219 (11-18)

Name <u>:</u>	Birth date	<u>//</u>	SS#:
	n	nm/dd/yyyy	(Optional)
Address	City	State	7:
Street	City	State	Zip
Me Healthy Women Project (SMHW). cervical cancer examinations free. If yo with SMHW and/or Department of Sooneeded, treatment. Income/Insurance Information (Pleater you receiving: Unemployment)	our test results are not cial Services to help your test results are not see check all that apply	normal, this e ou obtain addi	linic will work tional tests and, if
Medicare Part A □ and/or Part B□			
Do you have health insurance?	Yes □ No□		
Does your insurance have a deductible	? Yes □ No □		
Can you pay the deductible?	Yes □ No□		
ls your health insurance an HMO?	Yes □ No □		
CLIENT AGREEMENT I have not supplied documentation of he within SMHW present income guidelines at A staff person has informed me which I understand that the SMHW services at I understand that my health is my responsed to contact this clinic for my test I understand that no test is 100% accur I have read or had the above read to me As a client receiving services funded by SMI appropriate staff at the Department of Heal federal funding source. I acknowledge that and Senior Services Notice of Privacy Polici revisions to this Notice. If this document is Care (DPOA-HC), attach a copy of the Letter of the services (DPOA-HC), attach a copy of the Letter of the services (DPOA-HC), attach a copy of the Letter of the services (DPOA-HC), attach a copy of the Letter of the services (DPOA-HC), attach a copy of the Letter of the services (DPOA-HC), attach a copy of the Letter of the services (DPOA-HC), attach a copy of the Letter of the services (DPOA-HC).	delines	applicable, ple MHW. ram covers. e at no cost. sible for keep nformation about care informa d other agencie of the Missouri ere I can obtain r Durable Powe	ing my appointments ove is correct. tion will be shared with sas required by the Department of Health any subsequent r of Attorney for Health
Attorney for Health Care.			//
			/ /

	Fecha de Nacimiento_	mes día año	Seguro Social.	#(operional)
Dirección		THE UNIT WHEN		
rograma Mujeres Salu i los resultados fueran	Cuidad lud y de Servicios para Personas d dables de Missouri. Si usted calif anormales, trabajaremos con el E	ica, recibirá exá epartamento de	imenes del sei	no y cervical gratuitos.
exámenes adicionales,	ncluyendo el tratamiento si es neo	esario.		
Información de Ing	RESOS Y ASEGURANZA DE SALUI	(seguros) (Poi	r favor indiqu	e toda lo que aplica.)
Esta usted recibiendo:	Seguro de desempleo Medicare Parte A Ha aplicado para recibir Medicare	o Parte B	NF (Ayuda E]	statal) 🗌
	¿Tiene usted Seguro de Salud?	Si 🗌	No 🗌	
	¿Tiene usted un deducible en su ¿Puede usted pagar el deducible		No	
	¿Tiene usted el Seguros llamad		No 🗌	
	Acuerdo do	al Clianta		
	ne ha informado cuáles exámenes	paga el Mujere:	y califico para s Saludables d	
Entiendo que los servic Entiendo que es mi resp Entiendo que personas contacto para n Entiendo que necesito o Entiendo que ningún es Confirmo que he leído	ne ha informado cuáles exámenes ios disponibles a través del progra consabilidad cuidar mi salud. Soy asociados con el programa Mujero ecibir servicios médicos y aconse contactarme con la clínica para sal	paga el Mujeres ma Mujeres Sa responsable de es Saludables de ados. per los resultado aterior.	y califico pars s Saludables d ludables de M cumplir y ma e Missouri me	a este proyecto. le Missouri. lissouri son gratuitos. intener las citas médicas pueden entrarme en
Entiendo que los serviciones entiendo que es mi respentiendo que personas contacto para respentiendo que necesito de Entiendo que ningún es Confirmo que he leído Confirmo que toda informa el Departamento de Serequisitos de la fuente Políticas de Privacidad Missouri y que me hai documento es firmad	ne ha informado cuáles exámenes ios disponibles a través del progra consabilidad cuidar mi salud. Soy asociados con el programa Mujera ecibir servicios médicos y aconse contactarme con la clínica para salumen es 100% exacto.	paga el Mujeres ma Mujeres Sa responsable de saludables de ados. per los resultado aterior. recta. es por el progra dico será compas de Edad Avareconozco que servicios para l'evisiones subsider duradero per de subsider duradero per subsider subside	y califico pars s Saludables de ludables de M cumplir y ma e Missouri me os de mis exán partida con el anzada y de o e me han dac Personas de l iguientes a e ara atención	a este proyecto. le Missouri. lissouri son gratuitos. lissouri son gratuitos. litener las citas médicas pueden entrarme en menes. me Mujeres personal apropiado er tras agencias según los lo una copia de las Edad Avanzada de ste aviso. Si este médica, por favor
Entiendo que los serviciones entiendo que es mi respentiendo que personas contacto para respentiendo que necesito de Entiendo que ningún es Confirmo que he leído Confirmo que toda informo que toda informo el Departamento de Serequisitos de la fuente Políticas de Privacidad Missouri y que me har documento es firmad adjunte una copia de	ne ha informado cuáles exámenes ios disponibles a través del progra consabilidad cuidar mi salud. Soy asociados con el programa Mujero ecibir servicios médicos y aconse contactarme con la clínica para salumen es 100% exacto. Es se me ha leído la información ar rmación antes mencionada es con a recibiendo servicios financiado ación protegida del cuidado mé alud y de Servicios para Persona del financiamiento federal. You del Departamento de Salud y se dicho a dónde puedo obtener lo por el Tutor (Custodio) del poco	paga el Mujeres ma Mujeres Sa responsable de saludables de ados. per los resultado aterior. recta. es por el progra dico será compas de Edad Avareconozco que servicios para l'evisiones subsider duradero per de subsider duradero per subsider subside	y califico pars s Saludables de ludables de M cumplir y ma e Missouri me os de mis exán partida con el anzada y de o e me han dac Personas de l iguientes a e ara atención	a este proyecto. le Missouri. lissouri son gratuitos. lissouri son gratuitos. litener las citas médicas pueden entrarme en menes. me Mujeres personal apropiado er tras agencias según los lo una copia de las Edad Avanzada de ste aviso. Si este médica, por favor



MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES SHOW ME HEALTHY WOMEN (SMHW) PATIENT HISTORY

P. O. Box 570 Jefferson City, MO 65102-0570 (573) 522-2845

(TO BE COMPLETED BY CLIENT AND REVIEWED ANNUALLY)

ENROLLMENT SITE/SATELLITE CLINIC (IF ANY)				DATE OF VISIT (MM/DD	/YYYY)
A. PERSONAL HISTORY					
NAME (LAST, FIRST, MIDDLE INITIAL)				MAIDEN NAME	
E-MAIL ADDRESS	HOME PHONE NO.		WORK PHON	E NO.	CELL PHONE NO.
STREET ADDRESS	CITY/STATE		ZIP CODE		COUNTY
DATE OF BIRTH (MM/DD/YYYY) SOCIAL SECURITY N	LIUMBER (OPTIONAL)	WHAT IS		Anguage spoken in	YOUR HOME? Other
NUMBER OF HOUSEHOLD MEMBERS INSURANCE COVER.	AGE: ☐ Mo HealthNet		dicare	□ Private	MEDICAID DON/MEDICARE NUMBER
Race: (must be answered, choose all that apply) (1) White (2) Black or African American (3) Asian (4) Native Hawaiian or Other Pacific Islander (5) American Indian or Alaskan Native (6) Other (7) Unknown (please avoid using)		Highest grad (U. S. ed	of Hispanic e of school quivalent if e	origin? completed (circle educated in anoth	Yes □ No e one) her nation) 1 12 13 14 15 16
How did you hear about the Show Me Healthy Wom (please choose only one) (1) Physician (8) Health Care F (9) Health Fair (9) Health Fair (10) Health Coaliti (14) Radio (11) Outreach Wor (15) Printed Ad (12) Relative/Frier (6) Billboard (13) Other Locatio (7) Bus Sign (specify)	Provider on rker nd	appointment (1) E (2) A (3) C (4) T (5) F	? (please c Sus CT Van DATS Bus Taxi Personal Ve Relative/Frie BMTS	hoose only one)	o get to your clinic
Date of last Pap Test / / / / / YYYY		Date of Last	mammogra	am/_	//
Do you now smoke cigarettes? ☐ Everyday	y □ Son	ne days	□ Not at a	II □ Do	n't know
Name and telephone numbers of two people who can name	HOME PHONE	DU: WITH AREA CODE		WORK PHONE WORK PHONE	
MO 580-1800 (5-19)	()			_ (Ch. D-3




DEPARTAMENTO DE SALUD DE MISSOURI Y SERVICIOS PARA MAYORES DE EDAD UNIDAD DE CONTROL DE CÂNCER Y DE ENFERMEDADES CRÓNICAS DEL PROGRAMA MUJERES SALUDABLES DE MISSOURI HISTORIA CLÍNICA DA LA PACIENTE

· · · · · · · · · · · · · · · · · · ·		E Y REVISARÁ ANI	JALMENTE)			I	
SITIO DE INSCRIPCIÓN/CÍNICA SATÉLITE (SI H. ENROLLMENT SITE/SATELLITE CLINIC (IF ANY)						FECHA DE VISIT	ΓΑ (MES/DÍA/AÑO)
A. HISTORIA PERSONAL							
NOMBRE (APELLIDO, NOMBRE, INICIALES INTE	RMEDIAS)				APELLIDO	DE SOLTERA	
, , , , , , , , , , , , , , , , , , , ,	-7						
E-MAIL		TELÉFONO DE CASA		TELÉFONO	DE SU TRABAJO	TELÉE	ONO CELULAR
		, ,		, , ,			
DIRECCIÓN		() CIUDAD		CÓDIGO PO	ACTAI	COND)
DIRECCION		CIODAD		CODIGO PC	STAL	COND	ADO
FECHA DE NACIMIENTO (MES/DÍA/AÑO)	NUMERO DE L	A SEGURO SOCIAL <i>(OPC)</i>	IONAL) ¿.C	UÁL ES EL IDÍO	DMA PRINCÎPAL Q	JE SE HABLA EN S	SU CASA?
,				_	_	_	
NUMERO DE PERSONAS QUE VIVEN EN SU	QUE CLASE DE	E SEGURO TIENE:] Inglés	☐ Españo		AID DON/NUMERO DE MEDICAR
HOGAR	l	_			□ p		, as some memorial se mesion
	│	o ∐ Medicai		HealtNet	☐ Privac		
Raza: (Deben contestarse, escoja	todos las qu	e le conciernen)	Pertenencia	Étnica (La	s preguntas o	deben ser co	ntestadas)
(1) Blanco			¿Tiene u	d origenes	Hispanos [Si ∏No	
(2) Negro o Afro-Americano				Ü			
(3) Asiático							
(4) Nativo de Hawaii o de otr	o isla del Pad	cífico					n circulo uno)
(5) Indio Americano o Nativo	de Alaska		(Equiva	lente estad	lounidense, s	i es de otra n	nación):
(6) Otros			1 2 3	156	7 8 0 10	11 12 13	14 15 16
(7) Desconocido			1 2 3	4 3 0	7 0 5 10	11 12 13	14 15 16
¿Cómo supo usted acerca de este Muestreme Mujeres Saludables)?	e proyecto <i>(E</i>	in ingles, el	¿Que tipo d	e transporte	e utiliza para	acudir a su c	ita clínica?
(1) Médico	☐ (8) Enfe	rmera o otra	☐ (1) Aı	ıtobi'in			
(2) Clínica	persona clii		(1) Ai				
☐ (3) Televisión ☐ (4) Radio	(9) Feria	a de Salud alición de Salud	_ , ,	utobús OAT	S		
(5) Anuncio en diario	_ , ,	motora de Salud	(4) Ta	axi ehículo pers	conol		
(6) Anucio en carretera		iente/Amigo		ariente/Ami			
(7) Anucio en autobus	(13) Otra	as fuentes ⁻)	☐ (7) SI	MTS	-		
			(8) O	tra			
Fecha del examen de Papanicola	ou pasado: _		<u> </u>	Fecha de l	a última man	nografía:	
Actualmente, ¿fuma cigarillos?		A diaro	☐ Algunos	días	□ Nada	No :	sabe
Nombre y teléfono de dos persona	as que siemp	re puedan localiza	rse:				
Nombre		Teléfono de la Casa (inclu	uya el código de área	э)	Teléfon	o del Trabajo (inclu	ya el código de área)
		())	
Nombre		Teléfono de la Casa (inc	duya el código de án	ea)	Teléfono	del Trabajo (incluy	ra el código de área)
		()	-				
					()	




NROLLMENT SITE/SATELLITE SITE (NAME AND AC	DRESS)			REFERRIN	G PROVIDER (FOR D	IRECT BILLING)
A. PERSONAL DATA						
AME (LAST, FIRST, MIDDLE INITIAL)				SOCIAL SE	CURITY NUMBER	
				l <u> </u>	.	
ATE OF BIRTH	CLIENT ELIGIBILITY VERIFIED	INSURANCE COVERAG			1	
MM DD YYYY	☐ Yes ☐ No	☐ Yes ☐ No	☐ Yes ☐ N	<u> </u>	□ Part A	☐ Part A and B
^{ISITTYPE} □ Initial □ Annual □ Initial CBE only □ Annual CBE only	Rescreen Mammogram only	Height Weight		Blood Pressure 1st Re	ading/ eading/	Average /
B. BREAST CANCER SCREENIN		11.	bs.	ZHATK		□ Reporting Only
B 1. Does client report any BSE sy		o (If "YES" complete B	2.) Date	of CBE/_	/ (MM/DD/	
B 2. Symptoms Reported By Client	(Check any that apply. If 1, 2	2, 3 or 4B is checked, m	ıy have two (2) dia	agnostics at clinician	's discretion.)	
□ (1) Lump		☐ (4A) Pain/	Tenderness - 1st	toccurrence 🗖 (4B) Pain/Tender	rness - 2nd occurrence
☐(2) Nipple discharge		☐ (5) Other	(specify)			
□ (3) Skin changes (dimpling, retraction	ion, new nipple inversion,					
ulceration, Paget's disease)						
B 3. CBE within normal limits and fir	ndings Present at CBE (check yes or no and o	ne explanation)			
☐ Yes ☐ Within normal limits ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐	changes, diffuse lumpiness,	clearly defined thickening	a tenderness or	nodularity)		
□ No - Suspicious for cancer (Ar		•		••	ed on nurnle hrea	set form)
☐ (2) Discrete palpable mass (inc		*		new nipple inversion;		
diffuse, poorly defined thicl	kening, cystic or solid)			ent veins, unilateral;		
(3) Nipple discharge	44			hard palpable supra	aclavicular, infracla	vicular or axillary
☐ (4) Nipple or areolar scaliness	or erythema		odes; also swellin ain and tenderness			
B 4. High Risk for Breast Cancer	□ (1) Yes □ (2) No	□ (9) Not as	sessed/Unknown			
Rescreen CBE Planned	s • No /	-	Diagnostic Wo (must be less than		☐ Yes ☐ ☐	No
B 5. Mammogram Results				MM	DD YYYY	☐ Reporting On
(4) Mammogram not done or CBI	E done and	(5) Cervical	record only, no br	east service provide	d	
diagnostic workup planned ☐ (1) Routine screening mammogra		☐ (6) Referred	to direct biller	•		
(1) Notatine screening mainting is				one by a non-progra er results in Mammo		patient referred in for orting Only)
☐ Personal history of breas ☐ Previous abnormal mam		Date cli	ent referred for dia	agnosis.	<i></i>	
	g			MM	DD	YYYY
Mammography provider facility (facility name/city)						☐ Mammogram Var
Previous mammogram ☐ Yes ☐ No	□ Unknown Date of	last mammogram .		Date of this ma		
Type of mammogram □ Screening	T Disgnestie □ Temes	vertheoio.	Mothod use	ed for mammo	mram □ Digit	
Type of mammogram □ Screening SMHW mammogram result (check on	•	•	wethod us	ed for mammo	grain 🗖 Dight	ai 🗖 Conventional
Left Right (Indicate why only one br	reast had mammogram in CON	MMENTS) Left	Right			
Normal (1) Negative (Category 1)		Abnormal		y Benign (Category		
☐ ☐ (2) Benign Finding (Cates	gory 2)			ous Abnormality (© Suggestive of Mali		5)*
Further diagnostic planned for: (3) Probab	oly Benign: 🛮 Yes 🗖 No			actory-not interprete		
				valuation or film com		
Rescreen mammogram planned (must be less than 10 months)		agnostic work-up p (must be less than 60 days)	/_	/		
	YYYY		MM D	D YYYY		
	ct bill (physician/facility na	ime)				
Referred for diagnostic testing/direc			_ /			
			s. / / D	J D YYYY		

* *	exam only 🔲 (1) Routine Pap	• • •	High Risk for
(No Cervical Service	- (-,	or surveillance for previous abnormal (rescreen) done. Patient proceeded directly for diagnostic work-up or HPV testing	Cervical Cancer
		mary HPV positive (+)	□ (1) Yes □ (2) No
	(3) Non-progran	n Pap referred in for diagnostic evaluation	(2) Not assessed/
	(9) Unknown	MM DD YYYY	unknown
C 1. Pelvic Exam R	esults	C 2. Pelvic Exam Findings	☐ Reporting Only
Pelvic Exam WNL? (Additional information red	☐ Yes ☐ No quired in "No" selected, See C 2	Findings Present at Pelvic Exam (check only one) 1) Cervix	
Hysterectomy?	☐ Yes ☐ No	a) Polyp f) Ectropion	
□ Cervix absent		b) Leukoplakia (white lesions) g) Stenotic OS	
	lue to cervical cancer	□ c) Friable □ h) Cervical mass □ d) Ulceration □ i) Other:	
(needs annual F ☐ Cervix present	-ap (est)	e) Exophytic growth	
☐ Reason for hyst	erectomy unknown		
Date of Pelvic Exam		☐ 2) Exam Complicated by Obesity	
	MM DD YYYY	Rescreen planned Yes No/_	
Reproductive Status (cl	•		
□ a) Premenopaus □ b) Postmenopau		Diagnostic planned Yes No MMM DD YYYY	-
C 3. Pap Test Resul	ts		☐ Reporting Only
Previous Pap test	□Yes □No □Unkr	own Date of last Pap test Date of this Pap tes	et / /
	2.00 2.00 2.00	MM YYYY	MM DD YYYY
Specimen adequacy	□ Satisfactory	Specimen type ☐ Conventional Smear	
	☐ Unsatisfactory due to _	☐ Liquid Based	
	■ Unknown		
Annual Pap due to pro	evious treatment for cervical	cancer	
Pap test result (check	one) (Results with (*) require a	additional follow-up)	
Normal	☐ (1) Negative for intraepit	nelial lesion or malignancy	
		cells of Undetermined Significance	
Abnormal		UD\/ test\ □ (7) Atypical Glandular Cells* (i	includina atvoicalendocervica
Abnormal	(ASC-US) (May have	adenocarcinoma in situ and a	
Abnormal	(ASC-US) (May have	Mild Dysplasia/CIN I)* Cells, cannot exclude HSIL (ASC-H)* Cells, cannot exclude HSIL (ASC-H)*	
Abnormal	(ASC-US) (May have ☐ (3) Lowgrade SIL (HPV.☐ (4) Atypical Squamous	Milid Dysplasia/CIN)* Cells, cannot exclude HSIL (ASC-H)* features suspicious for invasion/CIN - /CIS * adenocarcinoma in situ ad a Adenocarcinoma in situ* General HSIL (ASC-H)* General HSIL (ASC-H)* General HSIL (ASC-H)*	adenocarcinoma)
	(ASC-US) (May have ☐ (3) Lowgrade SIL (HPV.☐ (4) Atypical Squamous	### adenocarcinoma in situ and a ### Cells, cannot exclude HSIL (ASC-H)* ### Cells, cannot exclude HSIL (ASC-H)* #### Cells, cannot exclude HSIL (ASC-H)*	adenocarcinoma)
Endocervical Cells	(ASC-US) (May have (3) Lowgrade SIL (HPV. (4) Atypical Squamous (5) Highgrade SIL (w∦h	Milid Dysplasia/CIN I)* Cells, cannot exclude HSIL (ASC-H)* features suspicious for invasion/CIN II-III/CIS)* adenocarcinoma in situ and a	adenocarcinoma)
Endocervical Cells C 4. HPV Test Dat	(ASC-US) (May have (3) Lowgrade SIL (HPV. (4) Atypical Squamous (5) Highgrade SIL (with	Mild Dysplasia/CIN)* Cells, cannot exclude HSIL (ASC-H)* features suspicious for invasion/CIN II-III/CIS)* Adenocarcinoma in situ and a	□ Reporting Only
Endocervical Cells C 4. HPV Test Dat	(ASC-US) (May have (3) Lowgrade SIL (HPV. (4) Atypical Squamous (5) Highgrade SIL (with Yes No (1) Cotesting/Screening	### Adenocarcinoma in situ and a denocarcinoma in situ and	□ Reporting Only
Endocervical Cells C 4. HPV Test Dat	(ASC-US) (May have (3) Lowgrade SIL (HPV. (4) Atypical Squamous (5) Highgrade SIL (with) Yes No (1) Cotesting/Screening (2) Reflex	Milid Dysplasia/CIN)* Cells, cannot exclude HSIL (ASC-H)* features suspicious for invasion/CIN II-III/CIS)* MM/DDYYYY HPV Test Result Adenocarcinoma in situ and a □ (8) Adenocarcinoma in situ and a □ (9) Adenocarcinoma □ (11) Other □ (11) Other □ (11)	□ Reporting Only
Endocervical Cells C 4. HPV Test Dat	(ASC-US) (May have (3) Lowgrade SIL (HPV. (4) Atypical Squamous (5) Highgrade SIL (with) Ves No (1) Cotesting/Screening (2) Reflex (3) Not Done	### Adenocarcinoma in situ and a concarcinoma in	□ Reporting Only
Endocervical Cells C 4. HPV Test Dat	(ASC-US) (May have (3) Lowgrade SIL (HPV. (4) Atypical Squamous (5) Highgrade SIL (with) Yes No (1) Cotesting/Screening (2) Reflex	Mild Dysplasia/CIN)* Cells, cannot exclude HSIL (ASC-H)* features suspicious for invasion/CIN - /CIS * MM/DDYYYY HPV Test Result (1) Positive with genotyping (5) Positive with not done/unknown (5) Positive genotyping (7) Yes	□ Reporting Only 18 Positive (Only report if Pick Group Positive)
	(ASC-US) (May have (3) Lowgrade SIL (HPV. (4) Atypical Squamous (5) Highgrade SIL (with) (1) Cotesting/Screening (2) Reflex (3) Not Done (9) Unknown	### Adenocarcinoma in situ and a calculation of the properties of	□ Reporting Only 18 Positive (Only report if Pick Group Positive)
Endocervical Cells C 4. HPV Test Dat Indication for HPV Test Rescreen Pap planr (less than 10 months)	(ASC-US) (May have (3) Lowgrade SIL (HPV. (4) Atypical Squamous (5) Highgrade SIL (with) (1) Cotesting/Screening (2) Reflex (3) Not Done (9) Unknown	Mild Dysplasia/CIN)* Cells, cannot exclude HSIL (ASC-H)* features suspicious for invasion/CIN - /CIS * (3) Adenocarcinoma in situ and a denocarcinoma in situ a	Reporting Only 18 Positive (Only report if P
Endocervical Cells C 4. HPV Test Dat Indication for HPV Test Rescreen Pap plann (less than 10 months) Referred for diagno	(ASC-US) (May have (3) Lowgrade SIL (HPV. (4) Atypical Squamous (5) Highgrade SIL (with) Yes No e/	Mild Dysplasia/CIN)* Cells, cannot exclude HSIL (ASC-H)* features suspicious for invasion/CIN - /CIS * (3) Adenocarcinoma in situ and a denocarcinoma in situ a	Reporting Only 18 Positive (Only report if P
Endocervical Cells C 4. HPV Test Dat Indication for HPV Test Rescreen Pap plann (less than 10 months) Referred for diagno (physician/facility name)	(ASC-US) (May have (3) Lowgrade SIL (HPV. (4) Atypical Squamous (5) Highgrade SIL (with) Yes No e / / (1) Cotesting/Screening (2) Reflex (3) Not Done (9) Unknown	Mild Dysplasia/CIN)* Cells, cannot exclude HSIL (ASC-H)* features suspicious for invasion/CIN - /CIS * (3) Adenocarcinoma in situ and a denocarcinoma in situ a	Reporting Only 18 Positive (Only report if P
Endocervical Cells C 4. HPV Test Dat Indication for HPV Test Rescreen Pap plann (less than 10 months) Referred for diagno (physician/facility name)	(ASC-US) (May have (3) Lowgrade SIL (HPV. (4) Atypical Squamous (5) Highgrade SIL (with) Yes No e // (1) Cotesting/Screening (2) Reflex (3) Not Done (9) Unknown ned Yes No stic work-up/direct bille	Mild Dysplasia/CIN)* Cells, cannot exclude HSIL (ASC-H)* features suspicious for invasion/CIN - /CIS * (3) Adenocarcinoma in situ and a denocarcinoma in situ a	Reporting Only 18 Positive (Only report if P
Endocervical Cells C 4. HPV Test Dat Indication for HPV Test Rescreen Pap plann (less than 10 months) Referred for diagno (physician/facility name)	(ASC-US) (May have (3) Lowgrade SIL (HPV. (4) Atypical Squamous (5) Highgrade SIL (with) Yes No e // (1) Cotesting/Screening (2) Reflex (3) Not Done (9) Unknown ned Yes No stic work-up/direct bille	Adenocarcinoma in situ and a construction of the construction of t	Reporting Only 18 Positive (Only report if P
Endocervical Cells C 4. HPV Test Dat Indication for HPV Test Rescreen Pap planr (less than 10 months) Referred for diagno	(ASC-US) (May have (3) Lowgrade SIL (HPV. (4) Atypical Squamous (5) Highgrade SIL (with) Yes No e // (1) Cotesting/Screening (2) Reflex (3) Not Done (9) Unknown ned Yes No stic work-up/direct bille	Adenocarcinoma in situ and a construction of the construction of t	Reporting Only 18 Positive (Only report if P
Endocervical Cells C 4. HPV Test Dat Indication for HPV Test Rescreen Pap plann (less than 10 months) Referred for diagno (physician/facility name) Date of next routine	(ASC-US) (May have (3) Lowgrade SIL (HPV. (4) Atypical Squamous (5) Highgrade SIL (with) Yes No e // (1) Cotesting/Screening (2) Reflex (3) Not Done (9) Unknown ned Yes No stic work-up/direct bille	Adenocarcinoma in situ and a construction of the construction of t	Reporting Only 18 Positive (Only report if P
Endocervical Cells C 4. HPV Test Dat ndication for HPV Test Rescreen Pap plann (less than 10 months) Referred for diagno (physician/facility name)	(ASC-US) (May have (3) Lowgrade SIL (HPV. (4) Atypical Squamous (5) Highgrade SIL (with) Yes No e // (1) Cotesting/Screening (2) Reflex (3) Not Done (9) Unknown ned Yes No stic work-up/direct bille	Adenocarcinoma in situ and a construction of the construction of t	Reporting Only 18 Positive (Only report if P
Endocervical Cells C 4. HPV Test Dat Indication for HPV Test Rescreen Pap plann (less than 10 months) Referred for diagno (physician/facility name) Date of next routine in	(ASC-US) (May have (3) Lowgrade SIL (HPV. (4) Atypical Squamous (5) Highgrade SIL (with) Yes No e // (1) Cotesting/Screening (2) Reflex (3) Not Done (9) Unknown ned Yes No stic work-up/direct bille	Adenocarcinoma in situ and a construction of the construction of t	Reporting Only 18 Positive (Only report if P
Endocervical Cells C 4. HPV Test Dat Indication for HPV Test Rescreen Pap plann (less than 10 months) Referred for diagno (physician/facility name)	(ASC-US) (May have (3) Lowgrade SIL (HPV. (4) Atypical Squamous (5) Highgrade SIL (with) Yes No e // (1) Cotesting/Screening (2) Reflex (3) Not Done (9) Unknown ned Yes No stic work-up/direct bille	Adenocarcinoma in situ and a construction of the construction of t	Reporting Only 18 Positive (Only report if P



·	DRESS)				REFERR	ING PROVIDE	R (FOR DIR	ECT BILLING)	
A. PERSONAL DATA									
IAME (LAST, FIRST, MIDDLE INITIAL)									
DATE OF BIRTH //	SOCIAL SECURITY NUMBER						CLIENT E	LIGIBILTY VERI	
INSURANCE COVERAGE	DEDUCTIBLE MET	REFERRALF	EE	TYPE C	F MEDIC	ARE		BCCT	
□ Yes □ No	☐ Yes ☐ No			□ Par	t A	☐ Part.	A and B	☐ Yes	□ No
BREAST DIAGNOSTIC PROCE	DURES								☐ Reporting o
Diagnostic Mammogram □ Co	onventional 🗆 Digital 🗖	Tomosynthesi	s	/	DD /	YYYY			
Additional Mammographic view	(s)								
L R		L	R						
Normal		Other □	l 🗆 (7)	Unsati	sfactory-	not interpre	ted-repea	t (not paid)	
Abnormal 🗆 🗀 (3) Probably Ben	nign (Category 3)		l 🗆 (5)	Highly	Sugges	tive of Mali	gnancy (C	ategory 5)	
	sbnormality (Category 4)		□ (14) Additio	nal Ima	ging Pendir	g (Catego	ry 0)	
Jitrasound//	_							☐ Rescreer	n □ Reporting o
				L	R				
eft: ☐ Complete ☐ Limited			Normal			Negative (Benign Fin			
- O			Abnorm			Probably E	•	• • •	
Right: ☐ Complete ☐ Limited			Abiloili						ry 4) - Refer to BCC
							anatius a	f Maliananay	(Category 5) -
Limited					□ (5)		to BCCT		(Galegory 5)
L Limited			Other		(7)	Refe Unsatisfac	to BCCT tory - not		repeat (not paid)
Specialist Consultation Date	_// Diagno	stic Work-up			(7) (14)	Refe Unsatisfac Needs Add	to BCCT tory - not ditional Ev	interpreted aluation (Ca	repeat (not paid) tegory 0)
Specialist Consultation Date	DD YYYY	stic Work-up			(7) (14)	Refe Unsatisfac Needs Add	to BCCT tory - not ditional Ev	interpreted aluation (Ca	repeat (not paid) tegory 0)
Specialist Consultation Date MM CBE WNL	o" indicate finding below)		Planned	□ [□ Nor	(7) (14)	Refe Unsatisfac Needs Add	to BCCT tory - not ditional Ev	interpreted aluation (Ca	repeat (not paid)
Specialist Consultation Date MM CBE WNL	o" indicate finding below) cystic changes, diffuse lumpin	ness, clearly	Planned	□ [□ Nor	(7) (14) ne	Refei Unsatisfac Needs Add 0-60 days dularity	to BCCT tory - not ditional Ev	interpreted aluation (Ca 0 days	repeat (not paid) tegory 0)
Specialist Consultation Date MM	o" indicate finding below) cystic changes, diffuse lumpin	ness, clearly Nipple disch	Planned defined that	□ [□ Nor Nor Nickenin □ (4) N	(7) (14) ne	Refei Unsatisfac Needs Add 0-60 days dularity	to BCCT tory - not ditional Ev 61-9	interpreted aluation (Ca 0 days	repeat (not paid) tegory 0) Reporting o
Specialist Consultation Date MM	o" indicate finding below) cystic changes, diffuse lumpin ete palpable mass (3) dimpling, retraction, new nippl inent veins, or unilateral increa	ness, clearly Nipple disch e inversion, ase in size	Delanned defined the arge [peau d'on	□ [□ Nor ickenin □ (4) N range, t	(7) (14) g, or no ipple or allocaration	Refei Unsatisfac Needs Add 0-60 days dularity areolar so	tory - not ditional Evaluation 61-9	interpreted aluation (Ca 0 days	repeat (not paid) tegory 0) Reporting of
Specialist Consultation Date MM	o" indicate finding below) cystic changes, diffuse lumpin ete palpable mass (3) dimpling, retraction, new nippl	ness, clearly Nipple disch e inversion, ase in size	Delanned defined the arge [peau d'on	□ [□ Nor ickenin □ (4) N range, t	(7) (14) g, or no ipple or allocaration	Refei Unsatisfac Needs Add 0-60 days dularity areolar so	tory - not ditional Evaluation 61-9	interpreted aluation (Ca 0 days	repeat (not paid) tegory 0) Reporting o
Specialist Consultation Date MM	o" indicate finding below) cystic changes, diffuse lumpin ete palpable mass (3) dimpling, retraction, new nippl inent veins, or unilateral increa ged, tender, fixed, or hard pal	ness, clearly Nipple disch e inversion, ase in size pable supra	Delanned defined the arge [peau d'on	□ [Nor	g, or no ipple or avicular,	Refei Unsatisfac Needs Add 0-60 days dularity areolar sc n; also on	tory - not ditional Evaluation 61-9	interpreted aluation (Ca 0 days	repeat (not paid) tegory 0) Reporting of sual; or unilateral welling of upper an
Specialist Consultation Date MM	o" indicate finding below) cystic changes, diffuse lumpin ete palpable mass (3) dimpling, retraction, new nippl inent veins, or unilateral increa ged, tender, fixed, or hard pal	ness, clearly Nipple disch e inversion, ase in size pable supra	Defined the arge peau d'or clavicular,	□ II □ Nor nickenin □ (4) N range, u infracla	g, or no ipple or allocration avicular,	Refei Unsatisfac Needs Add 0-60 days dularity areolar so n; also on- or axillary	to BCCT tory - not ditional Ev 61-9 caliness c e breast I	interpreted aluation (Ca 0 days	repeat (not paid) tegory 0) Reporting of sual; or unilateral welling of upper an
Specialist Consultation Date BE WNL	o" indicate finding below) cystic changes, diffuse lumpin ete palpable mass (3) dimpling, retraction, new nippl inent veins, or unilateral increa ged, tender, fixed, or hard pal	ness, clearly Nipple disch e inversion, ase in size pable supra	Delanned defined the arge peau d'or clavicular, plogy Perf	□ II □ Nor nickenin □ (4) N range, u infracla	g, or no ipple or avicular,	Refei Unsatisfac Needs Add 0-60 days dularity a areolar st n; also on or axillary No	to BCCT tory - not ditional Ev 61-9 caliness c breast I	interpreted aluation (Ca 0 days r erythema ower than us	repeat (not paid) tegory 0) Reporting of sual; or unilateral welling of upper ar
Specialist Consultation Date MM Pes	o" indicate finding below) cystic changes, diffuse lumpin ete palpable mass	ness, clearly Nipple disch e inversion, ase in size pable supra	Delanned defined the arge peau d'or clavicular, plogy Perf	□ II □ Nor nickenin □ (4) N range, u infracla	g, or no ipple or allocration avicular,	Refei Unsatisfac Needs Add 0-60 days dularity areolar se n; also on or axillary No	to BCCT tory - not ditional Ev 61-9 caliness c breast I	interpreted aluation (Ca 0 days r erythema ower than us odes; also so	repeat (not paid) tegory 0) Reporting of sual; or unilateral welling of upper ar Reporting or
Specialist Consultation Date MM MR Pes	o" indicate finding below) cystic changes, diffuse lumpin ete palpable mass	ness, clearly Nipple disch e inversion, ase in size pable supra	Delanned defined the arge peau d'or clavicular, plogy Perf	□ II □ Nor nickenin □ (4) N range, u infracla	g, or no ipple or allocration avicular,	Refei Unsatisfac Needs Add 0-60 days dularity areolar so n; also on Or axillary No Supe Deep	to BCCT tory - not ditional Ev 61-9 caliness c e breast I right lissue ur est Lesion Ultrasoul	interpreted aluation (Ca 0 days r erythema ower than us odes; also so der guidance	repeat (not paid) tegory 0) Reporting of sual; or unilateral welling of upper ar Reporting or te ditional Lesion Ultrasound
Specialist Consultation Date MM	o" indicate finding below) cystic changes, diffuse lumpin ete palpable mass	ness, clearly Nipple disch e inversion, ase in size pable supra	Delanned defined the arge peau d'or clavicular, plogy Perf	□ II □ Nor nickenin □ (4) N range, u infracla	g, or no ipple or allocration avicular,	Refei Unsatisfac Needs Add 0-60 days dularity areolar sc n; also on or axillary No Supe Deep Fii	to BCCT tory - not ditional Ev aliness c breast I lymph n rficial tissue un st Lesion Ultrasou Fluorosc Cat Scar	interpreted aluation (Ca of days) r erythema ower than used and and and and and and and and and an	repeat (not paid) tegory 0) Reporting of sual; or unilateral welling of upper an Reporting or ditional Lesion Ultrasound Fluoroscopy Cat Scan
Specialist Consultation Date MM	o" indicate finding below) cystic changes, diffuse lumpin ete palpable mass	ness, clearly Nipple disch e inversion, ase in size pable supra	Delanned defined the arge peau d'or clavicular, plogy Perf	□ II □ Nor nickenin □ (4) N range, u infracla	g, or no ipple or illocration avicular,	Refei Unsatisfac Needs Add 0-60 days dularity areolar sc n; also on or axillary No Supe Fi Fi G	to BCCT tory - not ditional Ev aliness c breast I lymph n rficial tissue un st Lesion Ultrasou Fluorosc Cat Scar MRI	interpreted aluation (Ca of days) r erythema ower than used and and and and and and and and and an	repeat (not paid) tegory 0) Reporting of sual; or unilateral welling of upper ar Reporting or ditional Lesion Ultrasound Fluoroscopy
Specialist Consultation Date MMM CBE WNL	o" indicate finding below) cystic changes, diffuse lumpin ete palpable mass	ness, clearly Nipple disch e inversion, ase in size pable supra	Delanned defined the arge peau d'or clavicular, plogy Perf	□ II □ Nor nickenin □ (4) N range, u infracla	g, or no ipple or illocration avicular,	Refei Unsatisfac Needs Add 0-60 days dularity areolar so or axillary No Supe Fi Given	to BCCT tory - not ditional Ev aliness c breast I lymph n rficial tissue un st Lesion Ultrasou Fluorosc Cat Scar MRI egative	interpreted aluation (Ca ol days older guidance older guidance older guidance older guidance older guidance older guidance older old	repeat (not paid) tegory 0) Reporting of sual; or unilateral welling of upper ar Reporting or ditional Lesion Ultrasound Fluoroscopy Cat Scan
Specialist Consultation Date MMM CBE WNL	o" indicate finding below) cystic changes, diffuse lumpin ete palpable mass	ness, clearly Nipple disch e inversion, ase in size pable supra Cytopatho	Delanned defined the arge peau d'or clavicular, plogy Perf	□ II □ Nor nickenin □ (4) N range, u infracla	g, or no ipple or illocration avicular,	Refei Unsatisfac Needs Add 0-60 days dularity areolar so or axillary No Supe Pie Deep Company (1) Ne (2) Inc	to BCCT tory - not ditional Ev aliness of breast I lymph n rficial tissue un rst Lesion Ultrasou Fluoroso Cat Scar MRI egative determina	interpreted aluation (Ca of days) r erythema ower than us odes; also so odes; also so odes opy defined	repeat (not paid) tegory 0) Reporting of sual; or unilateral welling of upper ar Reporting or de ditional Lesion Ultrasound Fluoroscopy Cat Scan MRI
Specialist Consultation Date CBE WNL	o" indicate finding below) cystic changes, diffuse lumpin ete palpable mass	ness, clearly Nipple disch e inversion, ase in size pable supra Cytopatho	Delanned defined the arge peau d'or clavicular, plogy Perf	□ II □ Nor nickenin □ (4) N range, u infracla	g, or no ipple or illocration avicular,	Refei Unsatisfac Needs Add 0-60 days dularity rareolar so n; also on or axillary No Supe Fi Call 10 Ne Call 11 Ne Call 20 Inc Call 3) St	to BCCT tory - not ditional Ev aliness c be breast I by lymph n rficial tissue ur rst Lesion Ultrasou Fluorosc Cat Scar MRI ggative determina	interpreted aluation (Ca of days) r erythema ower than us odes; also so odes; also so odes opy defined	repeat (not paid) tegory 0) Reporting of sual; or unilateral welling of upper ar Reporting or te ditional Lesion Ultrasound Fluoroscopy Cat Scan MRI

MM DD YYYY		☐ Reporting only
	Anesthesia 🗖	
Primary Biopsy Type: Clear		
Percutaneous □ Left □ Right □ Stereotactic Guided (19081) □ US Guided (19083) □ Needle Core, No Guidance (19100)	☐ Add Lesion	Additional Primary Pathology No additional pathology 1 additional pathology
□ Incisional, No Guidance (19101) □ Mammogram Guided (19281) □ Stereotactic G □ Excisional (19120 or 19125) Radiological exam of specimen? □ Yes □ No	uided (19283)	☐ 2 additional pathology☐ 3 additional pathology
Additional Lesion: Clear		
□ Incisional, No Guidance (19101) □ Mammogram Guided □ Stereotactic G □ Excisional (19120) Radiological exam of specimen? □ Yes □ No	uided 🔲 US Guided	Additional Secondary Patholo No additional pathology 1 additional pathology 2 additional pathology 3 additional pathology
Additional Facility Fee Yes No		
□ (2) Benign/Atypical □ (2) Work-up Pe □ (3) Indeterminate □ (3) Lost to Foll □ (4) Malignancy □ (4) Work-up Re	emplete (Complete Section C) ending	- FOR STAFF USE ONLY)
Next Breast Cancer Screening Date		MM DD YYYY
	ma In Situ (DCIS) (Stage 0)*	e Date:
☐ (4) Lobular Carcinoma In Situ (LCIS) (Stage 0)* ☐ (2) Invasive Breast	t Cancer*	
, , ,		
MM DD YYYY		
D. BREAST TREATMENT		
D. BREAST TREATMENT	Tyne	
	Type (1) Surgery (2) Radiation (3) Chemotherapy (4) Hormone (5) Immunotherapy (6) Other Cancer The	erapy
D. BREAST TREATMENT Status of Treatment (1) Started (2) Pending (3) Lost to F/U (Describe in comment section) (4) Refused (Describe in comment section/Must have signed waiver)	☐ (1) Surgery ☐ (2) Radiation ☐ (3) Chemotherapy ☐ (4) Hormone ☐ (5) Immunotherapy	erapy
D. BREAST TREATMENT Status of Treatment (1) Started (2) Pending (3) Lost to F/U (Describe in comment section) (4) Refused (Describe in comment section/Must have signed waiver) (5) Not Needed	☐ (1) Surgery ☐ (2) Radiation ☐ (3) Chemotherapy ☐ (4) Hormone ☐ (5) Immunotherapy ☐ (6) Other Cancer The	эгару
D. BREAST TREATMENT Status of Treatment (1) Started (2) Pending (3) Lost to F/U (Describe in comment section) (4) Refused (Describe in comment section/Must have signed waiver) (5) Not Needed Treatment Facility (Facility Name/City)	☐ (1) Surgery ☐ (2) Radiation ☐ (3) Chemotherapy ☐ (4) Hormone ☐ (5) Immunotherapy ☐ (6) Other Cancer The	erapy
D. BREAST TREATMENT Status of Treatment (1) Started (2) Pending (3) Lost to F/U (Describe in comment section) (4) Refused (Describe in comment section/Must have signed waiver) (5) Not Needed Freatment Facility (Facility Name/City) Date Treatment Started MM / DD / YYYY	☐ (1) Surgery ☐ (2) Radiation ☐ (3) Chemotherapy ☐ (4) Hormone ☐ (5) Immunotherapy ☐ (6) Other Cancer The	erapy



ENROLLMENT SITE/SATELLITE (NAME AND ADDRE	ESS)			REFERRING PROV	VIDER (F	OR DIRECT BILLING)	
A. PERSONAL DATA							
NAME (LAST, FIRST, MIDDLE INITIAL)							
DATE OF BIRTH	SOCIAL SECURITY NU	IMBER			ı	TELIGIBILITY VERIFIED	
MM DD YYYY INSURANCE COVERAGE	DEDUCTIBLE MET	REFERRAL FEE	TYPE O	MEDICARE	☐ Yes	■ No BCCT	
Yes No	YES No		l	■Part A and B		☐ Yes ☐ No	
B. CERVICAL DIAGNOSTIC PRO	CEDURES		l				
Specialist Consultation	J					☐ Reporting	g Only
Diagnostic Work-up Planned ☐ No	one 🗖 0-60 Day	/s □ 61-90 days					
☐ Colposcopy without Biopsy	MM DD Y	YYY				□ Reporting	g Only
□ Colposcopy/	/ 					☐ Reporting	g Only
Polypectomy/	/					☐ Reporting	g Only
☐ Colposcopy inadequate, need ☐ Diagnostic procedures, choose Ol				al Cervical Biops al Cervical Biops		□ Reportin	g Only
□ LEEP ← OR	(3)	•	→	□ Endocervic	al Cur	ettage (alone)	
Other Cervical Procedure (Specify) (Use only fo	or procedures perfo	rmed for management of a ce	ervical les	sion.)		MM DD YYY	
Next Cervical Cancer Screening D	ate/_	YY					
Status of Final Diagnosis (1) Work-up Complete (Con (2) Work-up Pending (3) Lost to F/U (Describe in (4) Work-up Refused (Desc (5) Irreconcilable (Does not	comment section)			e:/	/		Ch. D-2

☐ (6) Invasive (Biopsy Diagnosed)* (Reference ☐ (7) Other	Biopsy Diagnosed)* Diagnosed)* (Refer to BCCT) Ie SIL/Carcinoma In Situ (CIS), Stage 0 (Biopsy Diagnosed)* (Refer to BCCT)
inal Diagnosis Date//	
D. CERVICAL TREATMENT	
Status of Treatment Started Pending Lost to F/U (Describe in comment so Work up refused (Describe in comm	
Treatment Facility Facility Name/City	
ate Treatment Started//////	YYYY
omments	

MISSOURI DEPARTMENT OF SOCIAL SERVICES FAMILY SUPPORT DIVISION BCCT TEMPORARY MO HEALTHNET AUTHORIZ (0)	DO NOT mail to address on form. DO MAIL the application as quickly as possible to: FSD Customer Relations Unit 101 Park Central Square Springfield, Missouri 65806
Dear You are eligible for Temporary MO HealthNet based uprogram screening results. Your temporary coverage eligibility for on-going MO HealthNet coverage. MO HealthNet medical provider you use accepts MO HealthNet page.	will continue althNet can pa medical services only when
An application for MO HealthNet based upon your ris enclosed. Please complete the application and m Buchanan County office as quickly as possible. If y application by the last day of next month, your MO	ail it to the Family Support Division's (FSD) ou fail to complete and return the enclosed
You will receive a white MO HealthNet card in approxicard, use this letter when you go to your doctor, phan have questions about MO HealthNet providers or how the county FSD office of your residence.	macy or other medical service provider. If you
If you have any questions pertaining to continuing me office of your residence or Missouri Family Support Divnumber at 1-888-275-5908.	
SMHW Contracted Provider:	
SMHW Eligibility confirmed by:	
Date:	
Name MO HealthNet N	Number Beginning Date of Coverage
A	

MO 886-3078 (6-08)

DO NOT mail to address on form. DO MAIL the application as quickly as possible to: MISSOURI DEPARTMENT OF SOCIAL SERVICES DIVISION OF FAMILY SERVICES **FSD Customer Relations Unit BCCT MEDICAL ASSISTANCE APPLICATION** 101 Park Central Square Send completed application to Springfield, Missouri 65806 Family Support Division TELEPHONE NUMBER PO Box 2320 Jefferson City MO 65102-2320 SUPERVISOR DIAGNOSIS DATE FAX: 573-751-3091 COMPLETE IN INK A. MAILING ADDRESS SOCIAL SECURITY NUMBER ADDRESS (HOUSE NO., STREET, RURAL ROUTE, PO BOX NO.) CITY, STATE, ZIP CODE COUNTY HOME TELEPHONE NUMBER WORK TELEPHONE NUMBER MESSAGE PHONE NUMBER B. INSTRUCTIONS: Please answer each question completely. NO YES 1. Are you a U.S. citizen? If "NO", list immigration status and registration number, date of entry: 2. Do you currently have healthcare insurance? NAME OF COMPANY AND POLICY NUMBER TYPE OF COVERAGE DOCTOR HOSPITAL If limited coverage explain: NO YES 3. Do you have children under the age of 19 residing in your home? 4. Are you pregnant? 5. Are you blind? 6. Are you disabled? C. PLEASE READ CAREFULLY AND SIGN BELOW: I agree to provide Social Security Numbers of all persons applying for Medicaid as required by law. The social security number is used to determine eligibility and verify information. I agree that my statements and information provided may be verified. • I will report any changes in circumstances within TEN DAYS of when they happen. · I know that it is against the law to obtain benefits to which I am not entitled. Any false claim, statement or concealment of any material fact whatsoever, in whole or in part, may subject me to criminal and/or civil prosecution. · I agree that medical information about me can be released if needed to administer this program. I understand Healthcare benefits based on a person being blind, disabled, age 65 or over, pregnant women, child or parent, is not determined by completing this application. If I want eligibility for healthcare benefits explored on the basis of one of these, I must complete a different application for these benefits. Provided I am found to be eligible for Medicaid, I know the state of Missouri will pay for covered services on my behalf and agree the state may collect payments from any third party (i.e., insurance, estate, etc.) for services paid by the state. · I understand the decision on my eligibility will be released to the State of Missouri BCCCP Program for tracking purposes. I understand that if I disagree with the decision concerning my eligibility, I may request a fair hearing within 90 days of the date of the · I understand I am entitled to fair and equal treatment regardless of my age, sex, race, color, handicap, religion, creed, national origin or political belief I agree that the signature below certifies under penalty of perjury that all declarations made in this eligibility statement are true, accurate, and complete, to the best of my knowledge. CALL 1-888-275-5908 IF YOU HAVE ANY QUESTIONS. MO 886-3977 (1-18) IM-1BC (1-18)

企业	MISSOURI DEPARTM	ENT OF SOCIAL	SERVICES		Save		Print	Rese
	FAMILY SUPPORT DIV	/ISION						
STATE OF THE PARTY	CERTIFICATION (OF NEED FOR	TREATMEN	T – BREAST/CI	ERVICAL CA	ANCER		
PATIENT NAME								
PATIENT DOB (MM/DD/YYYY)							
PATIENT MO HE	EALTHNET NUMBER (DCN)							
ALIENT MOTE	EXETTINE THOMBER (BON)							
I ce	ertify that the above	e patient:						
			_					
	Was diagnosed	as having 🗆 l	oreast or 🗌 (CHECK ON			MM/DD/YY		and,
	Is in need of tre	atment for bre	east or cervi	cal cancer: OR				
						4! 4		
	Is currently rece	-			ncer. The e	estimat	ea aate	wnen
	the current cour	se of treatme	nt will end is	DATE (MM/D	IDAYYY			
				DATE (MINITE	D/1111)			
Note: Eligibi	ility Specialist must set	a priority for follo	w-up based on e	estimated treatment	completion dat	е.		
		a priority for follow	w-up based on e	estimated treatment		e. TE		
		a priority for follow	w-up based on e	estimated treatment				
PHYSICIAN'S S		a priority for follo	w-up based on e	estimated treatment				
PHYSICIAN'S S	SIGNATURE	a priority for follo	w-up based on e	estimated treatment				
PHYSICIAN'S S	T NAME OF PHYSICIAN	a priority for follow	w-up based on e	estimated treatment				
PHYSICIAN'S S	T NAME OF PHYSICIAN	a priority for follo	w-up based on e		DA	ΤE		
PHYSICIAN'S S TYPE OR PRINT	T NAME OF PHYSICIAN	a priority for follow	w-up based on e	estimated treatment	DA	ΤE	BER	
PHYSICIAN'S S TYPE OR PRINT PHYSICIAN SPI	T NAME OF PHYSICIAN ECIALTY T PROVIDER NUMBER				DA	ΤE	BER	
PHYSICIAN'S S TYPE OR PRINT PHYSICIAN SPI	T NAME OF PHYSICIAN				DA	ΤE	BER	
PHYSICIAN'S S TYPE OR PRINT PHYSICIAN SPI	T NAME OF PHYSICIAN ECIALTY T PROVIDER NUMBER				DA	ΤE	BER	
PHYSICIAN'S S TYPE OR PRINT PHYSICIAN SPI	T NAME OF PHYSICIAN ECIALTY T PROVIDER NUMBER				DA	ΤE	BER	
PHYSICIAN'S S TYPE OR PRINT PHYSICIAN SPI	T NAME OF PHYSICIAN ECIALTY T PROVIDER NUMBER				DA	ΤE	BER	
PHYSICIAN'S S TYPE OR PRINT PHYSICIAN SPI	T NAME OF PHYSICIAN ECIALTY T PROVIDER NUMBER				DA	ΤE	BER	
PHYSICIAN'S S TYPE OR PRINT PHYSICIAN SPI	T NAME OF PHYSICIAN ECIALTY T PROVIDER NUMBER				DA	ΤE	BER	

CERTIFICATION OF NEED FOR TREATMENT - BREAST/CERVICAL CANCER

<u>Purpose</u>: To provide a signed statement from the diagnosing/treating physician as to the date of the diagnosis and/or the length of time treatment will be for breast or cervical cancer. This form is used to tell the eligibility specialist the date of diagnosis and the time limit the treatment will last for the claimant.

Number of Copies and Distribution: Complete on copy of the form in ink or type and file in the case record.

Instructions for Completion:

The following parts of this form are to be completed by the eligibility specialist prior to sending to the treating physician:

- · Patient Name
- · Patient's Date of Birth
- · Patient's MO HealthNet Number (DCN)
- · Address of where to send the completed form

The form is then sent to be completed by the diagnosing/treating physician.

If initially applying for BCCT through a county office, the physician must certify the following:

- · Date of diagnosis, and either
- · Need for treatment, or
- · If currently receiving treatment, the estimated date the current course of treatment will end.

Upon receiving the completed BCC-2, the eligibility specialist will set a priority based on the patient status:

- · Initial application with diagnosis only-Set priority to check on treatment status in three (3) months; or
- Active case-Set priorities as needed to redetermine whether treatment is still needed for breast or cervical cancer.
 Priorities are based on the date the current course of treatment is expected to end.

MO 896-3979 (5-13)
BOC-2 INSTRIUCTIONS (05/2013)




MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES BUREAU OF GENERAL SERVICES

	INFORMATION BEI 3) 751-1574	LOW AND RETURN	TO: MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES GENERAL SERVICES WAREHOUSE P.O. BOX 570, JEFFERSON CITY, MO 65102-0570	WAREHOUSE CONTROL NO.
		FOLLOWIN	G LITERATURE:	
QUANTITY* EQUESTED	WAREHOUSE USE ONLY SUPPLIED	STOCK NO.	TITLE (PLEASE LIST <u>EXACT</u> TITLE)	DHSS WAREHOUSE USE ONLY
			TRICT QUANTITIES SUPPLIED. BE COMPLETED IN FULL TO PROCESS YOUR REQUEST	
	GANIZATION NAME			DATE
TACT PERSO	N'S NAME			PHONE NO.
PING ADDRE	SS (P.O. Box holder	s MUST include street	address) CITY, STATE, ZIP CODE	()
0-0393 (7-04)		DISTRIBUTE	ON: WHITE / LIT. LIBRARY: YELLOW / REQUESTER RETURNED: PINK / REQUESTER	
5 3000 (r-04)		AN E	OQUAL OPPORTUNITY/AFFIRMATIVE ACTION EMPLOYER – services provided on a nondiscriminatory basis	L

Forms for MOHSAIC Entry

Overvie	ew of Client Forms for MOHSAIC Entry11.1
	Green Patient History Form Blue Screening Report Purple Breast Diagnosis and Treatment Form Yellow Cervical Diagnosis and Treatment Form
MOHSA	AIC Access11.3
Navigat	ting MOHSAIC11.8
	Lesson 1: The CLIENT Lesson 2: Financial



Overview of Client Forms for MOHSAIC Entry

Providers entering on-line information are not required to fill out paper forms but must have documentation of the information submitted in the Missouri Health Strategic Architectures and Information Cooperative (MOHSAIC) in client files for quality assurance (QA) review.

Access the Patient History, Screening Report, Breast Diagnosis and Treatment, Cervical Diagnosis and Treatment, and Client Navigation forms online at:

https://health.mo.gov/living/healthcondiseases/chronic/showmehealthywomen/forms.php. Alternatively, call 866-726-9926.

All forms contain a 'Comment' section at the bottom of the form. This is used for additional notes on the client or procedures entered by provider or DHSS staff. Explanations should be kept brief as space is limited. Comments are not mandatory, but helpful to retain information not covered in the form. Providers must submit completed client forms within 60 days of service.

If waiting for insurance reimbursement/approval forms, do not submit complete billing until the amount insurance paid is available. See page 9.3 for Insurance Guidelines.

Green Patient History Form

The Patient History form (**green form**, pages 10.8-.9) shall be completed by each client at the initial screening visit and at every annual screening thereafter. The provider shall enter the green history form into MOHSAIC when reporting the initial screening visit and update the information each year, as needed. Enter the green history form into MOHSAIC before entering any other form.

Blue Screening Report

A completed Screening Report form (**blue form**, pages 10.10-.11) shall be submitted at the initial, rescreen, and annual screening for all clients participating in SMHW. Document the first mammogram a client receives on the screening report.

Purple Breast Diagnosis and Treatment Form

Breast Diagnosis and Treatment form (**purple form**, pages 10.12-.13) shall be fully completed for all clients with abnormal breast cancer screening results that require further diagnostic procedures and/or treatment. If needed, diagnostic service(s), date of service(s), results of diagnostic service(s), final diagnosis, and treatment (date, type and place) are also required on the purple form. This information is crucial for the successful follow-up and/or treatment of all clients with abnormal screening results.

Yellow Cervical Diagnosis and Treatment Form

Cervical Diagnosis and Treatment form (**yellow form**, pages 10.14-.15) shall be fully completed for all clients with abnormal cervical cancer screening results that require further diagnostic procedures and/or treatment. If needed, diagnostic service(s), date of service(s), results of diagnostic service(s), final diagnosis, and treatment (date, type, and place) are also required on the yellow form. This information is crucial for the successful follow-up and/or treatment of all clients with abnormal screening results.

MOHSAIC Access

MOHSAIC is an online data system used to collect and manage client service records for the SMHW and WISEWOMAN programs.

MOHSAIC also tracks funding allocations and expenditures and is linked to the Statewide Advantage for Missouri (SAM II) accounting system for reimbursing providers. Prior to reimbursement, SMHW and WISEWOMAN staff review all submitted forms to ensure client services meet program standards.

SMHW must submit Minimum Data Elements (MDE) reports to the Centers for Disease Control and Prevention (CDC) from the MOHSAIC reporting data forms.

How to apply for access to MOHSAIC

To apply for access to MOHSAIC, applicants will need to follow the instructions in the following pages.

AUTOMATED SECURITY ACCESS PROCESSING (A.S.A.P)

REQUESTING ACCESS TO SHOW ME HEALTHY WOMEN

STEP A. Creating A.S.A.P User profile

(This step is to be completed only once per user.)

Please read.

- If you have an ASAP profile already and know your login credentials, please skip to Step B (submitting the request)
- If you are unsure you have an ASAP profile, here are a few steps to determine that
 - If you already have an LPHA e-mail account, DHSS health applications and/or DSS prod/mainframe access, you mostly likely have an ASAP profile.
 - If you try to create an ASAP profile and you receive a red message indicating that first name and last name is already in use, please contact the ITSD Call Center at 800.347.0887 for assistance. This most likely means you have an ASAP profile and the call center can assist with profile updates, password resets, logging into ASAP, and/or submitting requests.

Creating A.S.A.P User profile

- Open Internet Browser and enter address http://webapp02.dhss.mo.gov/asap_web/ASAPLogin.aspx
- Click "Yes" to any security messages


Steps	Screen Print			
1. Click the NEW USER option	DEPARTMENT OF HEALTH AND SENIOR SERVICES a. s. a. p. automated security access processing DHSS Home >> arap. web >> ASAPLogin Welcome to the Missouri Department of Health and Senior Services Intermeted Security Access Processifus, Apri site. User's sequest new access or change existing access for various network or section systems supported by the Department of Health and Senior. Section systems supported by the Department of Health and Senior. Section systems supported by the Department of Health and Senior. Section systems supported by the Department of Health and Senior. Section systems supported by the Department of Health and Senior. Section systems supported by the Department of Health and Senior. Section systems supported by the Department of Health and Senior Section Section Senior Section S			
 Enter your first name, last name and last four digits of your SSN. Enter a Preferred First Name, if desired. Click the CREATE USERID button. 	ENTER FIRST NAME, LAST NAME AND LAST FOUR DIGITS OF S.S.N TO CREATE ASAP PROFILE First Name: Last Name: Last Name: Used As part of your email Address. ex:PreferredFirstName LastN CREATE USERID			
3. Make note of your UserID.	*Agency: Your ASAP User ID has suc User ID is: USERJ Choose the appropriate agency DHSS Employee or Contractor LPHA (Local Public Health Agency) Others (Schools, Private Providers, etc)			
 Choose 'Others (Schools, Private Providers, etc.)' for the Agency. Choose 'DHSS DIVISION OF COMMUNITY HEALTH' for Local Security Officer County. Choose 'SHOW ME HEALTHY WOMEN LSO – (Paula Fox)' for Local Security Officer. 	*Agency: *Local Security Officer: Others (Schools, Private Providers, etc) DIVISION OF COMMUNITY AND PUBLIC HEALTH - DCPH *HOW ME HEALTHY WOMEN LSO (MARY NOVINGER)			
Type your work street number; it will provide a drop-down list. Click your address	*Address Search (Type in your address starting with Street Number)			
Enter your e-mail address, telephone number, and fax number	'Email1 ' Phone1 Ext Fax Number			


8.	Enter a password Retype your password Enter a challenge question. This should be a question only you know the answer to. Type the response or answer to the challenge question Retype the response or answer to the challenge questions **If ASAP did not prompt you to create a password, your password was automatically set to first initial of first name, first initial of last name, and last four digits of your social security number.**	Password Retype Password Challenge Question Challenge Response Retype Response	[Password length between 6-8] ex.What is your favorite color? ex.Blue
9.	Click the CREATE PROFILE button	CREATE PROFILE	
10.	You should see a message about the profile being successfully created. Make note of your User ID	PROFILE SUCCESSFULLY CRE Your ASAP User ID has successful	 Your User ID is: USERL Request Access

------ Please continue to Step B. ------

STEP B. Request SMHW access

- Open Internet Browser and enter address https://healthapps.dhss.mo.gov/asap-web/ASAPLogin.aspx
- Click Yes to any security messages





If you experience any problems or have questions while using the ASAP system, please notify the DHSS ITSD Call Center using one of the following methods:

Telephone: 573.751.6388 or 1.800.347.0887

E-mail: Support@health.mo.gov

Navigating MOHSAIC

Lesson 1: The CLIENT

This is for the Provider or MOHSAIC Customer. In this lesson, learn how to:

- Develop a new password
- Log onto the SMHW application
- Search for existing clients
- View Medicaid information
- Register new clients

MOHSAIC HELPFUL TIPS:


- Use Internet Explorer
- 2. Check Compatibility setting
- 3. Check text size for screens with overlapping words or adjust zoom setting if needed
- 4. Turn off Pop-Up Blockers (MOHSAIC uses pop-up screens for data information)

Steps to Access the MOHSAIC Application and Log onto the SMHW Application

Log-in Process

Open the Internet browser and enter the Web address on the address line: https://healthapps.dhss.mo.gov/smhw/.

- If this is the first time to login, a password must be established:
 - Use the username and assigned password provided to you by e-mail from SMHW, when approved. User name is usually the first five letters of last name and first name initial. Initial password is first and last name initials and last four digits of SSN.
 - Click on 'Change Password.'
 - If you do not login to MOHSAIC for 30 days, the system will 'lock out.' You must call the ITSD Help Desk at 800-347-0887 to unlock and enter new password.
 - After a password is established, the program will ask to change your password every 30 to 60 days. This can be numbers, letters, or a combination, as desired. Password requires six (6) to eight (8) characters and one numeric value.
- Once logged in, your agency name will appear and stay constant throughout the application.
- Click the 'Login' button to proceed.



Entering or Viewing a Client

The main screen for the SMHW program appears. To enter or view a client:

- · Click on the 'Client' link on the menu bar
- Choose 'Submit New Forms/Billing'




Client Search

In 'Submit New Forms/Billing' screen under the 'Client Information' section, choose either to 'Search and Select' or 'Register a New Client.'

Type the Social Security Number (SSN) with no spaces or hyphens; the Departmental Client Number (DCN) or the last and first name of the client separated by a comma (Example: Doe, Jane). **Do not click return – wait until drop down menu appears.**

If the screen returns more names than the screen will hold, use the scroll down bar to see the full screen. If there are more than 15 names on the screen use the double arrow at the bottom of the screen to proceed to the next search result screen.




Searching for Current Client

If the client name appears, then select the correct name by clicking on it. Verify the name by checking the date of birth (DOB) and DCN number, if available. The client may be in the system with multiple names. Choose the name of the client as she presents to you. If not available, select one and then correct with 'Update Client Information.'


The client information screen will display the client demographic information. If any information is missing, add the correct information in the 'Update Client Information' screen.

If the client name is not in the database, this screen will say 'No Results Found'. Press the tab key to continue.



Adding a New Client

If the client name does not appear, then hit the 'enter' or 'tab' key and the message to add a new client appears. Click the 'OK' button and proceed to the 'Add Person' screen.




The search will check the MOHSAIC and DSS databases. If the client name is not in the system, the screen appears with the 'No results found matching search criteria.' Click the 'Create New Client on MOHSAIC' link.



Adding new client, continued


The 'Client Information' screen is displayed. The next step is to enter the address and telephone number. Then proceed to the 'Provider Information' section or view Medicaid information.



Address Verification

If the system does not recognize the address, 'Address Verification' will pop up. If the address is correct, enter the county and click "save." Or change the address to a valid address and click save.


If the county and address match the database, the pop-up box will turn orange. If not, and both fields are correct, call SMHW at 866-726-9926 to request an address fix. Normally this fix will be done overnight.



Checking for Medicare/Medicaid

If the client name is not on Medicaid, the screen will be empty. The 'View Medicaid Information' is transferred from the DSS database. **This screen is 'read only'**. The screen will display the current client at the top of the screen.

If a client name is displayed at the top of the screen and is on Medicaid, the screen will be filled in.



Checking for Medicare/Medicaid, continued

This screen shows all of the client and guardian (if applicable) information as well as the managed care information. If there is an open date but no close date, the client is on some sort of assistance.




Please remember when pulling up or entering another client under client demographics, <u>verify</u> the client address and other personal information is correct. We have encountered several forms that were entered for a different client, but only the client name was changed. This leads to duplicate records in the system and results in errors on the data submitted to CDC. <u>Until a software programming change is complete</u>, <u>please make sure the date of birth and SSN are correct for the client form being entered</u>.

Entering Provider and Form Type Information

On the 'Provider Information' section, select either 'Regular' or 'Direct Billing'. If 'Direct Billing' is selected, a referring provider must be entered. Type in the provider's name and select the appropriate provider. If 'Regular Billing' is selected, a referring provider is not necessary.

When entering information in this section is complete, proceed to the next section – 'Form Type/Version.'


This section has two parts: a) when one of the forms is selected, the version will be filled in and b) during the first few months of the new grant year, there could be multiple versions. By default, the software automatically selects the version based on the present date. To enter a form with a different date of service, select a different version from the drop down box.



Entering Provider and Form Type Information continued

Under the gray heading, 'Form Type/Version', click on the correct form 'Type' for the submitted information:


- Breast Diagnosis and Treatment (purple)
- Cervical Diagnosis and Treatment (yellow)
- Patient History (green)
- Screening Reporting Form (blue)
- WISEWOMAN Form (pink)



Entering Provider and Form Type Information continued

Click on the correct form 'Version': ('Forms for Services Provided On or After June 30, 20__.'). Dates must correspond with the service dates being submitted. Click on the correct form 'Version' for the submitted information:

Forms for Services Provided On or After June 30, of the appropriate grant year.




Filling Out a Form

The name is displayed before entering the data. The form on the screen is the same as the paper form. Fill in the form and click the 'Submit' button at the bottom of the screen to submit/save.

To fill in the forms use the mouse, tab key, or the space bar. To use the mouse, click on the drop down arrow and then select the appropriate choice. If using the mouse for buttons, just click inside the circle. All forms work the same way.


- If content of the drop down box is known, then tab to the empty field and type the first letter. The word will appear.
- Tab to the next field.
- When tabbing and encountering a square radio button, hit the space bar to fill it in.
- Tabbing to a radio button will automatically fill in the circle when highlighted.



How to Complete 'Reporting Only' Process

EXAMPLE: A client who is eligible for SMHW diagnostic services is referred from an outside provider. The client has had a breast or cervical screening/diagnostic that is suspicious for cancer. Cancer diagnosis by a tissue biopsy is unconfirmed.

- Verify client eligibility
- Have client sign SMHW Client Eligibility Agreement form
- Complete green History form
- Enter data into MOHSAIC from green History form
- Enter the abnormal screening information on the blue Screening form as Reporting Only.



Screening Report Form

If a SMHW provider performs additional breast/cervical procedures, enter the data and check the appropriate visit type.

If no SMHW screening services are provided by a SMHW provider, check the appropriate 'Visit Type' and check the 'Referral Fee' box if requesting the \$20 referral fee. Provider reimbursement is for the referral fee only, not an office visit.

Report any other outside diagnostic procedures completed prior to enrollment on the appropriate diagnostic form as 'Reporting Only' and report SMHW follow-up procedures as usual.




Screening Report Form, continued

An error message may appear at the bottom of the screen after the 'Submit' button is clicked. If this happens, the system will require form correction before proceeding. Upon form correction, click the 'Submit' button again and the system will proceed to the next screen.

After the successful submission of the form the 'Submit Form' screen will again be displayed. If you wish to continue with this client for additional forms, return to 'Submit New Form/Billing.'

To search for another client, type over the current name and the new search result screen will appear. Select the new SSN and the screen will refresh with the new client name and information.



Lesson 2: Financial

In Lesson 2, learn how to:

- Check provider contract information
- · Check daily summary of forms submitted
- Review pay status of forms

Provider Contract Information

When clicking the 'Provider Contract Information' the financial information is automatically displayed. This screen tracks and displays the amount of funding given, amount billed, amount paid, and amount available. The billed amount subtracts from the amount available upon submission.

If this information does not correspond with your records, contact the SMHW billing coordinator at 866-726-9926. SHMW encourages you to monitor/track your funds through your internal system.

Daily Summary of Forms Submitted

Click on the 'Daily Summary of Forms Submitted' and then click on the month and day to display. Click the arrows on the month bar to change the month and then select the day to display. This will display the client's financial information by type, date and amount.

Clicking on 'Display Full List to Print' will display the screen for sending to the default printer. Clicking on the 'Print Listing' button will generate a print job. Choose the printer on the print screen and click print. If a printout is not needed, click the 'Close' button to return to the main screen.



Review Pay Status of Forms

Searching for all records submitted or for a specific client is possible. There are four form status types:

- · Submitted by Provider,
- Approved,
- Released to Finance for Payment, and
- Check Mailed.

Each indicates a different step in the review and payment process.

Searching for a client will display all forms submitted for that client and the pay status. Click on 'Form Status' to view all clients under the criteria or click multiple items to display all the selections. (Example: 'Check Mailed')

Entering the date range will display all forms status for the range. Click the 'Search' button to display results.



Review Pay Status of Forms, continued

The 'Form Type' and 'Total Amount Paid' columns show in blue. Clicking on either one brings up the form or the claim screen to review. **The claim screen form is 'read only'.**



Review Pay Status of Forms, continued

Clicking on the 'Amount Billed' link will display the detailed information for that client and date. **This form is 'read only'.**




Address questions and general assistance requests to the central office staff by calling SMHW/WISEWOMAN at 866-726-9926.

Direct specific questions or concerns with MOHSAIC to the ITSD Help Desk 800-347-0887 or by e-mail at support@health.mo.gov.

Patient Navigation

Patient Navigation	.12.1
'Navigation – Only' Enrollment Status	.12.2
Patient Navigation Services	.12.3
MOHSAIC Navigation Form Sections	.12.5
The SMHW Navigation Form Link	.12.11
Terminating Patient Navigation	.12.12
Case Management	.12.12
Terminating Case Management	.12.13
Lost to Follow-up Cases	.12.13
Quality Assurance/Quality Improvement	.12.14
SMHW Cancer Resources	.12.15



Patient Navigation

Navigation

The CDC's National Breast and Cervical Cancer Early Detection Program (NBCCEDP), defines Patient Navigation as an individualized intervention providing patients who have never been screened or not screened within the last 3-5 years, (females 50-64 years of age for breast cancer screening and females 35-64 years of age for CBE and cervical cancer screening), assistance to obtain screening services. Patient navigation is time intensive; therefore, navigation focuses on clients who otherwise would not complete recommended screening or diagnostic testing.

In order to more accurately capture the reach of the NBCCEDP, and therefore Missouri's SMHW program, reporting of patient navigation services for age and income eligible patients is encouraged and will now be a billable service under the SMHW program. Patient navigation services are not limited to enrolled eligible SMHW clients.

Patient navigation is primarily provided through primary care providers facilitating screening services.

Patient navigation assists a patient so they can move through health care in a timely manner without the road stops of a complex health care environment. This includes moving the patient through distinct health care settings such as primary care (clinic) and tertiary care (hospital). The goal is to eliminate barriers to timely health care through a one-to-one relationship between a navigator and the patient. No matter what phase of health care, the patient should benefit from an appropriately trained navigator at the phase of health care.

A patient navigator works with patients to reduce real and perceived barriers to health care. The services provided depend on barriers identified and actions taken to alleviate the barriers. Common barriers include the inability to schedule and keep appointments, English as a second language, confusing medical information, lack of insurance, limited finances, and lack of or limited transportation to and from home. Other barriers may emerge and must be recognized and addressed as the navigation plan develops.

Navigation is an early phase of health care and includes education about cancer prevention, cancer risk factors and the need for screening for those patients not engaged with obtaining health care or not a part of a health care system. It may also include educating patients already within a health care organization who have not received screening services. For patients already engaged with a health care organization, navigation may include education regarding timely follow up appointments for further studies or beginning treatment.

If patient navigation is delivered consistently with CDC policy, the woman meets age and income requirements, and the patient completes the screening/diagnostics then navigation services can be reimbursed. The navigation form completion must reflect the CDC's six (6) requirements:

- Written assessment of individual patient barriers to cancer screening diagnostics/initiation of treatment
- 2. Provision of education and support for the patient
- 3. Resolution of barriers to obtaining cancer screening/diagnostics/initiation of treatment
- 4. Tracking of the patient to assure completed screening/diagnostics/initiation of treatment

- 5. A minimum of two (2), preferably more, patient contacts
- 6. Data collection and data review in aggregate to evaluate outcomes of patient navigation (the delivery of cancer screening and/or diagnostic testing, final diagnosis and treatment initiation if needed).

CDC considers case management for women with abnormal screening results a type of patient navigation, as long as the aforementioned activities are performed.

Navigation services are not limited to enrolled eligible SMHW clients. Women who meet age and income requirements but who have insurance to pay for screening and diagnostic services can receive navigation services. This enrollment status is called 'Navigation Only'.

'Navigation-Only' Enrollment Status

Beginning in 2019, SMHW has added an enrollment status in MOHSAIC called 'Navigation-Only'. The enrollment status of 'Navigation-Only' allows payment for navigation services provided to a woman who meets age and income requirements and has group or private insurance to pay for the screening and diagnostic services. 'Navigation-Only' enrollment is prioritized for populations that are predominantly low-income (<200 FPL) and are of appropriate age per screening guidelines. Women receiving 'Navigation Only' services will be included in CDC's reporting of women served through NBCCEDP.

Payer Sources Eligible for 'Navigation Only' Services						
Payer Source Eligibility						
Private or Group Insurance	Yes					
Medicaid	Yes					
MO HealthNet	Yes					
Medicare Part B	No					
Susan G. Komen	No					
Title X	Yes					

When the patient completes the screening/diagnostic services paid by insurance and patient navigation is delivered consistently with CDC policy (meets age and income requirements), navigation services for that patient can be paid by SMHW. The client can be enrolled in the SMHW program with an abbreviated record. The abbreviated record includes the SMHW Patient History form (green) and the Patient Navigation Form (gray). Reporting the results of the screening or diagnostic services is necessary for payment by selecting 'Reporting Only' on the screening or diagnostic forms as applicable. A process for report/result sharing between agencies is required, as is informing each patient their record/result is shared.

To qualify for enrollment into 'Navigation Only' with a SMHW abbreviated record, **the following six (6)** requirements must be met.

- Assessment of individual patient barriers to cancer screening/diagnostics/initiation of treatment
- 2. Provision of education and support for the patient
- 3. Resolution of barriers to obtaining cancer screening/diagnostics/initiation of treatment

- 4. Tracking of the patient to assure completed screening/diagnostics/initiation of treatment
- 5. A minimum of two (2), preferably more, patient contacts
- 6. Review in aggregate, date to evaluate primary outcomes of patient navigation, which are cancer screening and/or diagnostic testing, final diagnosis and treatment initiation if needed.

CDC considers case management for women with abnormal screening results a type of patient navigation, as long as the performances of aforementioned activities are complete.

Populations/Patients Navigation Services Eligibility					
Patient Types					
SMHW Eligible	Females Age 35-64 Cervical and CBE				
SMHW Eligible	Females Age 35-64 with a Breast Abnormality				
SMHW Eligible	Females Age 50-64 Breast				
Non-Eligible SMHW	'Navigation Only' females Age 35-64 Cervical and CBE				
Non-Eligible SMHW	'Navigation Only' females Age 35-64 with a Breast Abnormality				
Non-Eligible SMHW	'Navigation Only' Females Age 50-64				

Patient Navigation Services

Health care organizations must assess their capacity to support increased patient activity and anticipate increases in screening rates.

Health care organizations with patient navigation involving medical record review and required documentation know exactly who is due for breast or cervical cancer screening and subsequently contact those patients to encourage them to come in for the screening.

In managing navigation services, the organization asks the following in their capacity assessment:

- What setting -- primary care clinic, community-based affiliate, or regional-based tertiary care?
- Who is the target audience and priority population?
- How to provide services in person, by phone, or both?
- Who will serve as navigator—lay person, nurse, other?
- Who will all the partners be and how will they work together?

These organizations dedicate staff time to the appropriate phase of health care navigation for their patients.

Effectiveness evaluation components are "no-show" rates, completion of screening exams, and timely follow-up. A successful navigation program will see a reduction in "no-show" rates, an increase in completion of screening exams, and consistent timely follow-up of abnormal test results.

Assigning responsibility for specific tasks increases an organization's accountability for patient navigation. Consider these tasks for patient navigation:


Navigation Services Tasks	
In Reach/Outreach	Person Responsible
Identify clinic patients win need of screening	
Contact and educate eligible patients about screening	
Educate individuals in the community about breast and/or cervical cancer screening	
Obtain Release of Information documentation	
Financial	
Verify income and insurance status	
Help patient apply for financial assistance programs as applicable to reduce out-of-pocket costs	
Education	
Explain screening procedures and what preparation may be required	
Explain anatomy	
Emphasize the medical need for screening services	
Provide printed and verbal information at an appropriate level of understanding for the patient	
Provide printed and verbal information in the appropriate language	
Barrier Reduction	
Assure patient has transportation to and from screening services; schedule transportation services as necessary	
Work with the patient to overcome perceived barriers and actual common barriers	
Provide language translation services	
Optimize clinic visits to limit the number, as applicable	
Dependency care (children, elderly)	
Recognize health information can be complicated and therefore intimidating in all phases of health care	
Reminders	
Place reminder calls to decrease no-show rates	
Keep a tickler system for follow-up	
Provide reminders in the appropriate language	

Care Coordination	
Obtain reports/results from diagnostic agencies. Provide Release of Information form obtained from the patient	
Follow-up with patients about results of testing; be sure they understand results; when they should be re-screened; how to access further care as necessary	
Assist with setting up medical and transportation appointments	
Provide a primary contact for questions	
Program Reporting	
Maintain files/records for fiscal and quality improvement evaluation	
Participate in program updates	

MOHSAIC Navigation Form Sections

Sample form for patient navigated for Screening Services

Assessment:




Barrier Identification:

BARRIERS		i
SYSTEMBARRIERS(CHOOSE ALL THAT AP	PLY)	
✓ Healthcare provider is >60 miles No healthcare provider Transportation schedule is inconvenient	Housing is sue/homeles s No phone/hv alld phone number Unable to schedule an appointment	Larcke capacity to entol in a health insurance plan Provider unable to bill insurance Unable to take off work
Other		
FINANCIAL BARRIERS (CHOOSE ALL THAT	APPLY)	
Has dependents its a caregiver No Health Insurance plan	Insurance has high deduct to le Underlins used	✓ Lack of/cannot afford transportation
Other		
PSYCHOSOCIAL BARRIERS (CHOOSE ALL	THAT APPLY)	
Cultural/faith-based concerns Education required on lifestyle changes	Education level Education required on refusing services/care/treatment	Education required on canoer
Education required on	Education required on self-care vis. medical care	
Fear/denial	Has concerns about health	
Other		
COMMUNICATION BARRIERS/CHOOSE ALL	THAT ADDI VI	
Conflused for envirenced	Cultural con perms	Does not understand(health literacy)
☐ Need's Interpreter	Unableto read	
Other		

Actions:


ACTION PLAN	
COUNSELING/COMMUNICATION/EDUCATION(CHOOSE ALL THAT APPLY)	
Advocated on client's behalf (specify)	
Counseled regarding (specify)	
☐ Discussed client concerns	
☐ Discussed diagnostic plan options	
☑ Discussed options of available services	
☐ Discussed treatment plan options	
Educated client on available resources	
Educated client with "teach-back" method on (specify)	
Not field Regional Program Coordinator (RPC) for assistance	
Provided interpreter services (specify language)	
Provided culturally appropriate brochure/information	
Provided educational level appropriate brochure/information	
Provided literacy, level appropriate brochuse/information	
□ on er	
REFERRALS/APPOINTMENTS (CHOOSE ALL THAT APPLY)	
Referred to SMHW Provider (specify)	
Referred to breast and/or cervical care provider (specify)	
Referred to other health care services (specify)	
Referred to Breast and Cervical Cancer Treatment (BCCT) Program	
Referred to trainsportation resources	
Sche duled appointment for screening se vices	
Scheduled appointment for diagnostic services	
Sche duled appointment for transportation services	
Referred to legal services	
Referred to local agency for assistance (specify)	
Other	
SERVICES ENROLLMENT (CHOOSE ALL THATAPPLY)	
✓ Enrolled for Nav Igation Services only	
Enrolled in SMHW Program	
Facilitated enrollment in BCCTProgram	
Facilitated enrollment in health insurance plan	
Facilitated enrollment in Medicare/Medicald	
Other	
SERVICES IMPLEMENTATION PLAN (CHOOSE ONE)	
0-60 days	
D. COMMENTS	(Clear Section)
BARRIERS/ ACTION PLAN/ MANAGEMENT/ NAVIGATION NOTES. Maximum length is 1536 characters	

Outcome




Sample form for patient navigates for Diagnostic Services

Client/Patient Navigation



BARRIERS		
SYSTEMBARRIERS(CHOOSE ALL THAT A	PLY)	
Healthcare provider is >50 miles	Hou sing is sue/homeless	Lacks capacity to enroll in a health insurance plan
✓ No healt hoare provider	No phone/hy alid phone number	Provider unable to bill insurance
Transportation schedule is inconvenient	Unable to schedule an appointment	Unable to take off work
Other		
FINANCIAL BARRIERS (CHOOSE ALL THAT	APPLY)	
✓ Has dependents its a caregiver	Insurance has high deductible	✓ Lack of/cannot afford transportation
No Health Insurance plan	Und erins ure d	
Other		
L ONE		
PSY CHOSOCIAL BARRIERS (CHOOSE ALL	THAT APPLY)	
Cultural/faith-based concerns	Education level	Education required on cancer
Education required on if estyle changes	Education required on refusing	
_	service signification en t	
Education required on screen in gld is gnostics	Education required on self-care vis. medical care	
▼ Fear/denial	✓ Has concerns about health	
Other		
COMMUNICATION BARRIERS (CHOOSE AL	L THAT APPLY)	
Conflused lov, eight elimed	Cultural concerns	Does not understand(health literacy)
Need's Interpreter	Unable to read	
Other		

ACTION PLAN	
COUNSELING/COMMUNICATION/EDUCATION(CHOOSE ALL THAT APPLY)	
Advicated on client's behalf (specify)	
✓ Counseled regarding (specify) follow up on care	
☐ Discussed client concerns	
☐ Discussed diagnostic plan options	
☐ Discussed options of available services	
☑ Discussed treatment plan options	
Educated islent on available resources	
Educated client with "teach-back" method on (specify)	
✓ Not field Regional Program Coordinator (RPC) for assistance	
Provided interpretense vices (specify language)	
Provided culturally appropriate brochure/information	
Provided educational level appropriate brochure/information	
Provided literacy, level appropriate brochuse/information	
Other	
REFERRALS/APPOINTMENTS (CHOOSE ALL THAT APPLY)	
▼ Referred to SMHW Provider (specify) iordan valley	
Referred to breast and/or cervical care provider (specify)	
Referred to other health care services (specify)	
Referred to Breast and Cervical Cancer Treatment (BCCT) Program	
Referred to transportation resources	
Scheduled appointment for screening selvices	
Scheduled appointment for diagnostic services	
Sche duled appointment for transportation services	
Referred to legal services	
Referred to local agency for assistance (specify)	
Other	
SERVICES ENROLLMENT (CHOOSE ALL THAT APPLY)	
Enrolled for Nav Igation Serv loes only	
✓ Enrolled in SMHW Program	
Facilitated enrollment in BCCTProgram	
Facilitated enrollment in health insurance plan Facilitated enrollment in Medicare/Medicald	
SERVICES IMPLEMENTATION PLAN	
(CHOOSE ONE)	
0-60 days V	
D. COMMENTS	(Clear Section)
BARRIERS/ ACTION PLAN/ MANAGEMENT/ NAVIGATION NOTES Maximum length is 1536 characters.	



The SMHW Navigation Form Link

https://health.mo.gov/living/healthcondiseases/chronic/showmehealthywomen/pdf/client-patient-navigation-form.pdf.

MDE data are required for women who receive NBCCEDP-funded 'Navigation Only'. The abbreviated record will include data on patient demographics, screening test type, date of test, test results, and final diagnosis.

Access to medical record information is necessary to complete the MDE record. MDE data for 'Navigated Only' clients are analyzed separately and excluded at this time in calculating the NBCCEDP core indicators.

In order to complete billing for Patient Navigation Services, reporting results of the screening and/or diagnostic is required in MOHSAIC. The table on the next page outlines required forms by Navigation Type.

SMHW is a payer of last resort. If a patient is eligible for navigation services through other funding, that funding source must be used, i.e., Komen.

Resources that may assist navigating clients through obtaining healthcare coverage include the Missouri Department of Social Services' Medicaid Program (https://mydss.mo.gov/healthcare).

		Арр	ropriate F	orm	
Navigation Service Type	Eligibility Agreement	Patient History Form	Navigation Form	Screening Form	Diagnostic Form (as applicable)
SMHW Navigation	Х	Х	Х	Х	х
SMHW Navigation 'Reporting Only'	х	Х	х		
Non Eligible SMHW 'Navigation Only'		Х	х	Х	Х
Non Eligible SMHW 'Navigation Only' 'Reporting Only'		X	Х		

Terminating Patient Navigation

Depending on screening and diagnostic outcomes, patient navigation services terminate when a client:

- 1. Completes screening and has a normal result,
- 2. Completes diagnostic testing and has normal results,
- 3. Initiates cancer treatment, or
- Refuses treatment.

Case Management

Clients who have abnormal screening results receive follow-up services, up to the point of a final diagnosis and treatment start date. Achieve this through case management. The goal of case management is to ensure clients enrolled in the program receive timely and appropriate diagnostic and treatment services. An abnormal screening result is determined based on nationally recognized screening guidelines identified in the Provider Manual Chapters 5 and 6.

Non-clinical professionals may provide required case management activities, and a qualified health care professional (Registered Nurse, Nurse Practitioner, Physician Assistant or Physician in good standing to provide health care in Missouri) must have oversight. Although case management services vary based on an individual client's needs, at a minimum, case management must include the following activities:

- Notify the client of an abnormal result within a reasonable period of time (i.e., two (2) weeks from the date the
 procedure was performed),
- Assessment and resolution of barriers to diagnostics services,
- Assessment and resolution of barriers to initiation of cancer treatment, if treatment is indicated,
- Client education and support,
- Arrange diagnostic appointments on the client's behalf,

- Clients may not be given a referral list and asked to schedule their own appointment,
- Client tracking and follow-up to monitor client progress in completing diagnostics and initiating treatment, and
- A minimum of two contacts with the client over the course of the screening and diagnostic cycle.

Terminating Case Management

When a client concludes cancer treatment, the treating physician releases the client to return to a schedule of routine screening, and the client continues to meet SMH eligibility requirements, the client may return to the program and receive all services, including patient navigation or case management.

Clients screened through SMHW clinical services who are subsequently insured may continue to receive patient navigation services. In such instances, agencies are encouraged to continue navigating clients to ensure diagnostic procedures are completed, and if a diagnosis of cancer, that treatment is initiated.

Lost to Follow-up Cases

Funding received from the CDC is contingent upon SMHW meeting or exceeding several quality assurance parameters of the CDC Core Performance Indicators. Case managers must ensure and meet the following indicators for all SMHW clients with abnormal screening results:

- Ninety (90) percent or more of SMHW clients with abnormal findings achieve a definitive diagnosis.
- Seventy-five (75) percent or more of SMHW clients with an abnormal finding achieve a definitive diagnosis within 60 days or less.

A SMHW client **contact and tracking system must be in place** to notify clients of abnormal results. Contacts with a client should be clearly documented in a client's medical record and should include what type of follow-up is needed, the recommended timeframe for follow-up, and the clinical implications if the follow-up does not occur. Client contact continues until one of the following occurs and is documented in the medical record:

- Recommended follow-up evaluation complete and the client referred for treatment (if indicated),
- Made two documented attempts in contacting the client. If the client has a valid address, one of these
 attempts must either be in writing and sent as a certified letter or sent via client portal/email with a read
 receipt confirmation. Use of certified letters or read receipt emails early in the course of follow-up can
 expedite the notification process,
- Notified the Regional Program Coordinator after no response,
- Documented informed refusal in the client's medical record, or
- Documented in the client's medical record at least two contact attempts made (considered lost to follow-up).
 - a. This documentation should include the dates, types of contact attempted, and the outcomes.
 - b. If the client has a valid address, at least one of the contact attempts should be a certified letter with a return receipt. Keep a copy of the certified letter and the return receipt in the client's medical record.

Every client has the right to elect or refuse treatment. A client is considered to have refused service when one of the following has been carefully documented in the client's medical record:

- Client has verbally refused the follow-up care recommended.
- Client has refused in writing the follow-up care recommended.

Keep documentation of the informed refusal in the client's medical record. Include refused service or treatment and when the client was informed of the risks involved if recommended follow-up is not completed.

The elimination of cancer disparities is critically important for lessening the burden of cancer. Patient navigator programs improve clinical outcomes.

In response to Missouri women and providers reaching out to SMHW to inquire about additional cancer navigational resources, SMHW developed a list of Cancer Navigational Resources to assist in filling a gap in the current health care system. The following pages contain the SMHW Cancer Resources to help navigate Missouri women and families to help at many points along the health care journey: insurance problems, identification of available cancer screening programs, medication assistance, financial assistance, housing assistance during travels, etc.

Quality Assurance/Quality Improvement

Documentation of Patient Navigation Services will be reviewing during the regular monitoring visits every two years and as necessary. Verification of eligibility for navigation services will be assessed. Notation of the assessment and appropriate interventions to assist with barrier reduction will be reviewed. Please refer to Section 8, Quality Assurance, for more information.

Show Me Healthy Women Cancer Resources								
Agency	Website	Name of Program	Enrollment Requirements	Services Offered	Primary Contact Name	Primary Contact Telephone	Primary Contact E-mail	Counties Covered
Access Family Care	http://www.accessfa milycare.org/	Discounted/Sliding Scale Fee	Medicaid, Medicare, insurance and self-pay accepted. Discount/Slide Scale Fee available to patients based on annual household income and current Federal Poverty Guidelines.	This is a Federally Qualified Health Center (FQHC) offering primary medical/dental care.	Administration Office-Neosho: 417-451-9450 Don McBride, CEO; Sheila Long, CFO; Debra Davison, COO	Clinic sites: Joplin 417-782-6200; Neosho 417-451-4447; Anderson 417-845-8300; Cassville 417-847-0057; Mount Vernon 417-461-0688; Lamar 417-681-0027	N/A	Barton, Jasper, Newton, Barry, Lawrence and McDonald Counties.
American Cancer Society	http://www.cancer.o rg/index	American Cancer Society	N/A	Webpage: cancer resources for wigs, transportation, support, local offices, etc.	N/A	800-227-2345	Web chat available.	Check website link for local offices.
American Cancer Society	www.cancer.org	Hope Lodge (associated with American Cancer Society)	Have a cancer diagnosis.	Free housing for cancer patients traveling to KC (must be 40 miles or > from home for any cancer treatment).	Karol Iser	816-218-7136	N/A	Live outside Kansas City area.
American Cancer Society	http://www.cancer.o rg/treatment/support programsservices/ho pelodge/stlouis/stlou is-about-our-facility	Hope Lodge-St. Louis	Have a cancer diagnosis.	Free housing for cancer patient plus 1 caregiver traveling to St. Louis. Must be 40 miles or greater from home, for any cancer treatment.	N/A	314-286-8150	N/A	N/A

Look Good, Feel Better	https://lookgoodfeel better.org/programs/ women/	Look GoodFeel Better	For women undergoing cancer treatment.	Free two-hour workshop for women undergoing cancer treatment. This program helps improve the self-image, appearance, and quality of life of patients by teaching beauty techniques to help cope with the temporary appearance-related side effects of cancer.	N/A	800-395-5665	N/A	Workshops offered as in-person or as on-line virtual workshops.
American Cancer Society	http://www.cancer.o rg/treatment/support programsservices/re ach-to-recovery	Reach to Recovery	Must have either a possible cancer diagnosis or a definite cancer diagnosis.	Support for patients with possible breast cancer, diagnosis, or recurrence, or late stage. Considering lumpectomy, reconstruction etc. Telephone or face-to-face is provided by volunteers who are breast cancer survivors.	N/A	Patient Service Center, American Cancer Society 888-227-6333 or 800-227-2345	N/A	All counties in Missouri.
American Cancer Society-Joplin	www.cancer.org	Reach to Recovery	Breast cancer patients/survivors.	Provides one-on-one mentoring for breast cancer patients. Current breast cancer patients are paired up with a breast cancer survivor from the community. Reach to Recovery volunteers have been screened and through extensive training to equip them to answer.	N/A	American Cancer Society 888-227-6333 or 800-227-2345	N/A	N/A

American Cancer Society SW Missouri Office	www.cancer.org Facebook: American Cancer Society - Southwest Missouri	N/A	N/A	Provides programs and services for cancer patients, survivors and caregivers, and provides many ways people can help fight cancer through volunteering, advocating, donating money or participating in fundraising activities such as Relay for Life.	Marti Helfrecht	417-881-4668 Toll-free: 800-915-8350	Marti.Helfrecht@ca ncer.org	N/A
Area Agencies on Aging (AAA)	http://health.mo.gov/ seniors/aaa/	Area Agencies on Aging (AAA)	Services are available under the OAA mandates to persons at least 60 years of age, in the greatest social and economic need, with special emphasis placed on lowincome minority elderly. Persons with disabilities aged 18-59 may receive assistance with transportation and nutrition services through Social Services Block Grant (SSBG) or other non-Title III funds.	Please check website for services provided.	Area Agencies on Aging DHSS PO Box 570 Jefferson City, MO 65102-0570	573-526-4542	info@health.mo.gov	Statewide
Beyond the Ribbon	N/A	N/A	Outreach to breast cancer families.	Identifies unmet needs such as wigs, lymphedema sleeves, makeup tutorials, medication co-pays.	Lori Turk	N/A	run4herlife5K@gma il.com	Randolph County
Boone Hospital Center	www.boone.org	Boone Hospital Center	Financial discount for services at Boone for breast and cervical services.	If unable to pay bill for services, offers 15% off automatically, then applies for financial assistance. No money required in advance.	Financial Counseling	573-815-3305	N/A	All Counties in Missouri.

Breast Cancer Foundation of the Ozarks (BCFO)	www.bcfo.org	Non-Medical Financial Assistance Program	Contact BCFO for application. Each application is individually considered.	Provides short-term, non-medical financial assistance to residents of the Ozarks who are in current treatment for breast cancer with demonstrated financial need.	Jill Gold	417-862-3838 Toll-free: 866-874-1915	N/A	Barton, Jasper, Newton, McDonald, Henry, Cedar, Dade Lawrence, Barry, Polk, Greene, Christian, Stone, Dallas, Webster, Douglas, Wright, Taney, Ozark, Laclede, Texas, Howell, Shannon, and Oregon Counties.
Breast Cancer Foundation of the Ozarks (BCFO)	www.bcfo.org	Children's Fund	Contact BCFO for more information.	BCFO offers assistance to children of families impacted by breast cancer. Financial assistance is provided on a case by case basis and may help with: School supplies, clothing, childcare, orthodontic continuation, and holiday gifts.	N/A	417-862-3838 Toll-free: 866-874-1915	N/A	Barton, Jasper, Newton, McDonald, Henry, Cedar, Dade Lawrence, Barry, Polk, Greene, Christian, Stone, Dallas, Webster, Douglas, Wright, Taney, Ozark, Laclede, Texas, Howell, Shannon, and Oregon Counties.
Breast Cancer Foundation of the Ozarks (BCFO)	www.bcfo.org	Free Screening Mammogram Program	Application for assistance must be completed and are individually evaluated. Application is based on need for screening mammogram and the inability to pay for such services through insurance or self-pay. Ages 25-80 and beyond.	Free screening mammograms for qualified women.	Jill Gold	417-862-3838 Toll-free: 866-874-1915	jill@befo.org	Barton, Jasper, Newton, McDonald, Henry, Cedar, Dade Laurence, Barry, Polk, Greene, Christian, Stone, Dallas, Webster, Douglas, Wright, Taney, Ozark, Laclede, Texas, Howell, Shannon, and Oregon Counties.

Breast Cancer Foundation of the Ozarks (BCFO)	www.bcfo.org	Lymphedema Garment Program	Contact BCFO for more information. Candidates must be uninsured or underinsured, and lymphedema must be a result of breast cancer treatment.	BCFO provides lymphedema garments through area medical supply providers to uninsured or uninsured candidates that have lymphedema as a result of breast cancer treatment.	Jill Gold	417-862-3838 Toll-free: 866-874-1915	N/A	Barton, Jasper, Newton, McDonald, Henry, Cedar, Dade Laurence, Barry, Polk, Greene, Christian, Stone, Dallas, Webster, Douglas, Wright, Taney, Ozark, Laclede, Texas, Howell, Shannon and Oregon Counties.
Breast Lifecare Clinic at Wes & Jan Houser Women's Pavilion - Freeman Health System	https://www.freema nhealth.com/service/ breast-cancer	N/A	N/A	Comprehensive breast care center offering radiology, surgical and oncology services.	Wendy Chrisenbery, Women's Pavilion Supervisor	417-347-7777	N/A	Clinic located in Joplin (Jasper County) but serves the four corner state MO, KS, OK, and AR region.
Cancer Action	www.canceractionK C.org	Cancer Action	Have a cancer diagnosis.	Free Medical supplies, comfort items, financial assistance with Rx's, transportation, emotional and educational support.	Trish Rush	816-350-8881	tishr@canceraction KC.org	Jackson and Clay Counties. In Kansas Wyandotte and Johnson Counties.
CancerCare Co-Payment Foundation	www.cancercarecop ay.org	CancerCare Co-Payment Foundation	Women and children of all diagnosis.	Dedicated to helping afford co-payments for chemotherapy and targeted treatment drugs.	N/A	866-552-6729	Ninformation@canc ercopay.org	N/A
Community Breast Care Project of Central Missouri	N/A	Community Breast Care Project	Women diagnosed with breast cancer in the last 12 months and who meet criteria. Small grants to cover cost associated with breast cancer treatment.	Offers financial aid.	N/A	573-634-НОРЕ	N/A	Cole, Osage, Callaway, Miller, Moniteau, and Morgan Counties.
Community Clinic- Joplin	www.joplinclinic.or	Breast Cancer Screening	Breast cancer screening clinics are held twice monthly and open to any women or men without other access to these services.	Medical and dental care for the uninsured serving people birth to age 64.	Mary Fetters, Clinical Operations Manager	417-624-5500	opsmanager@joplin communityclinic.co m	Jasper County

	,						T	, , , , , , , , , , , , , , , , , , ,
Carrie J Babb Cancer Center- Citizens Memorial Healthcare	http://www.cccancer .com/	Central Care Cancer Center	Accepts Medicaid, Medicare, insurance and self-pay.	Comprehensive oncology services and support services for cancer patients through Central Care Cancer Center.	Kim Wallin - Medical Oncology	417-326-7200	N/A	Polk County
CoxHealth Breast Care Clinic at Hultston Cancer Center-Springfield	www.coxhealth.com	N/A	Insurance or self- pay. Financial assistance may be available for breast cancer patients through CoxHealth Foundation.	Comprehensive breast center. Screening/ Diagnostic imaging and breast biopsy services.	Manager: Susan Smith	417-269-6170	susan.smith2@coxh ealth.com	Greene County
CoxHealth Foundation- Springfield	www.coxhealthfoun dation.com	Various programs offering patient financial assistance for services provided at CoxHealth.	Patient application, physician referral, proof of income, and explanation of need required to request assistance.	*See website for all fund programs* Includes -Breast Care Fund for services provided to breast cancer patients at the Breast Care Clinic.	N/A	417-269-7150	N/A	Services must be provided through CoxHealth (Greene County).
CoxHealth Reach Together @ CoxHealth Breast Care Clinic- Springfield	N/A	CoxHealth Reach Together	A support group for those who have, or have had, breast cancer and their family members and caregivers.	A support group for those who have, or have had, breast cancer and their family members and caregivers.	Deanna Gunnett	417-269-6253	deanna.gunnett@co xhealth.com	Greene County
Ellis Fischel	http://www.muhealt h.org/locations/ellisf ischelcancercenter/	MU Health Care/Ellis Fischel	Financial discount for services at Ellis.	If unable to pay bill at Ellis and has no insurance, will get 60 % off hospital charges, 25% off physician charges, and additional 20 % off bill if paid in full within 39 days of bill statement. Charity Care program Financial Counseling services.	Call to speak to financial counselor and to request application.	866-608-8025	N/A	N/A
Ellis Fischel/ Cancer Screening Grant	N/A	Ellis Fischel	Women 40+ with no health insurance, make \$5,000.00 over what SMHW allows to qualify for screening mammogram.	Annual screening mammograms with identification and proof of income.	Sue Sinele	573-884-1140 or 573-884-8511	Sinclea@health.miss ouri.org	Any county in Missouri, but must be scheduled through Cancer Screening.

Ellis Fischel/Young Women Cancer Screening Grant	N/A	Ellis Fischel	Women 19-34 years of age with abnormal breast lump or discharge. Pain does not qualify.	Diagnostic mammogram, ultrasound, biopsy and follow-up. DOES NOT INCLUDE TREATMENT.	Sue Sinele	573-884-1140 or 573-884-8511	Sinelea@health.miss ouri.org	Any county in Missouri, but must be scheduled through Cancer Screening.
Faith Community Health-Branson	https://www.faithcommunityhealth.org/	N/A	Any individual with income, living in Stone or Taney Counties, qualifies for our services. Fees are determined based on household income and insurance status.	Faith-based, non-profit health organization that delivers affordable healthcare to residents of Taney and Stone counties.	Darla Howe, Clinical Director	417-336-9355	info@faithcommunityhealth.org Vision Office: Open one day each month times vary. Call 417-336-9355 for appointments. Contact Us: 610 S Sixth Street Branson, MO 65616 417-336-9355 info@faithcommunityhealth.org	Taney and Stone Counties.
Freeman Health System	www.freemanhealth.	Freeman Financial Assistance Program	Following denial of any available government program, applicants may qualify for the Freeman Financial Assistance Program. Approval is based on gross income and assets, compared to federal poverty guidelines.	Financial counselors are available to help patients at Freeman with available options to pay for services.	Financial counselors are available Monday-Friday 8 am-4:30 pm	417-347-6686 or 888-707-4500	N/A	Hospitals located in Joplin (Jasper County) and Neosho (Newton County) but services the four state region.
Fordland Clinic, Inc.	www.fordlandclinic. org	N/A	Insurance or self- pay based on income.	Offers comprehensive family practice, dental services, mental health counseling, and urgent care services based on income.	Office Manager: Joan Twiton	Medical: 417-767-2273 Dental: 417-767-2100	information@fordla ndclinic.org	Webster County

Gateway to Hope	http://www.gthstl.or	Gateway to Hope	Income < 350% of poverty level. Diagnosed with breast cancer or undergoing breast cancer treatment. Open to women of all ages.	Financial assistance to qualified individuals to assist with health insurance premiums associated with breast cancer care/treatment. Additional funding for qualified individuals for mortgages, utilities, gasoline cards.	Christine Lyss or available Clinical Intake Coordinator	314-569-1113	chris@gthstl.org	All Missouri counties.
Gilda's Club Kansas City	Info@GildasClubK C.org	Gilda's Club Kansas City	Have a cancer diagnosis.	Free emotional support groups and educational classes.	Merritt Benz	816-531-5444	N/A	Clay, Jackson, Platte, and Ray Counties.
Good Days from Chronic Disease Fund (CDF)	www.Mygooddays.o	Good Days from CDF	Online enrollment for qualification.	Cancer and chronic disease medication copay assistance.	Online chat available on Facebook.	877-968-7233 Hours 8-5 CST	N/A	N/A
Good Samaritan Care Clinic- Mountain View, MO	http://www.goodsa maritancareclinic.or g/	N/A	Uninsured	Free medical and dental consultation services for the uninsured in South Central Missouri. This clinic is ran by medical, dental, nursing, pharmaceutical, and administrative volunteers. Clinic open Monday evenings-doors open at 5:15pm.	N/A	417-934-6500	info@goodsamarita ncareclinic.org	Texas and Howell Counties
GYN Cancers Alliance (GYNCA)	www.gynca.org	Emergency Non- Medical Financial Support	Contact GYNCA for application and more information. Client must be in treatment and approval is subject to board approval. Program offers emergency nonmedical financial assistance for families facing gynecologic cancer. Assistance may include rental pay.	Emergency Non-Medical Financial support for women and their families facing GYN cancer. Per Client-Emergency financial assistance guidelines while in treatment-Monthly per client Max=\$500. Annual per client Max=\$2500.00.	Sylvia Terbrock	417-869-2220	info@gynca.org	Barry, Barton, Cedar, Christian, Dade, Dallas, Douglas, Greene, Hickory, Howell, Jasper, Lawrence, Laclede, McDonald, Newton, Ozark, Polk, Stone, Taney, Texas, Vernon, Webster, and Wright Counties.

Hope 4 You Breast Cancer Foundation	http://www.hope4yo ubef.org/	Surviving Together with HOPE	Breast cancer survivors.	A support group for Breast Cancer Survivors. We will help one another by embracing each other's lives, emotions, expectations, by way of close knit discussions,	Kim Sanders	417-437-0784	N/A	Jasper County
				activities, and educational seminars.				
Jordan Valley Community Health Center	http://jordanvalley.o rg	Assistance with access to Insurance Marketplace for Affordable Care Act (ACA) Insurance.	N/A	Jordan Valley has certified application counselors to assist over the telephone or make an appointment. Visit in person at 440 E. Tampa, Springfield, MO, or 1166 Banning St. Marshfield, Missouri.	Marketplace Application Counselor or Care Coordinator	417-851-1566	N/A	Greene and Webster Counties
Jordan Valley Community Health Center Federally Qualified Health Center (FQHC)	http://jordanvalley.o rg	FQHC- Accepts MO HealthNet, Medicare & Private Insurance. Financial Assistance for Uninsured may be available for medical/dental services provided at Jordan Valley. Application required. Eligibility for Slide Program based on household income/assets.	Slide Program- Application required. Eligibility based on household income/resources and lack of health insurance.	Medical Clinics in Springfield, Republic, Marshfield, Hollister, and Lebanon. Dental clinics in Springfield, Republic, Marshfield, Hollister, Lebanon and Forsyth.	Care Coordinators available at each location.	417-831-0150	PAweb@jordanvalle y.org	SW MO- Clinics located in Greene, Webster, Taney and Laclede Counties

Komen of Missouri	info@komenmissou ri.org	Susan G. Komen	Once contact is made, grantees will further determine eligibility and services available.	Grant funds for local diagnostic and screening mammograms, breast health education, patient navigation and support programs for women, men and families in 38 MO and IL counties.	not listed	Greater St. Louis Office 314-569-3900 or Mid-Missouri Office 573-445-1905	N/A	Adair, Audrain, Boone, Callaway, Camden, Chariton, Cole, Cooper, Franklin, Gasconade, Howard, Jefferson, Lincoln, Macon, Maries, Miller, Moniteau, Monroe, Montgomery, Morgan, Osage, Perry, Randolph, St. Charles, St. Francois, Ste. Genevieve, St. Louis, Warren, and Washington Counties
Lymphedema Support Group of the Ozarks	N/A	N/A	N/A	Educational and support group for those with lymphedema and their families.	Nora Burgess	417-863-1618	noraburgess@gmail.	SW MO Ozarks
MedZou Program	https://medicine.mis souri.edu/education/ medzou	MedZou	Serves clients without insurance who are waiting for insurance coverage to begin.	Diagnostic breast services	N/A	573-356-2499	N/A	Any Missouri County
Mercy Breast Center — "Chub" O'Reilly Cancer Center	www.mercy.net	N/A	N/A	Provides breast cancer screening and diagnostic appointments; helps patients, spouses and families with the many adjustments following the diagnosis and treatment of breast cancer.	Sharon Davis- Director	417-820-2500	N/A	Greene County


Mercy Cancer Resource Center	www.mercy.net	Cancer Resource Team	For cancer patients being treated at Mercy-Springfield.	Provides a central location where clinical expertise is coupled with educational, emotional, practical and spiritual support to help patients and their families deal with a life-changing diagnosis and to navigate through the health care system.	N/A	417-820-2588	N/A	Greene County
Mercy Hospital & Clinics	https://www.mercy. net/mercy-charity- care	Mercy Charity Care	Mercy grants hospital and clinic financial assistance to patients for emergency and other medically necessary care. Application required and available online.	Uninsured patient discounts for hospital services and financial assistance to patients for emergency or other medically necessary care provided at Mercy.	N/A	855-420-7900	N/A	*See Mercy website* Program only for services provided at a Mercy Hospital in MO, IL, OK, KS and AR.
Mercy Mobile Mammography Bus- Mercy Corporate Health and Wellness	http://wellnesspartne r.org/bus.cfm	Screening Mammogram Mobile Bus	Insurance or self-pay.	The Mobile Mammography bus is an outreach of the Mercy Breast Center, staffed by highly qualified Mercy health professionals. The bus travels to various SW MO Mercy Clinics and other locations- see calendar on Mercy website.	Carmen Losurdo, Coordinator- Corporate Health & Wellness Wellness on Tour Bus	417-820-2790	carmen.losurdo@me rcy.net	Greene and surrounding SW MO Counties Location varies.
Moniteau County Health Department	N/A	Moniteau County Health Department	Pap, well-woman exam, & Human Papilloma Virus (HPV)	Offers Pap and well woman exam for \$20.00, HPV may be around \$40.00. May be limited due to Affordable Care Act (ACA).	N/A	573-796-3412	N/A	All Missouri Counties

Missouri State University (MSU) Care Clinic (O'Reilly Clinical Health Sciences Center on MSU Campus)	http://msucare.misso uristate.edu/	N/A	Mercy and MSU operate the primary care clinic, which serves local uninsured adults who are not eligible for coverage under Medicare or Medicaid. As of 1/4/16: there is a waiting list for appointments.	Medical primary care services for uninsured adults.	Andrea Hastings, Clinic Director	417-837-2270	N/A	Greene County
NorthEast Health Care	www.nemohealthco uncil.com	NorthEast Missouri OB/GYN Clinics	Services available per sliding scale based on income.	Pap smears, lab work, colposcopies, Loop Electrosurgical Excision Procedure (LEEP).	N/A	660-627-5757	N/A	Adair, Schuyler, Scotland, Clark, Lewis, Sullivan, Knox, Macon, Shelby, Putnam, and Mercer Counties
Ozarks Area Community Action Agency (OACAC)	Facebook: OACAC Family Planning	Women's Health - Family Planning	Contact OACAC for information.	Provides individuals with family planning, low-cost contraceptive methods and reproductive health services including pregnancy testing, pap smears, breast exams and sexually transmitted disease (STD) testing and treatment, throughout the southwest Missouri area.	Diane Anthony	417-864-3410	danthony@oacac- caa.org	Greene, Barry, Lawrence, Dade, Polk, Christian, Stone, Dallas, Webster, and Taney Counties
Patient Advocate Foundation	www.copays.org	Patient Advocate Foundation	Must be currently insured, & have coverage for medications which financial assistance is sought.	Financial assistance to qualified patients for drug co- payments, relative to diagnosis.	N/A	866-512-3861	N/A	N/A
Planned Parenthood of Great Plains	www.plannedparent hood.org	Planned Parenthood of Great Plains	Abnormal pap with need for colposcopy.	Colposcopies regardless of age or income for \$400.00.	N/A	800-230-7526	N/A	Any Missouri County

Right Action for Women	http://rightactionfor women.org	Christina Applegate Foundation	Breast Magnetic Resonance Imaging (MRI) screening assistance for women at increased risk for breast cancer, who do not have insurance or the financial flexibility to cover cost for screening.	Breast Magnetic Resonance Imaging (MRI).	E-mail contact link on webpage	800-366-7741	N/A	National
Samuel Rodgers Health Center	https://www.rodgers health.org	Samuel Rogers Health Center	Those who do not qualify for Show Me Healthy Women (SMHW) payment based on household income.	Pelvic, Pap, Human Papilloma Virus (HPV) testing, mammogram, breast ultrasound.	N/A	816-474-4920	N/A	All Missouri. Counties
SSM Health Audrain St. Mary's Hospital	www.ssmhealth.com /cancer	SSM Audrain	Qualifying documentation of income.	FREE or discounted care programs.	N/A	855-989-6789	financialaid@ssmhc. com	All Missouri Counties
Swope Health Service	http://www.swopehe alth.org	Swope Health Service	Payment based on household income.	Medical services including GYN exams.	Not listed.	816-923-5800	N/A	All Missouri Counties
Truman Medical Center (TMC) Hospital	www.trumed.org	Truman Medical Center Hospital	Payment based on household income.	All hospital services.	Financial Counseling Call Center	816-404-3040	N/A	Jackson County
Vincent P. Gurucharri Foundation, Inc.	N/A	N/A	Financial assistance for patients undergoing cancer treatment.	Assist with medication expenses, medical services, medical equipment, dental care, transportation, and other needs indicated per social worker.	Maura Hodges	573-777-3314	N/A	Boone, Audrain, Callaway, Cole, Cooper, Howard, Moniteau, and Randolph Counties

Appendices

Providers	13.1
Client Referral RPC Contact Information	
SMHW Regional Program Coordinator County List	13.2
Request for Literature Form	13.3
Available Literature in English	13.4
Available Literature in Spanish	13.6
Most Commonly Asked Questions	13.8
Acronyms/Abbreviations	13.12
Glossary of Terms	13.16



Providers

Client Referral

A complete list of providers is on the DHSS website https://health.mo.gov/living/healthcondiseases/chronic/showmehealthywomen/providerlists.php. List is updated regularly. Refer clients with Internet access to the website or they may call the SMHW toll-free number 866-726-9926.

RPC Contact Information

RPC Contact Information

Rebecca Conway, RN; Kansas City/Northwest Area	P: 816-607-1021	F: 816-404-6986
Lisa Graessle, RN; Central/Northeast Area	P: 573-522-2855	F: 573-522-3023
Cameron Smith, RN; St. Louis Area	P: 314-657-1509	F: 314-612-5005
Missy Rice, RN; Southwest Area	P: 417-693-3409	F: 417-345-1069
Mary Costephens, RN; Southeast Area	P: 573-418-1358	F: 573-522-3023



SMHW Regional Program Coordinator County List

Northwest/K.C. A	rea	RN 816-607-1021	Fax: 816-404-6986
003 Andrew 005 Atchison 013 Bates 021 Buchanan 025 Caldwell 033 Carroll 037 Cass	047 Clay 049 Clinton 061 Daviess 063 DeKalb 075 Gentry 079 Grundy 081 Harrison	083 Henry 087 Holt 095 Jackson 101 Johnson 107 Lafayette 117 Livingston 129 Mercer	147 Nodaway 165 Platte 177 Ray 227 Worth
Northeast/Central	Area Lisa Graessle, RN	573-522-2855	Fax: 573-522-3023
001 Adair 007 Audrain 019 Boone 027 Callaway 029 Camden 041 Chariton 045 Clark 015 Cole 053 Cooper	073 Gasconade 089 Howard 103 Knox 111 Lewis 115 Linn 121 Macon 125 Maries 127 Marion	131 Miller 135 Moniteau 137 Monroe 141 Morgan 139 Montgomery 151 Osage 163 Pike 171 Putnam	173 Ralls 175 Randolph 195 Saline 197 Schuyler 199 Scotland 205 Shelby 211 Sullivan
St. Louis Area	Cameron Smith, RN	I 314-657-1509	Fax: 314-612-5005
	•		
071 Franklin 099 Jefferson	113 Lincoln 183 St. Charles	189 St. Louis 510 St. Louis City	219 Warren
	113 Lincoln	189 St. Louis	219 Warren Fax: 417-345-1069
099 Jefferson	113 Lincoln 183 St. Charles	189 St. Louis 510 St. Louis City	
O99 Jefferson Southwest Area O09 Barry O11 Barton O15 Benton O39 Cedar O43 Christian O57 Dade	113 Lincoln 183 St. Charles Missy Rice, RN 067 Douglas 077 Greene 085 Hickory 097 Jasper 105 Laclede 109 Lawrence	189 St. Louis 510 St. Louis City 417-693-3409 145 Newton 153 Ozark 159 Pettis 167 Polk 169 Pulaski 185 St. Clair 209 Stone	Fax: 417-345-1069 213 Taney 215 Texas 217 Vernon 225 Webster

Request for Literature

Request literature using the "Request For Literature" form available at https://health.mo.gov/warehouse/580-039.pdf.

R FAX TO: (57:	NFORMATION BEL 3) 751-1574	OW AND RETU	ERATURE RN TO: MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES GENERAL SERVICES WAREHOUSE P.O. BOX 570, JEFFERSON CITY, MO 65102-0570 ING LITERATURE:	WAREHOUSE CONTROL NO.
QUANTITY* REQUESTED	WAREHOUSE USE ONLY SUPPLIED	STOCK NO.	TITLE (PLEASE LIST <u>EXACT</u> TITLE)	DHSS WAREHOUSE USE ONLY
HE INFOR			ESTRICT QUANTITIES SUPPLIED. T BE COMPLETED IN FULL TO PROCESS YOUR REQUEST.	DATE
ONTACT PERSON				PHONE NO.
•	S (P.O. Box holden		reet address) CITY, STATE, ZIP CODE	()

Available Literature in English

Item #	Cover	Title	Limit	Vendor
159	How to Examine Your Breast	How to Examine Your Breast	100	Show Me Healthy Women
505	MAMOGRAMS & PAP TESTS We describe to five the langue, healthird If possible	SMHW / Free Mammograms & Pap Tests	100	Show Me Healthy Women
527	Convact Constr	HPV & Cervical Cancer, English	25	Missouri Department of Health and Senior Services
By request from progra m	THE WAR ALON TO THE WAR ALON T	WISEWOMAN Informational Brochure (English)	100	WISEWOMAN
539	Show Me Healthy Women breat and convoid cancer screenings for depity owners age 13 to 64. The state of the	SMHW, Flyer- Get the Facts! (Show Me Healthy Women program fact sheet)	100	Show Me Healthy Women
910	Couroscopy	Colposcopy: Taking a Closer Look at Your Cervix	25	Krames
913	Abnormal Pap Test Results	Abnormal Pap Test Results: Understanding Your Diagnosis and Treatment Options	25	Krames

Item #	Cover	Title	Limit	Vendor
919	Breast Lumps Comment of the Comment	Breast Lumps: A Guide to Understanding Breast Problems & Breast Surgery	25	Krames
931	Description of the second of t	LEEPLoop Electrosurgical Excision Procedure – Removing Abnormal Tissue From Your Cervix	25	Krames
941	STEPS FOR SUCCESS Succession of the state of	The MO. Tobacco Quitline, 6 Steps to Success (2-sided postcard)	1,000	Missouri Department of Health and Senior Services
958	The Missouri Tobacco Quitline Call Heine Heads Call bill free Labour Subsequent Subseq	Missouri Tobacco Quitline (2-sided business card)	500	Missouri Department of Health and Senior Services
976	Sterotacić Breast Biopsy A Sauly V Your Breast Those	Stereotactic Breast Biopsy, English	25	Krames

Available Literature in Spanish

Item #	Cover	Title	Limit	Vendor
534	MARGOGRAPHA BY PARAMETERS AND	SMHW / Free Mammograms and Pap Tests (Spanish) (Mamogramas y Pruebas Pap Gratis)	25	Show Me Healthy Women
By request from progra m	Money of its and the second of	WISEWOMAN Informational Brochure (Spanish)	100	WISEWOMAN
538	VPH y direct cervical	HPV & Cervical Cancer (Spanish) (El EPV y el cáncer cervical)	25	Missouri Department of Health and Senior Services
Item #	Cover	Title	Limit	Vendor
926	MUESTRAME MUJERES SALUDABLES La graphical for the saludable for t	Get the Facts! (Spanish) (Muéstrame Mujeres Saludables) (Show Me Health Women program fact sheet)	100	Show Me Healthy Women
936	Bultos en los senos senos senos senos reprincipar de hispaias Trigos de hispaias Opciones de	Breast Lumps (Spanish) (Nódulos Mamarios: Descripción y tratamiento de los problemas mamarios comunes)	25	Krames

979	Examinar SSS SCHOO	How to Examine Your Breast, Spanish	100	Show Me Healthy Women
1210	COLPOSCOPY	Colposcopy: Taking a Closer Look at Your Cervix (Spanish) (Colposcopía)	25	Krames

Most Commonly Asked Questions

- Q. We have several patients who have had an abnormal clinical breast exam reported as "discrete palpable mass, suspicious for cancer", followed by a mammogram with a result of "negative". The providers deemed this adequate follow-up and no further evaluation was scheduled or completed. Is this acceptable practice even though the NBCCEDP guidelines recommend further testing?
 - A. A negative mammogram does not rule out cancer for a patient with suspicious breast mass found on physical exam. To determine if the mass is malignant or not, complete additional evaluations such as an ultrasound or a needle biopsy. When providers identify a suspicious mass, they are obligated to follow-up with a complete evaluation and obtain a definitive diagnosis.
- Q. Since breast ultrasound CPT codes 76641 and 76642 are both unilateral, should we expect to see two CPT codes billed if a bilateral ultrasound exam is needed?
 - A. Yes. If complete examination is performed on both breasts, you should receive two ultrasound codes of 76641. If a limited exam is performed bilaterally, you should receive two 76642 codes.
- Q. Does CDC ever allow payment for services that exceed Medicare reimbursement rates?
 - A. No. As stated in the Breast and Cervical Cancer Mortality Prevention Act of 1990 that authorized the NBCCEDP, the program cannot provide reimbursements that are higher than Medicare reimbursement rates.
- Q. Is it appropriate to reimburse for an ultrasound prior to 6 months for BI-RADS 3 due to fat necrosis?
 - A. Yes, they should reimburse based on the findings; an earlier ultrasound is appropriate.
- Q. Would SMHW pay for HPV testing if the client has paid for the Pap and the results were ASC-US?
 - A. SMHW can cover the diagnostic work-up.
- Q. Is it appropriate to screen women with "Dense Breast" with an ultrasound alone without clinical risk assessment? Is it appropriate to use an ultrasound screening for women with dense breast tissue deemed high risk by a recognized clinical risk assessment tool?
 - A. Currently, there are no screening guidelines recommended for breast ultrasound. Use of ultrasound as a tool for breast cancer screening is still in an investigational phase. Inefficient use of any tool may provide the patient with false degree of relief or concern. The provider is accountable for any inappropriate use of BI-RADS results or testing.

- Q. How does the CDC address transgender-identified individuals in the health care setting?
 - A. Following the Breast and Cervical Cancer Mortality Prevention Act that authorized the NBCCEDP and specifically states "women". The focus of the NBCCEDP is women who are at risk for breast and cervical cancer. **Use the federal funds only to cover** screening for female-to-male transgender individuals who have not yet undergone complete hysterectomy or bilateral mastectomy because these individuals are genetically female. We do not use federal funds for male-to-female individuals who are genetically males.
- Q. What if a physician, who does not participate in the SMHW program, refers a woman with a BI-RADS IV or V ultrasound to a SMHW provider; can that woman be enrolled into SMHW and be eligible for Breast and Cervical Cancer Treatment (BCCT) services?
 - A. If a client has a BI-RADS IV or V ultrasound prior to enrolling into SMHW, the non-participating provider should refer the client to a SMHW participating provider. The client must meet SMHW eligibility requirements and complete enrollment forms. Then the SMHW provider should submit the woman's screening and diagnostic test results completed by the non-participating provider to SMHW by completing the MOHSAIC forms and submitting them as "reporting only". The SMHW provider may then proceed with performing additional diagnostic services such as a biopsy and submit results to SMHW for reimbursement. If the biopsy is positive for cancer, the client can be qualified for BCCT services. (SMHW must have reimbursed at least one screening or diagnostic service in order for a client to be eligible to receive BCCT services. Please note that if the only SMHW reimbursement is for a SMHW administrative referral fee for reporting only screening and diagnostic services, the client will not qualify for BCCT services).
- Q. What happens when Show Me Healthy Women (SMHW) has covered the screening and/or diagnostic services, but the client needs treatment?
 - A. Most women who receive SMHW-paid screening and/or diagnostic services and are in need of treatment for breast and/or cervical cancer will be eligible for a special MO HealthNet (Medicaid) BCCT program.
- Q. How much of the reimbursement for services from SMHW must be paid to the subcontractor?
 - A. SMHW does not require service providers to pay any specific rate to the subcontractors. The service providers can negotiate a reimbursement rate with the subcontractor, as they feel appropriate. SMHW will only pay the established reimbursement rate to the service provider.
- Q. Can our facility funding amount be increased?
 - A. Yes. SMHW can increase the funding amount based on the availability of funds and if 80% of the facilities existing funds have been expended. Request an increase by calling SMHW at 573-522-2845, or sending an e-mail to the program manager with the amount of increase needed. The SMHW program must be in receipt of the letter or e-mail 14 business days prior to the end of the contract period for consideration for a funding increase.

Q. If a woman under 35 contacts us reporting that she feels a lump in her breast, can we enroll her in SMHW program?

A. No. On June 30, 2003, SMHW raised the age eligibility to women 35 years or older for all services. If a provider needs assistance locating services for women under 35 years of age, please contact the Regional Program Coordinator assigned to your area.

Q. What do I do when the client does not keep her mammogram appointment and her breast screening is now over 90 days?

A. Continue to schedule the mammogram appointment and repeat the clinical breast examination (CBE), if recommended by the examiner. Client may have her screening mammogram any time before the ten (10) months have elapsed for her next annual screening. If the CBE was negative, she does not have to have a repeat CBE within the ten (10)-month period.

Q. Is a client with no Social Security number and no proof of income and residency eligible for SMHW?

A. Yes. The client must sign the client eligibility agreement form found in Section 12. The English version is on page 12.8 and the Spanish version is on page 12.9.

Q. How do I report when a SMHW client has surgery after I have sent in the reporting of her diagnostic services?

A. Contact your assigned RPC first. If the RPC is not available, call the SMHW central office toll-free at 866-726-9926, call 573-522-2845, or fax inquires to the SMHW office at 573-522-3023.

Q. Whom do I call if I have questions?

A. Contact your assigned RPC first. If the RPC is not available, call the SMHW central office toll-free at 866-726-9926, call 573-522-2845, or fax inquires to the SMHW office at 573-522-3023.

Q. I am waiting for lab results to complete paperwork. What should I do?

A. Hold paperwork until results are available. If it is close to the 60-day cutoff, contact the lab and express your need to have the results in order to be paid. Contact your RPC and document the lab contacts in the comments section.

Q. What should I submit for reimbursement?

A. The clients' reporting form(s).

Q. Who establishes subcontracts?

A. The service providers may establish subcontracts with different facilities. SMHW does not play any role in establishing or assisting to establish subcontracts.

Q. What happens if we submit our forms after 60 days?

A. Payment may be denied. If there are unusual circumstances, contact the billing coordinator at SMHW. Providers must file all forms in a timely manner.

Q. What is the MO HealthNet Breast and Cervical Treatment (BCCT) program?

A. Beginning on October 2000, federal legislation allowed funded programs in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) to participate in the new BCCT program. In July 2001, Governor Bob Holden signed legislation authorizing matching funds for Missouri to participate in the Medicaid Program, effective August 28, 2001.

Q. Who is eligible for BCCT?

A. Women screened and/or diagnosed with breast and/or cervical cancer, or certain precancerous conditions, through SMHW who are under 65 years of age and have a Social Security number or state identification number. SMHW works closely with Department of Social Services (DSS) FSD staff to enroll a client into the BCCT program.

Q. How do SMHW clients enroll in BCCT?

A. SMHW providers establish presumptive eligibility, which entitles a client to temporary full MO HealthNet benefits through BCCT by completing the BCCT Temporary MO HealthNet Authorization letter. Give the client a copy of the letter. The SMHW provider submits the BCCT Temporary Authorization letter to the Greene Co DSS FSD office following the directions found in the Provider Manual on page 7.4. The client and provider must also complete the BCCT Medical Assistance Application. The SMHW provider submits the completed application to the Green Co DSS FSD office after a cancer diagnosis from a tissue biopsy. Refer to Section 7: MO HealthNet for guidance and pages 10.16 and 10.17 for the appropriate forms.

Q. A client received an annual SMHW screening that was normal. She contacts her SMHW provider because she has found a lump in her breast. What will SMHW cover?

A. SMHW will not cover the cost of the office visit, but will pay for diagnostic testing if the CBE is abnormal. If the clinician does not find a lump and chooses to complete diagnostic testing as a direct result of the breast self-examination, SMHW will cover the cost of diagnostics.

Acronyms/Abbreviations

- **5** A's assess, advise, agree, assist, and arrange
- A1C test glycosylated hemoglobin test
- ACS American Cancer Society
- ADA American Diabetes Association
- **AGC** atypical glandular cells
- AGUS atypical glandular cells of undetermined significance
- AHA American Heart Association
- AIS adenocarcinoma in situ
- **ASCCP** American Society for Colposcopy and Cervical Pathology
- ASC-H atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion
- ASCUS atypical squamous cells of undetermined significance
- BCCCP Breast and Cervical Cancer Control Project is the former name of SMHW
- **BCCT** Breast and Cervical Cancer Treatment (through MO HealthNet)
- BMI body mass index
- **BSE** breast self-examination
- CBE clinical breast examination
- **CDC** Centers for Disease Control and Prevention
- **CHD** coronary heart disease
- CIN cervical intraepithelial neoplasia
- CIS Cancer Information Service: carcinoma in situ
- CLIA Clinical Laboratory Improvement Amendments of 1988
- **CPT** current procedural technology (code)
- CVD cardiovascular disease
- CVH cardiovascular health

DBP – diastolic blood pressure

DCN – departmental client number

DHSS - Missouri Department of Health and Senior Services

DNA – deoxyribonucleic acid

DOB - date of birth

DSS - Missouri Department of Social Services

ECC - endocervical curettage

EOB – explanation of benefits

EFT - electronic funds transfer

FDA – Food and Drug Administration

FLP - fasting lipid panel

FNA – fine needle aspiration

FPL – federal poverty level

FSD - Family Support Division

HBP – high blood pressure

HDL – high density lipoproteins

HDL-C – high-density lipoprotein cholesterol

HIPAA – Health Insurance Portability and Accountability Act

HPV – human papillomavirus

HSIL - high-grade squamous intraepithelial lesion

HTN – hypertension

IFG - impaired fasting glucose

ITSD – Information Technology Services Division

JNC 7 – Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7, 2004)

Kg – kilograms

LDL-C - low-density lipoprotein cholesterol

LEEP – loop electrosurgical excision procedure

LSP – lifestyle program

LSIL - low-grade squamous intraepithelial lesion

MDEs - minimum data elements

MI - motivational interviewing

MOAP - Missouri Arthritis & Osteoporosis Program

MOHSAIC - Missouri Health Strategic Architectures and Information Cooperative

MQSA – Mammography Quality Standards Act of 1992

NBCCEDP - National Breast and Cervical Cancer Early Detection Program

NCCDPHP - National Center for Chronic Disease Prevention and Health Promotion

NCEP - National Cholesterol Education Program

NCI - National Cancer Institute

NHLBI - National Heart, Lung, and Blood Institute

NIH - National Institutes of Health

NMR - nuclear magnetic resonance

OATS – Older Adults Transportation Service

Pap Stain – papanicolaou stain

Pap Test – papanicolaou smear

PHNPAT – Public Health Nurses Physical Assessment Training

RN - Registered Nurse

RPC – Regional Program Coordinator

SBP – systolic blood pressure

SMHW – Show Me Healthy Women – The current name of Missouri Breast and Cervical Cancer Control Project (BCCCP).

SMTS - Southeast Missouri Transportation Service

SSN – social security number

TC - total cholesterol

TLC – therapeutic lifestyle changes

WIC – Woman, Infants and Children Program

WISEWOMAN – Well-Integrated Screening and Evaluation for Women Across the Nation - A heart health risk assessment and education program for women receiving a Show Me Healthy Women cervical and breast cancer screening service.

WNL - within normal limits

Glossary of Terms

adenocarcinoma - A cancer that develops from the glandular epithelium.

adenoma - A benign growth starting in the glandular tissue. (Also, refer to *fibroadenoma*.)

- **advanced cancer -** A stage of cancer in which the disease has spread from the primary site to other parts of the body, directly or by traveling through the network of lymph glands (lymphatic) or in the bloodstream. Locally advanced means the cancer has spread only to the surrounding areas.
- **alert value -** A screening result that is abnormal and requires tracking by the provider and/or Show Me Healthy Women Regional Program Coordinators to assure appropriate follow-up care is documented.

American College of Radiology Accreditation - A voluntary mammography accreditation program that is one of the standards for quality assurance and assesses the following major areas:

- Personnel qualifications and experience
- Equipment specification and technical procedures
- Quality assurance practices
- Evaluations of mammograms from the applicant's practice and through the use of phantom images
- **anesthesia** A state characterized by loss of sensation, caused by a drug or gas. General anesthesia causes loss of consciousness. Local anesthesia is numbness in only a specified area.
- antibiotics Chemical substances, produced by living organisms or synthesized (created) in laboratories, for the purpose of killing other organisms that cause disease. Some cancer therapies interfere with the body's ability to fight off infection, so antibiotics may be needed along with the cancer treatment to protect against or kill infectious diseases. The word means "destructive of life."
- **areola -** The dark area of flesh that encircles the nipple of the breast.
- aspirate Removal of fluid or cells from a breast lump.
- **aspiration biopsy** A procedure in which the specimen for biopsy is removed by aspirating it through an appropriate needle that pierces the skin and penetrates into the underlying tissue to be examined. (Also, refer to *fine needle aspiration*.)
- **asymptomatic -** Without noticeable signs or symptoms of disease. Many cancers can develop and grow without producing symptoms, especially in the early stages. Detection tests, such as mammography, try to discover developing cancers at the asymptomatic stage, when the chances for cure are usually high.
- **atypia (also atypical) -** The condition of being irregular or not conforming to type not usual, abnormal. Cancer is the result of atypical cell division.
- axilla Also known as the armpit.

- Breast and Cervical Cancer Control Project (BCCCP) See Show Me Healthy Women.
- **benign -** Not malignant, not recurrent, favorable for recovery, not cancer. The main types of benign breast problems are fibroadenoma, fibrocystic changes, and cysts.
- **Bethesda System -** A comprehensive system for the reporting and classification of Pap smear specimens, developed in December 1988. The Clinical Laboratory Improvement Act (CLIA) regulations mandate the use of the Bethesda System for laboratory reporting and proficiency testing.
- **bilateral** Affecting both sides of the body, for example bilateral breast cancer is cancer occurring in both breasts at the same time (synchronous) or at different times (metachronous).
- **biopsy -** The removal and examination (by a pathologist) of tissue samples, cells or fluids from a living body. An examination of the appearance of the tissue under a microscope determines if cancer or other abnormal cells are present. Complete the biopsy with a needle or by surgery.
- breast augmentation Surgery to increase the size of the breast (also known as breast implants).
- **breast cancer -** Cancer that begins in the breast. The main types of breast cancer are ductal carcinoma in situ, infiltrating ductal carcinoma, lobular carcinoma in situ, medullary carcinoma, and Paget's disease of the nipple.
- **Breast Imaging Reporting and Data System (BIRADS) -** A uniform reporting system for reporting mammography results.
- **breast self-examination (BSE) -** A technique of checking your own breasts for lumps or suspicious changes.
- breast specialist A term describing health professionals who have dedicated interest in breast health.
- **calcifications** Also called microcalcifications. Tiny calcium deposits within the breast, singularly or in clusters, often found by mammography, which indicate a change within the breast.
- cancer A general term for more than 100 diseases in which abnormal or malignant cells develop. Some exist quietly within the body for years without causing a problem. Others are aggressive, rapidly forming tumors that may invade and destroy surrounding tissue. If cancer spreads, it usually travels through the lymph system or bloodstream to distant areas of the body.
- cancer cell A cell that divides and reproduces abnormally and can spread throughout the body.
- **capsule formation -** Scar tissue that may form around a breast implant as the body tries to "wall off" or encapsulate the foreign object; a contracture.
- carcinoma A malignant tumor that begins in the lining (epithelial) cells of organs. Epithelial cells are those that cover the surfaces of tissue. It can occur in any part of the body. Eighty percent or more of cancers, and all breast cancers, receive carcinoma classification.
- carcinoma in situ (CIS) An early stage of cancer in which the cancer is still only in the structures of the organ where it developed and the disease has not invaded other parts of the organ or spread; cancer in situ or pre-invasive. This classification of most cancers is curable.

- **case manager -** The member of the medical care team who acts as a liaison. This person coordinates all of the services needed by the client throughout diagnosis, treatment and recovery.
- **clinical breast examination (CBE) -** A physical examination of the breasts performed by a physician, registered or advanced practice nurse or physician's assistant.
- **cell -** The basic unit of which all living things are made. Cells carry out basic life processes. Organs are clusters of cells that have developed specialized tasks. Cells replace themselves by splitting and forming new cells; cancer disrupts this process.
- **cervical intraepithelial neoplasia (CIN) -** A cellular change to the mouth of the cervix that may include severe dysplasia and CIS. CIN 3 is the most severe of the three-category classification system.
- cervical precancerous lesions Cervical tissue biopsy results of CIN (CIN 1, 2, or 3) and AIS lesions are considered precancerous lesions. Treatment of many CIN 1 and 2 lesions is through simple excisional procedures. However, CIN 3 or AIS may require a hysterectomy.
- cervix The narrow outer end of the uterus that opens into the vagina.
- **chemotherapy -** A drug treatment program that destroys cancer cells. This method often accompanies surgery or radiation, or to treat recurring cancer.
- **clinical** Description of information that pertains to or is founded on actual observation and treatment of patients, as distinguished from theoretical or basic sciences.
- **clinical trials -** Research studies to test new drugs or procedures, or to compare to current standard treatments with others that may be better or equal.
- **coalition building -** The process of organizing individuals, groups or organizations for the purpose of furthering a common goal or ideal.
- **colposcope** A magnifying, lighted optical instrument, which allows for the direct observation and study of vaginal and cervical cells.
- **colposcopy -** Diagnostic procedure performed with a colposcope. Cervical biopsies are usually conducted by colposcopic examination.
- **Comprehensive Cancer Control Program (CCCP) -** A statewide strategic plan, which includes the interaction of a cancer surveillance system, public and professional education, and a screening and follow-up system.
- **cone biopsy -** The removal of a cone-shaped piece of tissue from the cervix. This is a more definitive procedure than a cervical biopsy. It is used when abnormal cells extend up into the cervical opening (Os) or through the tissue. This process also used to treat and cure carcinoma in situ and dysplasia.
- **conization -** The process of removing a cone of tissue, as in partial excision of the cervix uteri. To better preserve the histologic elements cold conization is performed with a cold knife.
- **consensus statements -** Recommendations for the management of a problem, in this case a disease or health problem, formulated by a group of experts based on scientific and clinical information.
- **cryosurgery -** The destruction of tissue by exposure to extreme cold in order to produce well-demarcated areas of cell injury and destruction. Used to treat malignant tumors, control pain, reduce lesions in the brain and control bleeding.

- cyst A fluid-filled mass that is usually benign. The fluid can be removed for analysis.
- **cytology -** Comes from "cyte" which means cell, the study or examination of cells, their origin, structure, function and pathology. The study determines whether cells are cancerous or benign.
- **detection -** The finding of a case of a disease. Early detection means that the disease is found at an early stage, before it has grown large or spread to other sites. Mammography and Pap tests are the principal ways to detect breast and cervical cancer early.
- **diagnosis -** Identifying a disease by its signs, symptoms and laboratory findings. The earlier a cancer is diagnosed, the better chance for cure.
- **diagnostic breast services -** Refers to specialist consultation; additional mammography views; ultrasound; fine needle aspiration; needle, incisional and excisional biopsies relating to breast cancer.
- **diagnostic cervical services -** Refers to specialist consultation, colposcopy with/without biopsy and diagnostic LEEP relating to cervical cancer.
- diagnostic mammogram Defined by the American College of Radiology as "mammography performed on women who, by virtue of symptoms or physical findings, are considered to have a substantial likelihood of having breast disease."
- dimpling A pucker or indentation of the skin on the breast. It may be a sign of cancer.
- dissemination In health education, the dispersal of information, products or services to a population.
- **duct -** A pathway. In the breast, a duct is a passage through which milk passes from the lobule (which makes the milk) to the nipple.
- **ductal carcinoma in situ -** Cancer cells that started in the milk ducts and has not penetrated the duct walls into the surrounding tissue. Surgery is the treatment option for this highly curable form of breast cancer.
- **ductal papilloma -** Small, finger-like, noncancerous growth in the breast ducts that causes bloody discharge and often found in women 45-50 years of age. When they exist, breast cancer risk is slightly higher.
- **dysplasia -** An abnormality in size, appearance and organization of adult cells that requires a biopsy for diagnosis.
- ectocervix The outside, visible portion of the cervix.
- endocervical curettage (ECC) The surgical scraping of the lining of the uterine cervix.
- **endocervix -** The mucous membrane lining the canal of the cervix, sometimes referred to as the endocervical canal.
- **endocrine glands -** Glands that release hormones into the bloodstream. The ovaries are examples of endocrine glands.

- endocrine therapy Manipulation of hormones for therapeutic purposes.
- endometrium The membrane lining of the uterus.
- epidemiology The collection and statistical analysis of data relating to the factors that have an impact on health and how they relate to one another. In the study of people who get cancer, the analysis of specific types of cancer and the factors that play a part in the development of that cancer.
- estrogen A female sex hormone produced primarily in the ovaries, possibly in the adrenal cortex. In men it is produced in the testes (in much smaller amounts than in women). In women, levels of estrogen fluctuate on nature's schedule, influencing the development of secondary sex characteristics, including breast size, regulation of the monthly cycle of menstruation and preparing the body for fertilization and reproduction. In breast cancer, estrogen may feed the growth of cancer cells.
- **etiology -** The study of the cause of disease. In cancer, there are many etiologies, although research shows that genetics is a major factor in many cancers.
- false negative Negative results of a screening test, when in reality the result should be positive.
- **false positive -** Positive results of a screening test that mistakenly identifies a disease when one is not present.
- **federal poverty level (FPL)** A measure of income determined annually by the U.S. Census Bureau based on the last calendar year's increase in prices as measured by the Consumer Price Index. For some programs, it helps determine a person's eligibility. A woman is eligible for SMHW if her income is at or below 200 percent of the FPL.
- **fibroadenoma -** A type of benign breast tumor composed of fibrous tissue and glandular tissue. On clinical examination or breast self-examination, it usually feels like a firm, round, smooth lump. These usually occur in young women.
- **fibrocystic changes -** A term that describes certain benign changes in the breast. Symptoms are breast swelling or pain. Signs are nodules, lumpiness and nipple discharge. Not cancerous.
- fibrocystic condition The presence of single or multiple benign cysts in the breasts.
- fibrosis Formation of fibrous (scar) tissue, which can occur anywhere in the body.
- **five-year survival -** Survival of cancer for five years after treatment of the disease. This is a milestone for most cancer patients, indicating treatment was successful.
- **genes -** Segments or units of DNA that contain information on hereditary characteristics such as hair or eye color and height. Women who have the BRCA1 gene have inherited a tendency to develop breast cancer.
- genetic Something related to the genes.
- **glands -** Organs that produce and release chemicals used locally or elsewhere in the body. Often, this term refers, incorrectly, to mean lymph nodes.
- grade The classification of the severity of a disease.

- **gynecological consultation -** A referral to a gynecologist for an abnormal screening examination follow-up.
- **health education -** Any combination of learning experiences designed to facilitate voluntary adaptations of behavior conducive to health.
- **health promotion -** Activities directed toward developing the resources of clients that maintain or enhance well-being.
- **hereditary cancer syndrome -** One or several types of conditions associated with cancers that occur within multiple family members, because they have an inherited, mutated gene.
- high-grade squamous intraepithelial lesion (HSIL) The Bethesda System classification for a Pap smear result that includes cellular changes of moderate to severe dysplasia (CIN 2 and 3/CIS).
- **high risk** A higher risk of developing cancer compared with the general population. Some factors that place a person at a higher risk are a family medical history, lifestyle choices and the exposure to environmental influences.
- hormone Chemical substance released into the body by the endocrine glands, such as thyroid or ovaries. The substance travels through the bloodstream and sets in motion various body functions. For example, prolactin, produced by the pituitary gland, begins and sustains the production of milk in the breast after childbirth.
- human papillomavirus (HPV) A sexually transmitted virus implicated in the pathogenesis of cervical cancer and its precursor lesions. HPV infections of the genital tract are often thought to be the most common sexually transmitted viral disease. The manifestations of HPV are variable, ranging from occult infection to overt disease in which there is clinical and pathological evidence of HPV infection. Of the approximately 70 types of HPV, 20 types are detectable in the female genital tract and 15 types are evident in the majority of invasive carcinomas.
- hyperplasia An abnormal increase in the number of cells in a specific area, such as the lining of the breast ducts. This overgrowth may be due to hormonal stimulation, injury or continuous irritation. It is not cancerous by itself, but when the proliferating cells are atypical, the risk of cancer developing is greater.
- **hysterectomy -** The surgical removal of the uterus. Types include a total hysterectomy, removal of the uterus and cervix, and radical hysterectomy, the removal of ovaries, oviducts, lymph nodes, lymph channels, uterus and cervix.
- **imaging -** Any method used to produce an image of internal body structures. Some methods used to detect cancer are x-rays, magnetic resonance imaging (MRI), bone scans, scintigraphy, computerized axial tomography (CAT scans), and ultrasonography.
- **immune system -** The complex system by which the body resists invasion by a foreign substance such as a bacterial infection or a transplanted organ.
- incidence The number of new cases of a disease or condition diagnosed during a specified time.
- **incisional biopsy -** The surgical removal of a portion of an abnormal area of tissue for microscopic examination.
- indicated but not performed (refused) An examination result that applies to the field used to record examination results. This entry is marked when a client does not want the recommended examination or when a client has periodically missed appointments.

- infiltrating ductal carcinoma A cancer that starts in the milk passages of the breasts (ducts) and then breaks through the duct wall, where it invades the fatty tissue of the breast. When it reaches this point, it has the potential to spread or metastasize elsewhere in the breast, as well as to other parts of the body through the bloodstream and lymphatic system. Infiltrating ductal carcinoma is the most common type of breast cancer, accounting for about 80 percent of breast malignancies.
- **inflammation -** A local response to cellular injury to the immune system that is marked by capillary dilatation, redness, heat, pain, swelling, or infiltration by cells.
- **inflammatory breast cancer -** A rare cancer, where the breast looks as if it is inflamed because of its red appearance and warmth. The skin shows signs of ridges and wheals or may have a pitted appearance, and the cancer tends to spread quickly.
- **infraclavicular nodes -** Lymph nodes located beneath the clavicle (collarbone). They are part of the network of axillary (armpit) nodes.
- **internal mammary nodes -** Lymph nodes beneath the breast bone on each side. The lymph glands of the breast drain into the internal mammary nodes.
- **intervention** A strategy incorporating methods and techniques that interact with a patient or population.
- intraductal papilloma A benign tumor that starts in the ductal system of the breast. It can cause discharge from the nipple. A woman with papillomatosis (multiple intraductal papillomas) is at increased risk of developing breast cancer.
- invasive cancer A cancer that has invaded surrounding tissue and spread to distant parts of the body.
- **invasive cervical carcinoma -** Infiltration of cancer cells into the tissue beyond the epithelium of the cervix. This term indicates that a malignant growth extends deeper than 3 mm into the stroma.
- **lobes**, **lobules**, **acini** Milk-producing tissues of the breast. Each of the breast's 15 to 20 lobes branches into smaller lobules, and each lobule ends in scores of tiny acini. Milk originates in the acini and is carried by ducts to the nipple.
- **lobular carcinoma (infiltrating or invasive) -** A type of breast cancer that starts within the lobules. It may be multicentric (occurring in multiple lobules). Compared with other types of breast cancer, this type has a higher chance of occurring in the opposite breast as well. It can often be difficult to diagnose, even with careful physical examination or mammography.
- **lobular carcinoma in situ** A very early type of breast cancer developing within the milk-producing glands (lobules) of the breast. It does not penetrate through the wall of the lobules. Researchers think that lobular carcinoma in situ does not eventually become an invasive lobular cancer. They believe, instead, that it places women at an increased risk of developing an invasive breast cancer later in life. This condition makes it important for women with lobular carcinoma in situ to have a physical examination three to four times per year and an annual mammogram.
- local excision The removal of a lesion or tumor confined to the breast.
- localized breast cancer A cancer that arose in the breast and is confined to the breast.

- loop electrosurgical excision procedure (LEEP) A surgical procedure used on the cervix by which an electrical current generating a radio frequency is passed through a wire loop, which is then drawn around the cervical opening (Os) to excise the tissue. The procedure, usually performed in an outpatient setting, uses local anesthesia. Either the transformation zone or a cone-like specimen can be obtained and depends on the size of the loop and lesion. Terms used for this procedure are LEEP and LLETZ (large loop excision of transformation zone).
- **low-grade squamous intraepithelial neoplasia (LSIL) -** The Bethesda System classification for a Pap smear result, which includes cellular changes of HPV, mild dysplasia (CIN 1) or koilocytotic atypia.
- lump Any kind of mass that can be felt in the breast or elsewhere in the body.
- **lumpectomy -** Removal of the breast lump plus a margin of normal tissue around it. If malignant tissue is found, radiation therapy or mastectomy often follows. Also known as limited breast surgery.
- **lymph -** Clear fluid that passes within the lymphatic system and contains cells known as lymphocytes. These cells fight infections. They have a lesser role in fighting cancer.
- **lymph nodes (lymph glands) -** Small masses of bean-shaped tissue located along the lymphatic vessels that remove waste fluids from lymph and acts as filters of impurities in the body.
- **malignant tumor -** A mass of cancer cells that may invade surrounding tissues or spread to distant areas of the body.
- mammogram An x-ray of the breast.
- **mammography facility** An entity that has met SMHW requirements to become an approved provider or provides mammography services for other SMHW-approved providers.
- **Mammography Quality Standards Act of 1992 (MQSA) -** The national accreditation of mammography units through the FDA.
- mastectomy Surgical removal of the breast(s): (1) Modified radical mastectomy: removal of the breast, skin, nipple, areola and most of the auxiliary lymph nodes on the same side, leaving the chest muscle intact. (2) Halstead radical mastectomy: removal of the breast, skin, both pectoral muscles, and all auxiliary lymph nodes on the same side. (3) Extended radical mastectomy: removal of the breast, skin, pectoral muscles (major and minor), and all auxiliary and internal mammary lymph nodes on the same side. (4) Partial mastectomy: removal of less than the whole breast, taking only part of the breast in which the cancer occurs and a margin of healthy breast tissue surrounding the tissue. (5) Prophylactic mastectomy: removal of the interior of one or both breasts. For cancer prevention, this procedure is done before any evidence can be found. It is a recommendation for a woman at a very high risk of breast cancer; its efficacy is unproven. (6) Quadrantectomy: a partial mastectomy that removes the quarter of the breast that contains the tumor. (7) Segmental mastectomy: partial mastectomy. (8) Total mastectomy: removal of only the breast.
- **medical professional/clinician -** Physician, physician's assistant, certified nurse practitioner, certified nurse midwife, or registered nurse.
- **medullary carcinoma -** A specific histology of infiltrating breast cancer in which the tumor appears well defined, with obvious boundaries between tumor tissue and normal tissue. Medullary carcinoma accounts for five percent of breast cancer.
- **menarche** The first menstrual period. Early menarche (before age 12) is a risk factor for breast cancer, possibly because the earlier a woman's periods begin the longer the exposure to estrogen.

- menopause The time in a woman's life when monthly cycles of menstruation cease forever and the level of hormones produced by the ovaries decreases. Menopause usually occurs in the late 40s or early 50s, but surgical removal of the ovaries (oophorectomy) or the ovaries and uterus (total hysterectomy) can induce it, as can some chemotherapy that destroys ovarian function. Some breast cancer chemotherapies are among those that can cause menopause.
- **metaplasia** Abnormal replacement of cells of one type by cells of another type. It does not represent a malignant or premalignant condition.
- **metastasis** The spread of cancer cells to distant areas of the body by way of direct extension, lymph system, or bloodstream.
- minimum data elements (MDE) Clinical data items submitted to CDC two times a year.
- **needle aspiration -** Removal of fluid from a cyst or cells from a tumor. In this procedure, a needle and syringe (like those used to give injections) are used to pierce the skin, reach the cyst or tumor, and with suction, draw up (aspirate) specimens for biopsy analysis. If the needle is thin, the procedure is called fine needle aspiration (FNA).
- needle localization A procedure used to do a breast needle biopsy, when the lump is difficult to locate or in areas that look suspicious in the x-ray but do not have a distinct lump. During the procedure, and after local anesthesia numbs the area, an X-ray guides a thin needle and wire to the area to be biopsied. A tiny hook on the end of the wire holds it in place. Then, using the wire path as a guide, the physician inserts a hypodermic needle (as the type used to give injections) and takes a sample of the tissue. The biopsy is complete. (Also see needle aspiration.)
- neoplasia The pathologic process that results in the formation and growth of a neoplasm.
- **neoplasm -** Any abnormal growth; neoplasms may be benign or malignant. Cancer is a malignant neoplasm.
- **nipple -** The tip of the breast; the pigmented projection in the middle of the areola. The nipple contains the opening of milk ducts from the breast.
- nipple discharge Any fluid coming from the nipple. It may be clear, milky, bloody, tan, gray or green.
- **nodal status** A count of the number of lymph nodes in the armpit (axillary nodes) to which cancer has spread (node-positive) or has not spread (node-negative). The number and site of positive axillary nodes help forecast the risk of breast cancer recurrence.
- node A lymph gland.
- **nodule -** A small, solid lump that can be located by touch.
- **Nolvadex -** Trade name for tamoxifen, an antiestrogen drug commonly used in breast cancer therapy. (Also see *tamoxifen*.)
- **noncancerous -** Benign; not malignant; no cancer is present.
- **normal hormonal changes -** Changes in breast and other tissues that are caused by fluctuations in levels of female hormones during the menstrual cycle.

- not needed (omitted) A category used to record examination results when it is not appropriate to perform a screening test on that particular woman. This choice might be marked under mammography results, if a woman had a mastectomy of one breast. Or, under the Pap smear results if she had a recent Pap smear at her provider's office, is pregnant, or has had a hysterectomy.
- **nucleus -** The powerhouse at the center of a cell where the cell's important activities are carried out. DNA resides and replicates in the nucleus.
- nurse practitioner A nurse who is licensed as a registered nurse (RN) and has taken additional highly specialized training and is nationally certified and recognized by the Missouri State Board of Nursing as an Advanced Practice Registered Nurse. Nurse practitioners must have written collaborative agreements with a physician. They take on additional duties in diagnosis and treatment of patients, and in many states they may write prescriptions. (Also, refer to oncology nurse specialist.)
- oncologist A physician who is specially trained in the diagnosis and treatment of cancer. Medical oncologists specialize in the use of drugs and chemotherapy to treat cancer. Radiologic oncologists specialize in the use of x-rays (radiation) to kill tumors. Surgical oncologists specialize in the use of surgery to treat cancer. Medical and radiation oncologists often cooperate in giving complicated treatments.
- oncology nurse specialist A nurse who has taken highly specialized training in the field of cancer after being licensed as a RN (registered nurse). Oncology nurse specialists may mix and administer treatments, monitor patients, prescribe and provide aftercare (only if the Missouri State Board of Nursing as an Advanced Practice Registered Nurse recognizes them), and teach and counsel patients and their families. Many oncology nurse specialists are also certified nurse practitioners. (Also see case manager, nurse practitioner.)
- oncology social worker A person who has a master's degree in social work and has specialized in the field of cancer. This person provides counseling and assistance to people with cancer and their families, especially in dealing with the crises that can result from cancer but are not medical, such as financial problems, housing when treatments must be at a facility far away from home, and childcare or eldercare.
- **ovary -** A reproductive organ in the female pelvic region. Normally a woman has two ovaries. They contain the eggs (ova) that joined with sperm, result in pregnancy. Ovaries are also the primary site of production of estrogen. (Also, refer to *estrogen*.)
- Paget's disease of the nipple A form of breast cancer that begins in the milk passages (ducts) and involves the skin of the nipple and areola. A sign of Paget's disease is a crusting, scaly, red inflamed tissue (dermatitis) lesion on the nipple. With true Paget's disease, cancer is usually also present within the breast. This rare breast cancer type occurs in only 1 percent of cases. If no lump felt, there is generally a good outcome or prognosis.
- **palliative treatment -** Therapy that relieves symptoms, such as pain, but does not cure the disease. Its main purpose is to improve the quality of life.
- **palpation -** A simple technique in which a health care provider presses on the surface of the body to feel organs or tissues underneath. One can feel a palpable mass in the breast.

- **Papanicolaou smear (Pap test) -** A screening test of the cells of the cervix used to detect early signs of cervical cancer.
- **Papanicolaou stain (Pap stain) -** A multichromatic staining process used primarily on gynecological specimens. It provides great transparency and delicacy of detail, which is important in cancer screening, especially of gynecologic screens.
- pathologist A physician who specializes in the identification of abnormalities and disease by examining body tissue under a microscope and organs. The pathologist determines whether a lump is benign or cancerous.
- pathology A study of disease through examination of body tissues and organs under a microscope for evidence of disease. Diagnosis of any tumor thought to be cancer by examination under a microscope.
- pectoral muscles Muscles attached to the front of the chest wall and upper arms; the larger muscle group is known as pectoralis major, and the smaller muscle group is known as pectoralis minor. Because these muscles are in close proximity to the breast, they may become involved in breast cancer or surgery to treat it.
- pelvic examination An internal physical examination used to detect a variety of gynecological disorders. Performed by a physician, nurse or physician's assistant, the pelvic examination is, and includes, a visual inspection of the vagina and cervix, as well as palpation of the uterus and ovaries.
- **pigment -** A class of substances that provide color, including in the human body. The areola and nipple of the breast are pigmented with melanin. Normally a brownish tint, melanin, in these areas of the breast can range from pale pink to deep brown.
- **predisposition -** Susceptibility to a disease that can be triggered under certain conditions. For example, some women have a family history of breast cancer and are therefore predisposed (but not necessarily destined) to develop breast cancer.
- **premalignant -** Abnormal changes in cells that may, but not always, become cancer; also known as precancerous. Most of these early lesions respond well to treatment and result in cure.
- **prevalence -** A measure of the proportion of persons in the population with a particular disease at a specified time.
- prevention Avoiding the occurrence of an event, such as development of cancer, by avoiding things known to cause cancer and participating in activities that can or might prevent cancer. For example, avoiding smoking may prevent lung cancer, and taking tamoxifen may prevent breast cancer in women who are at high risk for the disease.
- **preventive services -** Programs or products that are developed and provided for the purpose of health promotion and maintenance.
- **primary site -** The site where cancer begins; usually named after the organ in which it begins; for example, breast cancer.
- **progesterone -** A female sex hormone released by the ovaries to prepare the uterus for pregnancy and the breasts for milk production (lactation).
- **prognosis -** A prediction of the course of disease, including the prospects for a cure. For example, women with early detected breast cancer and receive prompt treatment have a good prognosis.

- **prosthesis (breast) -** An artificial form that can be worn under the clothing after a mastectomy to simulate the shape and form of a natural breast. (Plural: prostheses.)
- protocol A formalized outline or plan.
- **public health district -** Missouri is divided into six public health districts. In the manual, the word regions is used.
- **quality assurance -** The overall process of assessing and maintaining the highest possible quality in the acquisition and interpretation of results.
- radiologic technologist A health professional (not a physician) trained to properly position patients for x-rays, to load film and take the images, and to develop and check the images for quality. For mammograms (breast x-rays) machines, the technologist must have special training in mammography. A radiologist reads the films taken by the technologist.
- **radiologist** A physician who has taken additional years of training to produce and read x-rays and other types of images (for example, ultrasound or magnetic resonance imaging) for the purpose of diagnosing abnormalities.
- **radiology -** A branch of medicine concerned with the use of radiant energy in the diagnosis and treatment of disease.
- **radiotherapy** Treatment with radiation to destroy cancer cells. Methods used include linear accelerators, x-rays, cobalt, and betatrons. Radiation treatment may reduce the size of a cancer before surgery, or destroy any remaining cancer cells after surgery; also known as *irradiation* and *radiation therapy*.
- **Reach to Recovery -** A visitation program of the American Cancer Society for women who have a personal concern about breast cancer. Carefully selected and trained volunteers, who have successfully adjusted to breast cancer and its treatment, provide information and support to women newly diagnosed with the disease.
- **reactive changes -** Normal changes in tissue as a result of the body's reaction to an irritation or infectious agent.
- **recurrence** Cancer that has re-occurred or reappeared after treatment. *Local recurrence* is at the same site as the original cancer. *Metastasis* means that the disease has recurred at a distant site. *Regional recurrence* is in the tissue or lymph nodes near the site.
- **regimen -** A strict, regulated plan of diet, exercise, or other activity designed to reach certain goals. In cancer treatment, it is a plan to treat cancer.
- **regional involvement -** The spread of cancer from its original site to nearby areas such as muscles or lymph nodes, but not distant sites such as other organs.
- **Regional Program Coordinator (RPC) -** SMHW staff persons located in several regions of the state who assist with referrals for diagnosis and treatment and provide service coordination/case management services for women enrolled in SMHW.

- **rehabilitation** Activities to adjust, heal, and return to a full, productive life after injury or illness. This may involve physical restoration (such as the use of prostheses, exercises and physical therapy), counseling and emotional support.
- **risk factor -** Anything that increases a person's chance of getting a disease such as cancer. The known risk factors for breast cancer include being a woman over the age of 50; family history of the disease, especially in one's mother or sister; beginning menstrual periods at a young age (before age 12); obesity; never having completed a pregnancy; first pregnancy after age 30.
- saline solution A saltwater solution.
- scan A study using either x-rays or radioactive isotopes to produce images of internal body organs.
- scant cellularity An unsatisfactory Pap smear with inadequate cellularity.
- **scirrhous cancer -** A breast cancer with a hard, firm, fibrous texture; usually an infiltrating ductal carcinoma.
- **screening -** The search for disease, such as cancer, in people without symptoms. Screening may refer to coordinated programs in large populations. The principal screening measure for breast cancer is mammography.
- **screening guidelines -** Recommendations for the application of screening procedures, which are formulated by professional and governmental agencies.
- **screening mammogram -** American College of Radiology defines a screening mammogram as "an x-ray breast examination of asymptomatic women in an attempt to detect breast cancer, when it is small, nonpalpable and confined to the breast."
- screening provider(s) Health departments, primary care facilities, and/or any other entities under contract with Missouri's SMHW program to provide breast and cervical cancer screening services.
- screening services Refers to clinical breast examination, Pap smear, pelvic examination, mammography, instruction in breast self-examination, and informational and educational services relating to breast and cervical cancer by providers of SMHW services.
- secondary tumor A tumor that forms as a result of spread (metastasis) of cancer from its site of origin.
- **shall/must/should** Reference to the words "shall" and "must" indicate mandatory program policy.

 "Should" indicates recommended program policy relating to program management and patient care that the provider is urged to follow.
- Show Me Healthy Women (SMHW) The functional entity created within the Missouri Department of Health and Senior Services, Division of Community and Public Health, Section for Community Health Services & Initiatives, Bureau of Cancer and Chronic Disease Control, to implement and manage all components of the grant.
- **silicone gel -** Synthetic gel compound used in breast implants because of its flexibility, strength, and texture, which is similar to the texture of the natural breast. Silicone gel breast implants are available for women who have had breast cancer surgery. (See *breast augmentation*.)

- **sonogram -** An image produced by using high-frequency sound waves. This technique is used to examine and measure internal body structures and detect bodily abnormalities, but does not utilize radiation or x-rays.
- **speculum -** A metal or plastic instrument that permits visual inspection of the cervix and performance of a Pap smear.
- **staging -** A method of determining and describing the extent of cancer, based on the size of the tumor, whether regional axillary lymph nodes are involved, and whether distant spread (metastasis) has occurred. Knowing the stage at diagnosis determines the best treatment and the prognosis.

stages of breast cancer:

Stage 0: The earliest stage of breast cancer; the disease is in situ.

Stage I: The tumor is 2 cm or less in size and contained within the breast tissue; not spread beyond

the breast.

Stage II: The tumor is more than 2 cm and spread to regional lymph nodes, such as the lymph

nodes under the arm, or the tumor is more than 5 cm in diameter and no regional nodes

are involved.

Stage III: The tumor, any size, has spread to several regional lymph nodes and/or other tissues near

the breast.

Stage IV: The cancer has spread to other organs and/or tissues by way of direct extension, lymph

system and/or bloodstream.

stages of cervical cancer:

Stage 0: The earliest stage of cervical cancer; the disease is in situ.

Stage I: Cancer has not spread beyond the cervix and uterus.

Stage II: Cancer has spread beyond the uterus, but not to the pelvic wall or to the lower third of the

vagina.

Stage III: Cancer has spread to the pelvic wall and/or involves the lower third of the vagina and/or

regional lymph nodes.

Stage IV: The cancer has spread to other organs and/or tissues by way of direct extension, lymph

system and/or bloodstream.

- **stereotactic biopsy** A diagnostic procedure that combines the technology of radiological imaging with surgical biopsy. Images taken at different angles of the area surrounding a lesion and a computer precisely calculates the lesion's location. An automatic biopsy needle obtains samples of the tissue at the exact spot calculated by the computer.
- **subcutaneous mastectomy -** A surgery to remove internal breast tissue, yet the nipple and skin are left intact.

supraclavicular nodes - Lymph nodes that are above the collarbone (clavicle).

surgery - An operation, a procedure performed by a surgeon to repair or remove a part of the body or to find out if disease is present.

- **surgical or specialist consultation -** A referral of a woman to a surgical specialist for additional diagnostic evaluation, following detection of a breast or cervical abnormality.
- survival rate A way of expressing how long, on average, people may live after diagnosis of disease or after treatment of the disease and expressed as the percentage of people who live a certain period, as opposed to the percentage of those who die. For example, the five-year survival rate for women with localized breast cancer (including all women living five years after diagnosis, whether the patient was in remission, disease-free, or under treatment) was 78 percent in the 1940's, but in the 1990's it was 93 percent.
- **suspicious abnormality -** A finding on a test that indicates cancer might be present.
- **synchronous -** At once or at the same time.
- **systemic disease -** In breast cancer, a tumor that originated in the breast has spread to distant sites, such as the liver, chest, brain, bones, or lungs.
- tamoxifen (brand name: Nolvadex) A drug that blocks estrogen; an antiestrogen drug. Blocking estrogen is desirable in some cases of breast cancer because estrogen feeds the growth of certain types of tumors.
- target population The desired or intended audience, in this case for SMHW interventions.
- therapy Any of the measures taken to treat a disease. Alternative therapy is any unapproved therapy and sometimes called questionable methods or unproven methods. Sometimes alternative and standard therapies are used together. Some are harmless, some may be helpful, and others can be dangerous, especially if they divert a person with cancer from receiving standard therapy. Some people use alternative therapies along with standard therapy; in this approach, the health care team should be informed of the alternative method used. Experimental therapy is any new, as-yet-unproven method that is undergoing testing for specific purposes in a scientific clinical trial. Standard therapy is any method that has been scientifically tested and proven useful for specific purposes and is the standard treatment.
- **tissue -** A collection of similar cells, united to perform a particular function. There are four basic types of tissue in the body: epithelial, connective, muscle, and nerve.
- **tomosynthesis** An optional method of performing high-resolution mammogram with three-dimensional images of the breast.
- transformation A multistep process by which normal cells change into neoplastic cells.
- **tumor -** Tissue growth in which the cells multiply uncontrollably, also called *neoplasm*. It can be either benign or malignant. *Benign tumor* is a noncancerous tumor (i.e., does not invade and destroy adjacent normal tissue). *Malignant tumor* is a tumor that is cancerous and likely to cause death unless adequately treated.
- ultrasonography (ultrasound) An imaging method in which high-frequency sound waves, transmitted through the area of the body being studied, are used to outline a part of the body; the echoes are read, displayed and transmitted to a television screen. The painless procedure mainly determines if a structure is solid or liquid. It is useful in detecting breast cysts in young women with firm, fibrous breasts. No radiation exposure occurs.

- underinsured A patient is considered underinsured if she has medical insurance that does not cover SMHW screening services, or if she has an unmet deductible or required copayment for services covered by SMHW.
- underserved Groups of individuals who chronically lack access to health care for a variety of reasons.
- **unilateral** Affecting one side of the body. For example, unilateral breast cancer occurs in one breast only. (Also see *bilateral*.)
- unproven methods of cancer management Any therapy that has not been subjected to traditional scientific study and proved effective in clinical trials. Such methods range from harmless to life threatening, especially if used in place of medically sound methods of treatment. The American Cancer Society maintains a reference file on proven methods of cancer management. Information is available by request from the society's toll-free cancer information hotline, 1-800-ACS-2345. (Also see therapy.)
- **x-rays** One form of radiation that can, at low levels, produce an image of cancer on film, and at high levels can destroy cancer cells.